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This research aimed to determine whether education and advice from a specialist 
pharmacist in a chronic pain team (CPT) improved patient’s analgesia. 
 
Methods 
55 patients referred to a chronic pain service in Staffordshire, UK were reviewed, 
educated and advised by a specialist pharmacist, four months apart. Medication and 
pain scores were recorded using validated tools (BPI and S-LANSS). Data were 
compared and analysed for significant changes. Ethical approval was obtained. 
 
Results 
Significant changes between visits were identified in some areas of medicine taking 
behaviour (BPI). Patients’ mean ‘worst pain’ score improved (8.4 to 7.9, p=0.023), 
perceived percentage of ‘relief from treatment’ increased (41% to 51%, p<0.001), 
fewer patients reported analgesia as ‘ineffective’ (43% to 13%, p=0.003), perceived 
duration of effective analgesia increased (p=0.004) finally more patients reported 
their mild/moderate opioids ‘effective’(p=0.006). 
 
   
Between visits, patient attitudes to medication taking changed. Overall fewer patients 
required: stronger analgesia (57% to 37%, P=0.002); more analgesia than prescribed 
(33% to 21%, p=0.004) more analgesic information (76% to 45%, p=0.004). Fewer 
considered they were taking ‘too much’ analgesia (46% to 31%, p=0.004) 
 
Conclusion 
Results suggest that education about analgesia by a specialist pharmacist working in 
a CPT can positively impact on patient’s pain scores.  
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I’ve learned that people will forget what you said, people will forget what you did, but 
people will never forget how you made them feel. 
 




1.1. Overall layout of this thesis 
The aim of this research was to investigate the effect that a pharmacist had in a 
Chronic Pain Team (CPT) in relation to changes in pain scores and patient medicine 
taking behaviour.   It will firstly introduce the background of this research along with 
the medicinal treatment of chronic pain.  It will then cover the systematic review, the 
aims and objectives, the methods used in this research and the results.  The layout 
of the discussion follows the same format as that of the results and the discussion of 
each group of results finishes with its own conclusion.   The thesis then closes with 
the conclusion, appendices and references. 
1.2. Introduction  
This chapter commences with the audit basis for this research.  It then outlines the 
context of the chronic pain service within Staffordshire and the role of the pharmacist 
within that service.  It sets out the problems associated with chronic pain, its 
definition, epidemiology and background for the need to treat pain.  It concludes with 
an outline of the medicines used in the treatment of this condition.   
1.3. Audit basis for this research 
In 2013 an audit was carried out in the South Staffordshire chronic pain service 
(CPS) by the researcher to ascertain the use of medicines recommended for the 
treatment of neuropathic pain by General Practitioners (GPs).  One hundred 
sequential patients attending the pharmacist’s clinic were asked to self-complete the 
Leeds assessment of neuropathic symptoms and signs – short form (S-LANSS) 
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questionnaire prior to arrival at the clinic.  As part of the patient’s medicines use 
review (MUR) during the appointment a record was made of the medicines 
prescribed to treat the patient’s chronic pain.  The medicines prescribed by the 
patients’ GP were then analysed in relation to their S-LANSS score using the 
accepted S-LANSS score of >=12 as the definition for the presence of elements of 
neuropathic pain within the patients’ pain (Bennett et al., 2005).  
 
Fifty seven patients in this audit group reported an S-LANSS score of >=12 and of 
these 21 (37%) were not taking medicines which NICE recommends are appropriate 
for treating neuropathic pain (NICE, 2013a).  In addition, of the 21 not taking these 
medicines, 9 (43%) were taking strong opioids.  Cochrane reviews (McNicol, Midbari 
and Eisenberg, 2013; Els et al., 2017a) and the Faculty of Pain Medicine (FOPM) 
(NHS, 2015) all recommend that strong opioids may not be effective in the treatment 
of this condition.  As a result, it was decided to explore the use of medicines for 









1.4. South Staffordshire chronic pain service 
The South Staffordshire chronic pain service (CPS) treats patients at five centres, 
Burton, Lichfield, Rugeley, Stafford and Tamworth.  Patients from each of these 
locations were included in this research. 
 
Figure 1.1 Map of Staffordshire 
Map from the Trust Website 
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1.4.1. INITIATION AND ADMINISTRATION OF THE CHRONIC PAIN SERVICE 
In 2010 the South Staffordshire Primary Care Trust (PCT) sought providers for a 
biopsychosocial CPS.  This treatment modal suggests that at least some of a 
patients’ pain is self-manageable (Kamper et al., 2015; Cheatle, 2016; Kress et al., 
2015; BPS, 2013; NICE, 2013a) and the efficacy of this model has been 
demonstrated (Gatchel et al., 2007).  A Cochrane Review reported that there was 
moderate evidence to support this approach to the treatment of chronic pain (Kamper 
et al., 2015).  This was supported by a later analysis of the benefits that patients’ 
reported after being treated by an interdisciplinary pain team (Hapidou and Horst, 
2016). 
 
This represented a change from earlier treatments for chronic pain where the 
emphasis had been upon the biomedical model of treatment (Engel, 1977; Bendelow, 
2013).  In this model of care patients’ awaited treatment to be given to them by 
others.   
 
The South Staffordshire CPS was originally commissioned as a referral service to 
offer guidance to GP’s and their patients on the treatment and self-management of 
chronic pain.  The commissioners explicitly required the CPS to encourage patient 
self-management.  The aim was to minimise referrals for chronic pain into Secondary 




The biopsychosocial model of treatment, which developed slowly from its origins 
(Engel, 1977), was predicated on the principle that the experience of chronic pain 
could be managed by a combination of biomedical, psychological and social factors.  
The aim of treatment was twofold.  Firstly, to empower patients to accept that their 
condition was to some extent self-manageable and take the knowledge which was 
offered by the CPS and apply it to their lives.  Secondly, to provide patients with the 
knowledge and skills to manage their own pain in ways which facilitated their lives, 
albeit with some residual pain.  Much of the teaching necessary for such 
empowerment and self-management takes place during a Pain management 
program (PMP) course.  This means that patients need to be prepared to engage 
with the concept of self-management before being considered (eligible) for this 
course.  Without this acceptance and engagement, patients may not be able to move 
on from constantly seeking a biomedical solution for their pain.  Many patients find 
this approach difficult, at least initially. 
1.4.2. PROCESS FOR REFERRAL OF PATIENTS TO AND WITHIN THE CHRONIC PAIN 
SERVICE 
Patients’ are referred to the CPS by their GP, by letter.  These letters are reviewed 
and triaged by one of two Extended-Scope Physiotherapist (ESP), one of whom also 
has an additional prescribing qualification.  Following on from this triage, accepted 
patients are reviewed either by a multi-professional group (MPG) within the CPS or 
an individual physiotherapist.  The pharmacist is involved with some of the MPG 
reviews.  At their initial appointment patients are involved in a discussion about the 
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available therapeutic options, a treatment pathway agreed and their GP informed by 

























Figure 1.2 Flow diagram of referral process into the pharmacist clinic   
Patient referred to the 
CPS by GP letter 
Paper ‘triage’ by ‘Extended 
Role Physiotherapist’ 
Patient assessed by a multi-
professional group  
 
Specialist Pharmacist clinic 
Patient treated by CPT as set 




individual CPS team member 
 
Discharge 
Offer of place 




The consultation options that are available across the CPS for inclusion in the 
individual patients’ treatment plans include Physiotherapy, Occupational Therapy, 
Clinical Psychology, Pharmacy and Consultant medical staff.  The treatments offered 
include exercise guidance, cognitive behavioural therapy, eye movement 
desensitisation and reprogramming (EMDR), transcutaneous electric nerve 
stimulation (TENS), spinal and local injections and nerve ablations and medicines 
optimisation.  X-rays and scans can also be ordered if this would aid diagnosis and 
facilitate appropriate treatment. 
 
The pharmacist offers an initial appointment of one hour where an MUR is 
undertaken.  After this ‘medicines optimization advice’ is offered to the patient and as 
appropriate included within the post clinic letter for the GP.  Subsequent 
appointments are offered, if this is agreed with the patient to be appropriate either for 
the correct initiation of a complex medicinal intervention or the gradual reduction of 
inappropriate medicines.   
 
Over six, three-hour sessions, the PMP covers the physiological and psychological 
aspects of chronic pain and there are discussions about flare up management, 
pacing, problem solving and sleep hygiene.  The program explored various relaxation 
techniques, visualisation, distraction and breathing to allow patients to determine 
which was beneficial for them.  Lastly, participants were instructed in graded 




The pharmacist’s presentation occupies half of one session, approximately 90 
minutes.  The aim is to guide patients towards the appropriate and optimal use of 
their pain medicines.  Time is also allocated to counter any of the misinformation that 
the participants have about their pain medicines.     
1.5. Definitions and understandings 
There are three well recognised and accepted definitions of pain, which are important 
when talking to patients about their chronic pain.  
 
i. “Pain is whatever the experiencing person says it is, existing whenever or 
wherever the person says it does” (McCaffery, 1968).  
ii. (Pain is) “an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage or described in such terms”.   
International Association for the Study of Pain (IASP, 2018) 
iii. (Neuropathic pain is) “Pain arising as a direct consequence of a lesion or 
disease affecting the somatosensory system” (IASP, 2015) 
 
Acute pain can be divided into two groups.  Firstly, it occurs as a short-lived response 
when local nociceptive pain receptors send a message to the central nervous system 
(CNS) reporting tissue damage or injury.  It is a survival trait initially involved in the 
removal of the affected area from the possibility of further harm.  Secondly, there are 
a group of conditions which result in repeated nociceptive stimulation and which can 
be of unknown duration.  Included in this group are post-surgical pain, inflammatory 
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bowel disease or cancer pain.  Each of these pains relate to a specific condition.   
These conditions are treated in the same way as acute pain but over a longer period.   
 
Chronic pain or persistent pain, on the other hand, as seen in the CPS is much more 
difficult to define, except as a counterpoint to acute pain and often varies with the 
emotional state of the patient.  Unlike acute pain, the expected duration is often 
unknown and is independent of any underlying illness or injury (McAllister, 2015).  
Rather than being a single disease it is an immense and diverse range of disease 
conditions, which present with the similar clinical symptoms of pain (Treede et al., 
2015).  It was suggested by Grichnik and Ferrante (1991) that chronic pain should be 
regarded as a disease of its own.  The full list of conditions included within the overall 
definition of ‘Chronic Pain’ is available from the IASP website (IASP, 2012).  The 
positive survival traits of acute pain appear to have transmuted into inappropriate 
perceptions, which are harmful to the individual.  This transmutation may lead to pain 
unrelated to any discernible cause, with symptoms, which are often associated with 
the symptoms of neuropathic pain.   
 
Because the diagnosis and treatment of chronic or persistent pain does not relate to 
an underlying illness there has been a tendency to question the reality of the patients’ 
suffering.  It was recognition of this which led McCaffery (1968) to define pain in the 




The differentiation between acute and chronic pain is therefore important in order to 
provide appropriate management and treatment.  Analgesia for acute pain is 
generally administered on a regular basis and can be very effective. As healing 
occurs the analgesia can be stepped down and stopped.  Drug therapy for chronic 
pain on the other hand is often not very effective and once started it may continue, at 
some level, for an unspecified length of time (Ballantyne, Kalso and Stannard, 2016). 
 
There is no consensus of opinion on the length of time before acute pain becomes 
chronic pain (Mifflin and Kerr, 2014; Feizerfan and Sheh, 2015).  In discussions with 
patients’ it is often helpful to describe it as “pain that extends beyond the expected 
period of healing” (Loeser and Bonica, 2001).  
 
For a pharmacist, the vagaries of this pain bifurcation are important.  Chronic pain is 
not simply continuing acute pain because, over a period of time, the body changes in 
response to the experience (Section 1.5.1).  It is generally accepted with acute pain 
that “analgesia is more effective at keeping pain away then making it go away”, but 
once a patient has chronic pain, therapy may continue for a long time.  This extended 
duration of treatment should lead to a different risk-benefit analysis of efficacy versus 
side effects to determine which pain medicines are more appropriate for long term 
therapy.  Those side effects which take longer to develop such as opioid effects on 
the endocrine system and possibility of pregabalin induced weight gain need to be 
considered differently.  The potential for decreased patient wellbeing needs to be 




The Brief Pain Inventory tool, which was used during this research, uses the term 
‘pain medication’ rather than analgesic. Therefore, throughout this thesis, the term 
‘pain medication’ or ‘pain medicine’ is used where it is regarded as more appropriate 
to the context than analgesic or analgesia 
1.5.1. CLASSIFICATION OF PAIN 
The classification of pain can be helpful in providing a basis for choice of therapy.  At 
its simplest level there are only two types of pain: pain generated by damage to 
tissues (nociceptive pain) or pain resulting from damage to nerves (neuropathic pain) 
and patients can have either or both at the same time (Parker, Acland and Swire, 
2008).   
 
A more comprehensive classification divides pain into three groups 
i. Nociceptive pain – the body’s normal response to injury or trauma.  It results 
from direct stimulation of the nociceptive receptor e.g. broken bones, burns or 
post-surgery pain.  The quality of nociceptive pain was often described by 
patients as ‘deep’, ‘gnawing’, ‘throbbing’ or ‘aching’.  
ii. Inflammatory pain – resulted from activation or sensitisation of the nociceptive 
pain system by a variety of physiologically active compounds released at the 
site of an inflammatory reaction, symptoms included redness, swelling and 
warmth to the touch. 
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iii. Neuropathic pain – pain arising as a direct consequence of a lesion or disease 
affecting the somatosensory system.  Patients may describe these pains as 
‘burning’, ‘shooting’ or ‘stabbing’.  They may also express symptoms of 
numbness, hypersensitivity, paraesthesia or other unusual sensations.   
 
These three types of pain are defined by sets of symptoms, which in turn, suggest 
treatment options, but for any individual, the situation is more complicated than this. 
 
In a study by Hashmi et al. (2013) colleagues reported that if nociceptive stimulation 
is ongoing, the area of the brain which is activated by these stimuli moves from the 
area of the brain normally associated with pain to an area which is usually associated 
with emotion.  These changes are similar with pain from different locations or causes 
(Roussel et al., 2013). These changes are classified as ‘sensitisation’ (Latremoliere 
and Woolf, 2009) and are often involved in the ‘chronification’ of pain which can 
result in perceptions of pain that are totally out of proportion with the extent of any 
physical damage (Woolf, 2014).  Secondly, pain may also result from previous injury 
or trauma, which had not resolved as normally expected.  For physical injury or 
surgery, the pain should have resolved by the end of the trauma or wound healing 
process (Macrae, 2008; Tinastepe and Oral, 2013; Bruce and Quinlan, 2011) 
(Section 1.5).  Following psychological damage or trauma, the pain may be a somatic 
expression of something long repressed or denied (Afari et al., 2014; Burke et al., 
2017) and such hidden suffering has been associated with fibromyalgia (Hauser et 




Each patient’s pain may contain varying proportions of all three types of pain: 
nociceptive, inflammatory and neuropathic.  Yunus (1984) suggested that such pain 
could probably be most easily visualised in terms of a Venn diagram (Figure 1.3).   
The points where the circles intersect represents the pain of that patient and this may 
suggest treatment options.  This pain picture varies between patients and for an 








Figure 1.3  Suggested Venn diagram of a patient’s pain 










The dichotomy of patients’ perceived pain and suffering, coupled with the possibility 
that it may have a significant psychological component, which often predominates 
(Cruccu and Truini, 2009) complicates treatment.  Many patients find it challenging to 
understand that the pain, with which they may have lived for many years, may not 
result from actual damage to their bodies (O’Sullivan, 2015).   
 
We should not be surprised if ongoing pain changed the brain.  The brain changes 
when we learn anything: juggling (Driemeyer et al., 2008), the taxi drivers 
‘knowledge’ (Maguire, Woollett and Spiers, 2006) or pirouetting (Hanggi et al., 2010).  
Such is the plasticity of the brain that it has been suggested:  “‘we only use one 
particular brain once, because the next time we use it, it will have been changed.” 
(Villringer, 2010). 
 
If this is the case it is be difficult to escape the conclusion that much chronic pain is 
likely to be of mixed origin.  Therefore, patients who have chronic pain, resisting 
nociceptive analgesic therapy or which results in a reduced quality of life, should 
probably be assessed for the possibility of treatment with medicines used for the 
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1.5.2. AN OUTLINE OF THE PHYSIOLOGY OF PAIN 
Written accounts about the theory of pain go back as far as Epicurus (347-270BC) 
who suggested that there was a direct pain pathway from the wound to the brain via 
the spinal column with pain being proportional to the size of the wound.  There was 
no room in his proposals for pain without an obvious cause; this was regarded as not 
real; ‘plus ça change’. 
 
By the end of the first millennium Avicenna (980-1037AD) was proposing that there 
should be 15 adjectives to describe pain.  This proposition disappeared until 
relatively recently when researchers began to re-examine the subjective nature of 
pain (Melzack, 1975). 
 
During the Second World War at the battles for Monte Cassino and Anzio the pain 
responses of severely wounded soldiers were recorded by Beecher (1946).  Some of 
those with the most severe wounds were clearly not in pain.   This led to a 
questioning of Epicurus’ suggestion that the intensity of the pain was related to the 
size of the wound and the proposal that in some way pain was modulated by the 
body. 
 
More recently Melzack and Wall (1965) proposed that there was a lower limit to pain 
transmission and any impulses which crossed that threshold would be subject to 
modulation and control.  Their proposal also suggested that non-painful stimuli could 
close a ‘gate’ to a more painful stimulus.  This gave a theoretical basis to the 
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observation that a patient with pain is less aware of their pain when they are 
completely engaged in a distracting task. 
 
It is now understood that in common with many physiological systems, the body’s 
response to pain is a balance between excitation and inhibition within the overall 
central nervous system (CNS).  The upward transmission of excitatory pain impulses 
is via the dorsal horn into the CNS and is glutamate mediated.  This is balanced by 
descending controls from the brain which exert strong inhibition on the dorsal horn 
and is mediated in the main by endogenous opioids, 5-HT/serotonin, nor-adrenaline 
and adenosine, in different locations within the spinal cord. 
 
Pain pathways in the CNS are illustrated in Figure 1.5.  Ascending nerve routes from 
the periphery via the ‘dorsal horn’ of the spinal cord and descending modulating 
nerve pathways.  Painful stimuli terminate in the Somatosensory cortex.  Modulating 
messages originate in the Somatosensory cortex and the Hypothalamus and exert 
their influences in the Rostral Medulla and in the Spinal cord.  Pain medicines exert 


















1.5.3. EPIDEMIOLOGY OF CHRONIC PAIN 
Accurately determining the number of people with pain, nociceptive, neuropathic or 
chronic, is difficult.  Pain is subjective, often transient and modulated by personal 
circumstances and therefore difficult to measure consistently and objectively.  In 
Europe one in four people aged 15 and over “experienced chronic pain in the past 
week of a magnitude sufficient to restrict activities” (EU, 2007).  The Scottish 
Intercollegiate Guidelines Network (SIGN) report that 18% of the population in 
Western Europe suffered with moderate to severe chronic pain (Colvin, 2013).  
Within England, the Health Survey 2011 reported that 31% of men and 37% of 
women suffered with chronic pain.  This rose to 53% and 59% respectively for 
patients aged 75 and over (Bridges, 2011).  A systematic review in the UK (Fayaz et 
al., 2016) suggested that between a third and a half of the population suffered with 
some form of chronic pain and that between 10.4% and 14.3% of the population 
suffered with disabling chronic pain that was either moderately or severely limiting 
(Von Korff grades 3 & 4,)  (Von Korff et al., 1992).  This equated to more than seven 
million people in the UK.  These figures were higher than those reported in the 
National Pain Audit (Price et al., 2012), which suggested that 6.4% of the population 
suffered with chronic pain with “a high expressed level of need”  (Smith et al., 2001)  
 
In a randomly generated sample of 6,000 patients from six General Practices, 48% of 
patients suffered with chronic pain and 8% had pain which was predominantly of 
neuropathic origin as defined by the S-LANSS questionnaire (Torrance et al., 2006).  
A review of world data by van Hecke et al. (2014) reported a population prevalence 
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for pain with neuropathic elements of between 6.9% and 10%. A postal survey was 
undertaken in France and analysed 23,000 replies.  This reported 31.7% of the 
patients surveyed suffered with chronic pain and 19.9% regarded their pain as 
moderate to severe.  This survey used the DN4 questionnaire for neuropathic pain 
which suggested that 6.9% of patients suffered with neuropathic pain and in 5.1% of 
the sample this was regarded as moderate to severe (Bouhassira et al., 2008).   
 
The relationship between chronic pain and neuropathic pain is complex.  Research 
has suggested that up to 50% of patients with chronic lower back pain have elements 
of neuropathic pain (Freynhagen and Baron, 2009; El Sissi et al., 2010; Kaki, El-
Yaski and Youseif, 2005; Fishbain et al., 2014).  In addition, patients with neuropathic 
elements in their pain report higher pain intensities  (Torrance et al., 2006) and 
poorer quality of life (Smith et al., 2007) than those with chronic pain without 
neuropathic elements.   It is also reported that the complexity of the relationship 
between chronic pain and neuropathic pain is increased by the fact that the 
proportion of chronic pain patients who are regarded as suffering with neuropathic 
pain changes with the diagnostic tool used (Harrisson et al., 2017).  Another facet of 
the difficulty of measuring pain objectively and consistently. 
 
The extent of the problem of chronic pain is exemplified, on a more localised scale, 
by the work of the CPS in South Staffordshire.  The culmination of the therapeutic 
journey for many of the patients is the offer of a place on a PMP.  The CPS offers 
these courses back-to back in five locations.  On each course up to 15 places are 
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offered.  Therefore, in a twelve-month period up to 600 patients are offered the 
opportunity to attend a PMP.  The exact numbers who attend these courses at each 
location was not readily available because Trust records are filed by referring GP 
practices rather than by location of treatment. 
1.5.4. THE NEED TO ACHIEVE CHRONIC PAIN CONTROL 
Chronic pain is one of the commonest reason for a person to seek medical care 
(Hotchkiss, 2006).  The UK Chief Medical Officer’s report in 2008 suggested that the 
overall cost of chronic pain was approaching 1% of Gross Domestic Product (CMO, 
2008).  The total healthcare costs of UK patients with chronic lower back pain were 
double those of matched controls (Hong et al., 2013).  Patients with chronic pain 
were five times more likely to visit an Accident and Emergency (A&E) department 
than matched controls (Hadi and Alldred, 2015).  Similar figures are not available for 
the costs of neuropathic pain in the UK (O'Connor, 2009).  In the US in 2000 the 
healthcare costs of patients with ‘Painful Neuropathic Disorders’ were more than 
three times the costs of matched controls (Berger, Dukes and Oster, 2004).   
 
The need to achieve an overall improvement in pain control is therefore twofold: 
reduce personal suffering and reduce the cost of treatment and associated societal 
costs.  As a result, there needs to be an effective and efficient service for the 
treatment of people suffering with chronic pain.  In times of financial restriction, it is 
easy to focus on the cost of the medicines used and overlook the costs to the 
individual and society (RCGP, 2013).   
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1.5.5. GUIDANCE FOR TREATING CHRONIC PAIN 
Evidence-based guidance is the best way to ensure that pain medicines are used 
appropriately -  
i. The World Health Organisation (WHO) Pain Ladder sets out, in three easily 
understandable steps, how pain medicines should be used to achieve the 
greatest possible reduction in pain (WHO, 1986).  (This is laid out in more 
detail below) 
ii. The National Institute for Health and Care Excellence (NICE) Guidelines, lays 
out best practice guidelines for all aspects of health care pointing practitioners 
toward evidence-based practice.   
iii. The Cochrane Organisation – sets out to organise medical literature in a way, 
which facilitates evidence-based treatments.   
iv. ‘At a glance guide to prescribing analgesics for non-malignant chronic pain’ A 
guidelines published by the Staffordshire Area Prescribing Committee to offer 
guidance to local GPs (Appendix 8.1).  
v. The Oxford League Table of Analgesics in Acute Pain sets out the comparable 
efficacies of a number of analgesics in the treatment of acute pain based on 
their number needed to treat (NNT) (FOPM, 2007).  This table does not relate 
to chronic pain but this information may be helpful as an indication of the 
likelihood that a particular analgesic would be effective for the nociceptive 




Each of these guidelines offers an insight into an aspect of the treatment of chronic 
pain.  Taken together they represent the best route available towards the successful 
treatment of chronic pain.   
1.5.5.1. WHO Pain ladder 
In 1986 the WHO promulgated a logical framework for the treatment of cancer pain, 
the Analgesic Ladder (WHO, 1986) (Figure 1.6).  It suggested that when a small 
number of medicines were used appropriately, sequentially and progressively as pain 
increased in severity, the analgesic results were better (Ventafridda et al., 1987).  
This treatment plan become the foundation for many subsequent guidelines used in 
the treatment of different types of pain. 
 
Step one of the WHO analgesic ladder, suggests that patients, presenting with mild 
to moderate pain, should start with regular paracetamol or if the pain involves 
inflammation an NSAID.  For neuropathic pain this should be bolstered with an 
adjuvant such as a tricyclic anti-depressant or a gabapentinoid, as necessary.  
Patients whose pain is not controlled with these medicines or presenting with more 
severe pain would be offered the same combinations with the addition of a 
‘mild/moderate opioid’. Patients with even more severe pain would be offered a 
’strong opioid’.  Initial assessment is essential for correctly identifying appropriate 
pain medicines with regular ongoing reviews equally important especially in situations 




Figure 1.6 illustrates the three step WHO pain ladder and the medicines that are 





















Figure 1.6 The WHO pain treatment ladder  
As suggested by WHO (1986) 
 
The WHO also set out the rules for how analgesics should be taken, if they are to 
give the benefits claimed (Reid and Davies, 2004).  They should be taken ‘by mouth’, 
‘by the clock’ i.e. regularly, if appropriate, ‘by the ladder’ i.e. additive, and progressive 
following the increments suggested, ‘for the individual’ because each patients’ pain is 
Pain – Step 3 
Pain – Step 2 
Pain – Step 1 
Paracetamol or NSAIDs 
± adjuvant therapy 
 
  Paracetamol or NSAIDs 
plus strong opioids  
± adjuvant therapy 
 
Paracetamol or NSAIDs 
plus mild/moderate opioids 
± adjuvant therapy 
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unique to them and ‘with attention to detail’ because only the patient understands 
their pain’ (Manias, Botti and Bucknall, 2006).  These comments are incorporated 
into the advice from the CPS with one addition.  Chronic pain flares and wanes 
constantly, therefore regimens for pain medicines must somehow allow for this.   
 
By following the three steps of the WHO pain treatment ladder, it is reported that 
adequate pain relief could be achieved with nociceptive pain for between 70% and 
80% of patients (Vargas-Schaffer, 2010).  Partial relief for neuropathic pain could be 
achieved for between 40% and 60% of patients (Dworkin et al., 2007).   
1.5.5.2. Application of guidance for the treatment of chronic pain  
Within the South Staffordshire CPS, the WHO Pain Ladder is used as originally 
promulgated, with the following four provisos 
 
i. Many patients with chronic pain find NSAIDs helpful.  The Oxford League 
Table ranks many of these as having NNT’s of less than 2 (FOPM, 2007).  
However, these medicines carry the possibility of side effects, which worsen 
with age (Pirmohamed et al., 2004) and many of the patients that attend the 
CPS are in older age groups.  The British National Formulary (BNF) (JFC, 
2017) recommends using the ‘lowest dose’ for the ‘shortest possible time’.  
Because of this it is suggested to patients, for whom these medicines were 
effective and appropriate, that if possible they reserve NSAIDs for use either 
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when their pain flared or for pre-emptive use when they were going to engage 
in an essential activity, which they knew will cause them pain.   
ii. The consistent use of any opioid therapy leads to a rightward shift in the dose 
response curve i.e. the development of tolerance (Collett, 1998; Freye and 
Latasch, 2003; Chu et al., 2012).  It is reported that varying the dose on an 
ongoing basis delays the development of this tolerance (Duttaroy and Yoburn, 
1995; Dighe et al., 2009; Brennan, 2013; Sullivan, 2014).  Therefore, patients 
were advised to seek an opportunity to vary the dose of their opioids with the 
intensity of their pain.  Suggestions include varying doses in anticipation of the 
pain likely to be caused by their plans for the day, avoiding the maximum dose 
if possible and aiming for an ‘opioid free’ time as frequently as possible. 
iii. Strong opioids are retained for use only as a last resort. Their use in the 
treatment of chronic pain is controversial (NHS, 2015).  They create multiple 
overt and covert side effects and above a morphine equivalent dose of more 
than120mg daily it is suggested that the side effects are likely to outweigh any 
benefits (NHS, 2015).   
iv. Treatment is generally additive, one drug in addition to the previous regimen.  
Paracetamol is reported to offer dose sparing effects for opioids (Colvin, 2013; 
Valentine et al., 2015; Zeidan et al., 2014) and synergism with NSAIDs 
(Miranda et al., 2006).  The relative safety of paracetamol and NSAIDs are 
discussed in Section 1.6.1 and Section 1.6.4.  Additive therapy is premised 
upon the suggestion that higher potency analgesics will generally have greater 
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side effects and therefore it is important to take advantage of as much benefit 
a possible from lower potency medicines, with possibly fewer side effects. 
1.6. Drugs used for the treatment of pain 
The aim of this section is to outline the context for the use of medicines to treat 
chronic pain because medicines used for the treatment of nociceptive pain may not 
be effective in the treatment of chronic or neuropathic pain (Colvin, 2013).  It will then 
highlight those aspects of pharmacology and pharmacokinetics, which are relevant to 
the treatment of chronic pain.  
 
Our understanding about, and the treatment of chronic pain, is moving towards a 
more guidance based, multi-professional approach.  Medicines have a role in the 
treatment and management of chronic pain but they are rarely an answer in 
themselves.  Pain medicines will not, usually, create a chronic pain free state, but 
their appropriately targeted use by patients can help to facilitate the achievement of 
necessary everyday tasks, which are known to be painful.  The significance of any 
benefit varies with the particular condition and patient being treated.   
 
When a medicine is used to treat any condition there is always a balance to be struck 
between benefit and the possibility of side effects.  As a result, any discussion 
between the pharmacist or any other Health Care Professional (HCP) and the patient 
about their pain and medicines must fully explore the following questions.  Does the 
medicine elicit a therapeutic response?  Are the side effects, acceptable?  Are the 
 
 29 
directions for their use understandable and achievable?  Finally, regardless of the 
efficacy, tolerability or practicality is the patient willing or likely to take the medicine? 
 
The drug groups currently used in the treatment of chronic pain, with the commonly 




a. Mild/moderate – codeine, dihydrocodeine, tramadol 
b. Strong - morphine, oxycodone, fentanyl, buprenorphine, tapentadol 
iii. Anti-depressants – amitriptyline, nortriptyline, duloxetine. 
iv. Gabapentinoids – gabapentin, pregabalin. 
v. Non-steroidal anti-inflammatories (NSAIDs) – ibuprofen, naproxen, diclofenac  
vi. Topical applications – NSAID gel, lidocaine plaster (very occasionally), 
capsaicin cream 
 
Each of these groups, except the opioid subdivision, exhibit different mechanisms of 
action.  The examples within each group will have slightly different efficacy and side 
effect profiles and it is a combination of these two factors, which determine the ability 
of an individual medicine to affect a reduction in pain for a specific patient with an 
acceptable level of side effects.  As a result, it is important to remember that failure 
with any one medicine does not necessarily imply failure with any other (Moore et al., 




Paracetamol is classified as a mild/moderate analgesic and is widely available, being 
regarded as safe enough to be allowed unrestricted sale in a pack of 16 tablets.  The 
adult dose is 1g up to a maximum of four times a day i.e. one dose is effective for 
about six hours, with no flexibility for additional doses.  At this dose it is normally, but 
not uncontroversially, regarded as a safe, first line analgesic therapy for patients with 
normal liver function (Wise, 2015; Hall, 2016; Machado et al., 2015).  For acute lower 
back pain Bandolier suggests an NNT of 3.5 (FOPM, 2007), but for chronic lower 
back pain a Cochrane review suggested that it is probably ineffective (Saragiotto et 
al., 2016).  
 
As outlined above (Section 1.5.3) up to 50% of chronic lower back pain may contain 
elements of neuropathic pain.  To investigate the place of paracetamol in the 
treatment of neuropathic pain, either with or without codeine, Wiffen et al. (2016) 
undertook a systematic review and concluded that there was insufficient evidence to 
determine whether or not paracetamol provides effective analgesia.  Regardless of 
this, patients often actively report benefit when taking paracetamol for their pain. 
 
The balance of evidence about whether or not paracetamol should be regarded as 
suitable for first line therapy in chronic pain is constantly being reviewed.  In 
particular its effectiveness in the treatment of low back pain and osteoarthritis was 
questioned (Zhang, Jones and Doherty, 2004; Shamoon and Hochberg, 2001; 
Abdulla et al., 2013; Machado et al., 2015; Roberts et al., 2015).  Paracetamol, as 
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with all medicines has the potential to cause side effects and therefore there must be 
some benefit to balance against this possibility.  Most recently it has been suggested 
that paracetamol should be regarded as first line therapy with or without codeine 
because the alternatives, NSAIDs are generally regarded as less safe (Kress and 
Untersteiner, 2017).  In the treatment of mild to moderate pain the Drug and 
Therapeutics Bulletin suggests that paracetamol should be regarded as a first line 
therapy, with an analgesic efficacy similar to aspirin but with less gastro-intestinal 
irritation because of its different mechanism of action (DTB, 2018).  
 
In the treatment of osteoarthritis a systematic review by Zhang, Jones and Doherty 
(2004) suggests that paracetamol is effective but not as effective as NSAIDs, but 
because NSAIDs are not as safe as paracetamol these medicines should be 
reserved for patients for whom paracetamol is ineffective.  There is also support from 
Kress and Untersteiner (2017) for the use of paracetamol before NSAIDs, in 
vulnerable groups such as, the elderly, pregnant women and patients with gastro-
intestinal and cardiovascular conditions 
 
The mode of action of Paracetamol is not fully understood.  The main mechanism of 
action is the inhibition of the Cyclooxygenase system, more specifically a selective 
COX-2 inhibitor (Derry, Derry and Moore, 2013; Twycross et al., 2013).  Evidence of 
this inhibition has been observed in the CNS, spleen and lungs.  However, this 
cannot be the entire picture because paracetamol exhibits synergy with NSAIDs 
(Derry, Derry and Moore, 2013) and synergy demands a second mechanism of 
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action.  There is evidence that paracetamol also influences serotonin, opioid, nitric 
oxide (NO) and cannabinoid pathways  (Jozwiak-Bebenista and Nowak, 2014; 
Sharma and Mehta, 2014).  These modes of action may account for some of the 
unusual paracetamol side effects reported by patients in this research e.g. sedation, 
nausea/vomiting and dry eyes. 
 
Paracetamol is metabolised in the liver, mainly by two bio-transformational pathways.  
The majority is converted either to a glucuronide (~55%) or a sulfonate (~35%), 
which are then excreted via the kidneys.  Both of these metabolic steps are ‘rate 
limited’.  Less than 5% is excreted unchanged (Mazaleuskaya et al., 2015).  Between 
5% and 10% is converted along the cytochrome P450 (CYP) CYP2E1 pathway to the 
toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI).  At therapeutic doses of 
paracetamol, the NAPQI which is produced conjugates with glutathione (GHS) and is 
rendered safe.  During paracetamol over dosage, either acute or chronic, the quantity 
of paracetamol which remains after the glucuronide and sulfonation transformations 
are maximised increases.  This increased availability of paracetamol leads to an 
increase in the amount of NAPQI created.  The protective glutathione conjugation is 
then overwhelmed and toxic damage to the liver results (Buclin, Nicod and 
Kellenberger, 2009).   
 
Chronically malnourished patients may have diminished body stores of glutathione.  
This reduces the liver’s ability to undertake the GSH conjugation of the NAPQI.  The 
interaction of alcohol and or alcohol induced liver damage and paracetamol is not at 
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all clear.   There is no good evidence to support the suggestion that alcoholics are at 
increased risk of liver damage from therapeutic or toxic doses of paracetamol.  
(Rumack, 2004; Prescott, 2000) 
 
A Drug Safety Update from NICE (2010) reviewed the dosage recommendations for 
intravenous (IV) paracetamol.  The BNF contains a warning that there is an 
increased risk of toxicity with a daily IV dose of 4g of paracetamol for adult patients 
with a body weight of under 50kg and who have risk factors for hepatic damage.  It is 
also suggested that clinical judgement should be used to adjust oral doses of 
paracetamol for such patients (DTB, 2018).  At least one hospital formulary 
committee has formalised this by suggesting that for patients with a body weight 
between 41kg and 49kg the oral dose of paracetamol should be 750mg four times a 
day and between 31kg and 40kg, 500mg four times a day (NHS, 2018a).  However 
NICE reports no evidence that low body weight alone would lead to increased 
paracetamol toxicity (NICE, 2015a). 
1.6.2. OPIOIDS 
Opioid is the generic term used to describe medicinal compounds which produce an 
effect similar to the dried latex which exudes from the seed pods of Opium poppies.  
Almost all opioids have the ability to create analgesia and at the same time cause 




Opioids are commonly classified according to their potency.  Head to head 
comparisons of different opioids in equipotent doses failed to show any difference in 
their side effect burden (Drewes et al., 2013). 
 
Ø Mild/moderate opioids viz. codeine, dihydrocodeine and tramadol (NICE, 
2015b).  Doses of opioids are expressed in terms of their morphine 
equivalence, but this can vary depending upon the route and frequency of 
administration.  Mild/moderate opioids are regarded as having a potency of 
between one eighth and one tenth of morphine (NHS, 2012; NICE, 2015b).   
Ø Strong opioids viz. morphine, oxycodone, buprenorphine, fentanyl and 
tapentadol. 
 
Both tramadol and tapentadol sometimes demonstrate additional analgesic efficacy 
in the treatment of neuropathic pain over and above their nominal morphine 
equivalent dose.  They both act on other receptors in addition to their Mu opioid 
activity.  Tramadol inhibits the reuptake of both serotonin and noradrenalin and 
tapentadol inhibits the reuptake of noradrenaline.   
 
Opioids have two major therapeutic effects.  Within the dorsal horn they cause the 
inhibition of the upward transmission of pain. Centrally they offer downward 
modulation of pain.  In addition, it has been reported that opioid receptors are 
expressed in the periphery as part of the inflammatory response and therefore 




Some opioids, e.g. codeine, tramadol and to some extent oxycodone must undergo 
biotransformation either to make them effective or to increase their effectiveness.  
These transformations are undertaken via the CYP enzyme pathway in the liver.  The 
necessity for this transformation means that the time from administration to achieving 
an active blood level may be altered.  
 
Table 1.1 Variants of CYP enzymes involved in opioid bio-transformations 
(Ma, Woo and McLeod, 2002; Smith, 2009; Kapur, Lala and Shaw, 2014).  
 
Converted from Converted to Variant of CYP 
involved 
Codeine Active morphine 2D6 
Tramadol Active O-desmethyl 
tramadol 
3A4, 2D6 




The levels of expression of CYP enzymes in an individual are under the control of 
more than one gene which is described as polymorphism.  As a result, the level of 
their activity of these systems can vary between individuals.  It Is reported that 6-10% 
of Caucasians, 2-5% of African Americans and 1% of Asians are classified as having 
lower levels of the 2D6 variant.  Such people are classified as slow metabolisers and 
may be poorly served by analgesics which require these transformation (Ma, Woo 
and McLeod, 2002).  In addition, the MHRA suggests that between 3% and 6% of 




The influence of inter-patient variation in opioid metabolism and effect that this has 
on analgesia has long been reported, (Smith, 2009).  There is no reason to suspect 
that patients who were being treated for chronic pain would be exempt from these 
variations.  Therefore, for patients who receive no benefit from a dose of codeine, 
tramadol or to a lesser extent oxycodone, is this because the patient’s pain is 
resistant to these medicines, because the necessary bio-transformation has not 
taken place or they really just haven’t taken their medicine.   The lack of 
biotransformation may be tested by a trial with an alternative which has its own 
innate activity e.g. ‘switching’ from codeine to dihydrocodeine 
 
All opioids carry a side effects burden, which is related to their potency and the dose 
used.  The common opioid side effects are drowsiness, sedation, nausea, sickness, 
constipation and respiratory depression.  The FOPM (2018) suggested that in normal 
clinical practice more than 80% of patients will experience at least one side effect 
from opioid therapy.  Between 20% and 33% of patients are expected to experience 
nausea on initiation of opioid therapy and half of these will experience frank vomiting 
(Swegle and Logemann, 2006; Smith and Laufer, 2014).  Even with mild/moderate 
opioids such as codeine some patients will discontinue therapy because of side 
effects (Straube et al., 2014).   Constipation should always be expected with opioid 
therapy because tolerance to this effect develops much more slowly (Collett, 1998).  
Those patients who are able to tolerate the nausea, sickness and drowsiness until 
tolerance to these symptoms develops will probably experience them again if and 
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when the dose is increased.  Overall it is suggested that between a quarter and a half 
of patients will withdraw from opioid therapy because of adverse effects (Moore and 
McQuay, 2005; Kalso et al., 2004). 
 
Opioids also have a range of other significant but less obvious side effects.  These 
include cognitive impairment, sleep disturbance, effects on the immune system – 
itching, effects on the endocrine system – fertility, sex drive (hypogonadism), cortisol 
production and reduction in bone density (Baldini, Von Korff and Lin, 2012; Benyamin 
et al., 2008). 
 
There is one other point which is possibly relevant to opioid prescribing in the 
treatment of chronic pain.  It is reported that when equivalent doses of sustained 
release (S/R) and immediate release (I/R) opioid formulations are used to treat 
chronic pain S/R preparations are a greater driver towards hypogonadism than I/R 
formulations (Rubinstein, Carpenter and Minkoff, 2013).  This suggests that opioid 
side effects are not only related to the medication itself but also to the dosing 
regimen used. 
 
Opioid tolerance (OT) is an inevitable neuroadaptation of continuous and/or long-
term opioid therapy and it may even start with the first dose (Kornetsky and Bain, 
1968).  It is defined as the gradual loss of analgesic efficacy over time. (Collett, 1998; 
Freye and Latasch, 2003; Chu et al., 2012; Morgan and Christie, 2011).  The effects 
of tolerance to the different opioid side effects i.e. nausea, analgesia, respiratory 
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depression and constipation can be observed developing at varying speeds 
(Hayhurst and Durieux, 2016; Steinberg, 2017; Volkow, Benveniste and McLellan, 
2018).  This can be advantageous in clinical practice where tolerance to respiratory 
depression develops more quickly than to analgesia.  It is suggested that opioid 
tolerance can be reduced by ‘switching’ between different opioids (CADTH, 2017; 
Mitra et al., 2013; Gatti et al., 2010; Quigley, 2004) 
 
In some patients ongoing opioid therapy can also lead to opioid induced hyperalgesia 
(OIH).  This is a clinical condition in which the patient’s nociceptive receptors are 
sensitised in some way by exposure to opioids, thereby, paradoxically, causing them 
to feel greater pain (Lee et al., 2011; Ballantyne and Mao, 2003; Hayhurst and 
Durieux, 2016).  The differential diagnosis between OT and OIH can be difficult and 
is out with the scope of this thesis.  Either can lead to an apparent decrease in the 
efficacy of opioid analgesia and therefore an increase in the patient’s pain (Tawfic, 
Faris and Date, 2013).   
 
Opioid tolerance is specifically reported as a problem for chronic pain patients where 
there is an aspiration that a reduction in pain would lead to improved physical 
functionality (McAllister, 2016).  In such patients the continuous dose escalation, 
needed to overcome the development of tolerance/hyperalgesia, is not a real 
therapeutic option because of the increase in dose related opioid side effects 
(Baldini, Von Korff and Lin, 2012; Brennan, 2013).  As an alternative to ever 
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increasing doses others have reported phasing out the opioid therapy can lead to a 
reduction in pain (Baron and McDonald, 2006).   
 
The development of tolerance may not be inevitable and it is reported that continuous 
exposure caused greater tolerance than intermittent exposure (Duttaroy and Yoburn, 
1995; Morgan and Christie, 2011).  Ballantyne (2017) suggested that in the treatment 
of chronic pain occasional or intermittent use of opioids may provide equivalent or 
better analgesia, with the development of less tolerance.  In addition, patients often 
report a preference for intermittent therapy, because it allows them to tailor their 
analgesia more closely to their needs, enabling them to focus on their life rather than 
their pain (Fine, Mahajan and McPherson, 2009).  The availability of both I/R and S/R 
formulations within an individual’s analgesic regimen can facilitate an equi-analgesic 
state with a lower overall opioid dose (Ghodke et al., 2017). 
 
High efficacy opioids are reported to demonstrate less tolerance than low-efficacy 
opioids (Morgan and Christie, 2011) but this is not necessarily the case in practice.  
When used as transdermal formulations the use of the high-efficacy fentanyl 
demonstrates a greater development of tolerance than the low-efficacy 
buprenorphine (Sittl, Nuijten and Poulsen Nautrup, 2006).   It is suggested that this 
apparent contradiction may be due to the buprenorphine’s lower potential for down 





Prescribed opioids also carry the on-going risk of dependence and addiction (Morgan 
and Christie, 2011).  Patients frequently ask about the addiction potential of all pain 
medicines, not just opioids, because they conflated messages about opioids with 
other groups of medicines.  Such misinformation makes the job of educating patients 
about the possible side effects of their pain medicines even more challenging. 
1.6.2.1. Codeine 
Codeine is generally classified as a mild/moderate opioid analgesic.  When used for 
analgesia the BNF suggests a dose of 30mg-60mg up to four times a day as 
required. It has a potency of approximately one tenth of morphine. 
 
Codeine is inactive and needs to be bio-transformed by CYP2D6 enzymes into active 
compounds such as morphine before it is effective.  For patients who are slow 
metabolisers (Table 1.1) the analgesic response would develop slowly, if at all.  For 
those who are ultra-rapid metaboliser the effect would peak very quickly and then 
fade.   
1.6.2.2. Dihydrocodeine 
Dihydrocodeine has similar analgesic properties to codeine but does not require bio-
transformation.  When used for analgesia the BNF suggests is a maximum daily dose 
of 240mg.  The frequency of dosing and the size of the individual dose are 





There is a perception that dihydrocodeine may be more addictive than codeine.   
Roussin, Plalmaro and Lapeyre-Mestre (2016) reviewed this and reported that there 
had been no evaluation of experimental data regarding its abuse potential. 
1.6.2.3. Tramadol 
The BNF describes tramadol as an opioid for moderate to severe pain, but NICE 
classifies it as a mild/moderate opioid analgesic (NICE, 2015b) and recommends it 
as a rescue pain medicine in the treatment of neuropathic pain (NICE, 2013b).  It is 
included in the local Stoke guidance for the treatment of chronic non-malignant pain 
as a moderate analgesic (Njoku, Rosam and Ashworth, 2017).  McQuay et al. (1997) 
report from a meta-analysis that the NNT for a 50% reduction in pain using tramadol 
50mg (NNT = 8) is about half that of codeine 60mg (NNT = 17).  
 
NICE Clinical Knowledge Summaries (CKS) report that there is evidence that 
tramadol is effective for treating back pain and osteoarthritis.  The side effects are 
similar to codeine or dihydrocodeine but the possibility of drug interactions are 
greater (NICE, 2015b) 
 
The marketed tramadol product is a racemic mixture of (+) and (-) enantiomers.  
These enantiomers act directly upon two different receptor systems.  The (+) 
enantiomer is more selective for inhibiting serotonin reuptake whilst the (-) 
enantiomer is more selective for inhibiting the reuptake of noradrenaline.  The Mu 
 
 42 
opioid activity was almost entirely due to the o-desmethyltramadol metabolite.  The 
bio-transformed (+) enantiomer showing more analgesic potency than its (-) partner 
(Gibbison, Bailey and Klein, 2015; Dayer, Desmeules and Collart, 1997; Grond et al., 
1999).  The biotransformation of tramadol to the active O-desmethyltramadol uses 
the polymorphic CYP2D6 pathway.  This effect is not quite as clear-cut as with 
codeine because of tramadol’s other actions (Smith, 2011).  Therefore, in a similar 
way to codeine patients who are slow metabolisers may be poorly served by 
tramadol. 
 
Only about 30% of the analgesic action of tramadol are reversed by naloxone 
(Gibbison, Bailey and Klein, 2015).  Therefore, other mechanisms must be involved.  
The effects on serotonin and noradrenaline have already been mentioned.  In 
addition, it is suggested that tramadol has some activity at the N-methyl-D-aspartate 
(NMDA) receptor and that this action contributes to tramadol’s reported effectiveness 
in the treatment of neuropathic pain (Hollingshead, Duhmke and Cornblath, 2006; 
Hara, Minami and Sata, 2005).   
 
Tramadol’s effect on serotonin and noradrenaline reuptake increases the potential 
range and severity of side effects up to and including serotonin syndrome (Duehmke 
et al., 2017).  When used for analgesia the BNF suggested a licensed maximum daily 
dose of 400mg.  In the treatment of neuropathic pain NICE suggests that tramadol be 




Morphine is the standard against which the potency of all other opioid analgesics are 
equated/measured.  It may be prescribed orally as liquid, I/R or S/R preparations.   
 
The main routes of metabolism and excretion for morphine are glucuronide 
conjugation at the 3- or 6- hydroxyl groups (Christrup, 1997).  Morphine glucuronides 
are excreted via the kidneys.  Morphine-6- glucuronide (M6G) is 10-20 times more 
potent than its parent compound.  It has been reported that the majority of the 
analgesic effect of a dose of morphine results from the action of the M6G and 
therefore a patient’s optimum dose of morphine may, in some way, be related to their 
kidney function (Klimas and Mikus, 2014).  Therefore the dose of morphine should be 
reviewed regularly in patients with kidney failure (Neerkin, Brennan and Jamal, 
2006).  A proportion of the M6G passes out with bile into the intestine, from where it 
may be recirculated.  Between 7% and 10% of a dose of morphine is excreted in the 
faeces  (Stain-Texier, Sandouk and Scherrmann, 1998; FDA, 2012).   
1.6.2.5. Oxycodone 
Oxycodone is a partial pro-drug.  The parent compound is responsible for the largest 
proportion of the analgesia.  Some of the dose is bio-transformed by CYP2D6 to 
oxymorphone, which exhibited significant analgesic activity.  Therefore, it is 
suggested that patients who are slow metabolisers may have an altered response to 




On occasions it is necessary to change from one opioid to another and approximately 
equivalent doses were required.  For example, the BNF recommends that for oral 
dosing 10mg of morphine equates to 6.6mg of oxycodone.  On the other hand, the 
manufacturers suggest 10mg of morphine equated to 5mg of oxycodone and this 
particular ratio is supported by the West Midlands Palliative Care Physicians (NHS, 
2012).  Such conversion factors need to be approached with care.  Arbitrary equi-
analgesic dose ratios cannot take account of the genetic make-up, other metabolic 
differences and the tolerance status of individual patients.   
1.6.2.6. Buprenorphine  
Buprenorphine is used both as a transdermal patch and as a buccal/sublingual tablet.  
As a transdermal formulation its potency is approximately 80 times morphine.  The 
time to steady state depends upon the formulation used and is up to 60 hours and 
half-life after removal up to 36 hours.  For sublingual use its potency is approximately 
50 times morphine.  The buccal tablet had a bioavailability of 50% and is initially 
effective in about 30min.  This time increases significantly on repeat dosing.  Such a 
delay means that this formulation is not ideal for treating breakthrough pain (Foster et 
al., 2013).    
 
Buprenorphine is a partial agonist – antagonist and it is suggested that this 
combination has advantages in reducing some of the side effects associated with 
strong opioids.  It is claimed that buprenorphine is safe for use in renal impairment 
 
 45 
(Boger, 2006; Forrest and Kuczynska, 2016).  Therefore the transdermal formulation 
is often regarded as appropriate for elderly patients (Vadivelu and Hines, 2008). 
 
For those who can tolerate the systemic effects of buprenorphine, there is one 
additional adverse effect with the transdermal formulation, which can be troublesome 
i.e. a localised allergic reaction to patch.  This can be sufficiently acute to generate a 
blister and therefore termination of therapy.  Although the adhesive has been blamed 
for some of these occurrences, there are reports of a delayed hypersensitivity 
reaction to buprenorphine (Kyrklund, Hyry and Alanko, 2013).   
 
The major metabolite of buprenorphine is norbuprenorphine.  This and the parent 
compound are conjugated prior to excretion (Smith, 2011).  There is evidence of 
some enterohepatic circulation of buprenorphine (Cone et al., 1984; Foster et al., 
2013) which helps maintain its steady plasma levels and long biological half-life. 
1.6.2.7. Fentanyl 
Fentanyl is available as a transdermal patch, and as nasal spray and buccal 
preparations for more immediate effects.  The transdermal formulation has a potency 
of about 100 times morphine.  Time to steady state blood levels from a patch is 12-16 
hours with half-life of 16-22 hours after removal (Kornick et al., 2003) shorter that for 
a buprenorphine patch.  Bioavailability of the nasal spray is approximately 90% 
reaching an effective dose within 11-20minutes.  This makes the nasal route for 
fentanyl suitable for acute breakthrough pain.  For buccal preparations the 
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bioavailability varies between 50% and 70% with a much longer time to an effective 
dose 30-240minutes (Kuip et al., 2012).  The buccal preparations contain sucrose 
and therefore appropriate oral care is necessary.   
 
Fentanyl patches do not generally cause a local dermal allergenic response, but 
there are on-going problems with the adhesion of the patch.  Absorption of the drug 
from the patch varies with body temperature, skin type and placement.  Therefore, 
patients sometime experience variance in their dose after exercise, bathing or sitting 
in the sun, which was case reported as significant (Sindali et al., 2012).   
 
Fentanyl is more than 99% metabolised to norfentanyl by the CYP3A4 system but 
there is no evidence that any of the metabolites were active.  Therefore, conditions or 
medicines which alter the enzymatic profile of the liver have the potential to alter 
clearance of fentanyl (Smith, 2009). 
1.6.2.8. Tapentadol  
Tapentadol has a dual mode of action.  It interacts with the Mu opioid receptor and 
inhibits the reuptake of noradrenaline, neither of which require any bio-transformation 
(Langford et al., 2016).  It has an analgesic potency somewhere between Tramadol 
and Morphine. 
 
The double action of tapentadol, suggests that, as with tramadol, it may be effective 
in the treatment of neuropathic pain (Sugiyama et al., 2018).  Early reports indicate 
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that it will probably have a place in therapy but evidence is still scarce (Baron et al., 
2016; Langford et al., 2016; Vranken, 2015; Coluzzi et al., 2017; Reimer et al., 2017; 
Sugiyama et al., 2018).  It is licensed for use ‘third line’ in treatment of painful 
diabetic neuropathy in the US in 2013 (Games and Hutchison, 2013).  It has recently 
been added to local Stoke chronic pain guidance (Njoku, Rosam and Ashworth, 
2017) as a suggested treatment for neuropathic pain and is therefore beginning to be 
prescribed by local GPs in Staffordshire.   
1.6.3. DRUGS USED FOR THE TREATMENT OF NEUROPATHIC PAIN  
This section will address the available adjuvant medicines prescribed for the 
treatment of neuropathic pain.   
 
There are five medicines recommended in the BNF which may be used for the 
treatment of neuropathic pain; amitriptyline, nortriptyline, pregabalin, gabapentin and 
duloxetine.  The reported NNTs and NNHs for these medicines (Table 1.2) provide 











Table 1.2 NNT & of NNH medicines used in the treatment of neuropathic pain 
With placebo and tramadol included for comparison (Haroutounian and Finnerup, 
2018).   
 
Type of pain medicine NNT (95%Cl*) NNH (95%Cl*) Achieved analgesia 
with placebo (%) 
Tricyclic 
antidepressants 




6.4 (5.2-8.3) 11.8 (9.6-15) 
  
278/982 (28%) 
Gabapentin 7.2 (5.9-9.1) 25.6(15-79) 291/1430 (20%) 
Pregabalin  7.7 (6.5-9.4) 13.9 (12-17) 578/2410 (24%) 
Tramadol 4.7 (3.6-6.7) 12.6 (8.4-19) 96/361 (27%) 
 
* Confidence limits 
 
Overall, tricyclic antidepressants (TCAs) have the lowest NNT and a similar NNH to 
others in this group.  Tramadol has the second lowest NNT with an NNH in line with 
other medicines.  Gabapentin stands out as having the best NNH, much better than 
pregabalin.  For clinical practice this would suggests that the initial therapeutic option 
should be either a TCA or gabapentin.  The final choice between the two then being 
made by other factors such as medicines interactions with TCAs, the possibility of 





These figures also highlight that in the treatment of neuropathic pain, the 
recommended medicines were demonstrably effective in only a minority of patients.  
This table also includes data from trials which included a placebo arm.   
 
These data presuppose that all neuropathic conditions are treatable in the same way 
and this may or may not be the case.  Mendlik and Uritsky (2015) suggested that 
varying the medicine can sometimes bring unexpected benefits and needs further 
explanation.  This also gives support to Smith et al. (2012) whose Delphi study 
reported that at least four different medicines should be assessed before any 
neuropathic condition can be regarded as resistant to treatment. 
1.6.3.1. Tricyclic anti-depressants (TCA) 
There are two TCAs which are included in guidance for the treatment of neuropathic 
pain, amitriptyline a tertiary amine and the secondary amine nortriptyline.  They are 
differentiated pharmacologically by the ratio of 5-HT to noradrenaline reuptake 
inhibition.  Amitriptyline is regarded as a non-selective inhibitor whereas nortriptyline 
is noradrenaline selective.  Amitriptyline is licensed for the treatment of chronic pain 
(NICE, 2018).  If this demonstrates too much sedation then nortriptyline may be more 
acceptable.  In 2010 the International Association for the Study of Pain suggested 
that secondary amines, such as nortriptyline could be used in preference to the 
earlier tertiary products such as amitriptyline in an effort to minimise some of the side 
effects (Dworkin et al., 2010).  A Cochrane review in 2015 found no evidence that 
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nortriptyline was effective in the treatment of chronic pain in adults (Derry et al., 
2015).  
 
The side effects of both these TCAs relate to their antimuscarinic activity including 
dry mouth, sedation, blurred vision and vivid dreams (Bryson and Wilde, 1996).  
Paradoxically, some patients who take amitriptyline regarded the sedation as a 
bonus, because after a good night’s sleep they are better able to face their pain the 
following day.   
 
The mechanism of action of TCAs in the treatment of chronic pain is still not fully 
understood.  The major effect appears to be related to an increase of inhibitory 
serotonin neurotransmitters in the spinal column.  There is also some evidence that 
these medicines exert a direct effect on opioid and NMDA receptors (Onali, Dedoni 
and Olianas, 2010; Lawson, 2017). 
 
The major metabolic pathway for these TCAs is via the liver and as with opioids 
involves both 2D6 and 2C19 variants of the CYP pathway.  Therefore, the 
polymorphic state of individual patient may make it difficult to find the optimal 
therapeutic dose.  The ethnic variation in the 2D6 variant was mentioned above 
(Section 1.6.2) i.e.  6-10% of Caucasians, 2-5% of African Americans and 1% of 
Asians are classified as slow metabolisers.  For the 2C19 variant 3-5% of 
Caucasians and 12-23% of Asians are regarded as slow metabolisers (Ma, Woo and 
McLeod, 2002).  The situation becomes more complicated in older people.  The CYP 
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transformation of these medicines results in the formation of polar compounds, to 
facilitate renal excretion.  As patients age, renal clearance may become an issue 
(Rudorfer and Potter, 1999).   
 
In the treatment of chronic pain TCAs are usually taken once a day in the early 
evening to minimise sedation the following morning.  The half-life varies between 12 
hours and 36 hours (Bryson and Wilde, 1996). The possibility of genetic variations in 
the rate of metabolism and excretion of TCAs may explain why the timing of the dose 
can be crucial to the tolerability of these medicines (Rudorfer and Potter, 1999; 
Ingelman-Sundberg, 2011). 
 
All medicines in this group can have cardiac side effects and in overdose can cause 
cardiac arrest.  They should therefore be avoided in patients with concomitant 
cardiac disease. 
1.6.3.2. Gabapentinoids 
Pregabalin and gabapentin are both licensed for the treatment of neuropathic pain.  
They are structural analogues of gamma amino butyric acid (GABA) but do not 
appear to exert their analgesia via this system.  They selectively bind to the a2a1 
and a2a2 subunits of the voltage activated calcium channels (Bockbrader et al., 
2010) and act as calcium channel modulators, reducing the entry of calcium into the 
cell.  The action at this receptor increased the levels of L-glutamic acid 
decarboxylase, which in turn increased the level of extracellular GABA.  They act in 
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several different places in the CNS, but how these actions mediate the analgesic 
effects of these medicines is not fully understood  (Baillie and Power, 2006; Patel and 
Dickenson, 2016).  NICE guidance indicates that if pain control is poor, therapy 
should be switched between all four medicines recommended for the treatment of 
neuropathic pain (amitriptyline, duloxetine, gabapentin and pregabalin) until an 
effective therapy has been found or all four have been tried (NICE, 2019). 
 
The bioavailability and pharmacokinetics of these two medicines are different.  
Gabapentin is only absorbed in a short section of the duodenum: therefore, the 
bioavailability goes down as the dose increases (FDA, 2009).  Pregabalin is 
absorbed throughout the small intestine, which leads to a more consistent outcome 
(Narayanan, Venkantaraju and Jennings, 2015).  They both bear a structural 
similarity to L leucine, which allows for facilitated transport across cellular 
membranes.   
 
The metabolism of both of these drugs is independent of liver enzymes.  They are 
excreted almost entirely (98%) unchanged via the kidneys.  This means that there 
are less opportunities for drug interactions, but care is necessary in patients with 
reduced kidney function. 
 
Side effects that patients reported for both medicines included weight gain, sedation, 
memory loss, visual effects, irritability and erectile dysfunction.  However, clinical 
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practice suggests that there are many interpatient differences between the efficacy 
and tolerance of these two medicines.   
 
It is recommended that the doses of these two gabapentinoids be increased slowly 
and titrated to the patient’s response starting from 25 or 50mg pregabalin and 100 or 
300mg gabapentin depending upon the initial side effects.  The onset of analgesia is 
slow and so there appears to be little need for a rapid dose escalation (Hall, 2016). 
Some published guidelines for the treatment of chronic pain suggested that dose 
increases of gabapentin beyond 50% of the maximum should be done after 
consultation with a member of a chronic pain team (NHS, 2016; NHS, 2019c).  Other 
guidelines specifically suggest that if there is no response after titration to 50% of the 
maximum dose, the therapeutic choice should be reconsidered (Njoku, Rosam and 
Ashworth, 2017).  Evidence for these recommendations is lacking and therefore they 
are included as generalised local comments.   
1.6.3.3. Duloxetine 
Duloxetine is a serotonin and nor-adrenaline re-uptake inhibitor antidepressant, 
which is licensed for the treatment of diabetic neuropathy.  Duloxetine has an NNT of 
6.4 in the treatment of diabetic neuropathy (Haroutounian and Finnerup, 2018) and 8 
in the treatment of fibromyalgia (Lunn, Hughes and Wiffen, 2014).  This report goes 
on to suggest that the benefit for fibromyalgia sufferers may be more related to an 




The major metabolism of duloxetine was to 4, 5 or 6 hydroxy duloxetine via CYP1A2 
and CYP2D6 pathways.  The 2D6 pathway is polymorphic but any variation would be 
too small to be clinically significant (Knadler et al., 2011). 
 
Duloxetine is effective in the treatment of neuropathic pain, but trials comparing it 
with other anti-depressants such as venlafaxine have not suggested which might be 
best (Saarto and Wiffen, 2007; Lunn, Hughes and Wiffen, 2014).  Most patients who 
are treated with this medicine will suffer with at least one side effect such as 
dizziness, drowsiness and constipation (Lunn, Hughes and Wiffen, 2014). 
1.6.4. NON-STEROIDAL ANTI-INFLAMMATORY MEDICINES (NSAIDS) 
NSAIDs are classified as mild/moderate analgesics, with antipyretic and anti-
inflammatory effects.   They elicit more side effects than paracetamol both with 
regard to frequency and severity (Davis and Robson, 2016; Day and Graham, 2013).  
Because of their similarity, these medicines will be considered together rather than 
individually 
 
NSAIDs act mainly by inhibiting the actions of the cyclooxygenase-1 (COX-1) and 
cyclooxygenase-2 (COX-2) enzyme pathways.  Most of the medicines in this class 
are non-selective and effect both COX-1 and COX-2 but a few e.g. celecoxib and 




Cyclooxygenase enzymes are responsible for the transformation of arachidonic acid 
into prostanoids: prostaglandin, prostacyclin and thromboxane, which are short lived 
and therefore act either at the point of generation or initiated a signal from that 
location.  Therapeutic treatment with NSAIDs therefore reduces the formation of 
these active moieties in areas where the COX enzymes systems are extant 
(Cashman, 1996).  In addition, there are reports which indicate that the benefits of 
NSAIDs may also involve the, cannabinoid, nitric oxide (NO), noradrenaline, 
serotonin and cholinergic receptor systems (Hamza and Dionne, 2009).  The COX-1 
enzyme system is present in most bodily systems and the side effects of NSAIDs 
with this mechanism of action include irritation of the gastric lining and an increase 
risk of renal failure.  The COX-2 enzyme, on the other hand, is ‘induced’ in response 
to injury and the NSAIDs which are selective for this mode of action are much less 
likely to cause gastric irritation but the risk of renal failure remains the same and they 
are associated with an increased risk of heart attack and stroke. 
  
The overall analgesic effect of these medicines probably depends upon the way that 
they interact with COX systems in the painful areas of each individual.  This mode of 
action means that they will have maximal effect where inflammation is involved and 
limited efficacy against neuropathic pain (Hall, 2016; Moore et al., 2015a; Hamza and 
Dionne, 2009; Cashman, 1996).   
 
When diclofenac was taken in combination with paracetamol in a double-blind study 
of patients 120 patient with moderate to strong pain the analgesic efficacy was better 
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than either medicine alone (Breivik, Barkvoll and Skovlund, 1999).  Such a result 
would suggest that there is more than one mechanism at work.  However, it is also 
reported that their use in this way causes an increased incidence of side effects: 
increases in blood pressure and the incidence of cardiovascular events.  Therefore 
their use in this way should probably be avoided (Brune and Hinz, 2011). 
 
Non-specific COX inhibitors such as ibuprofen or naproxen will cross the blood-brain 
barrier and will therefore exert an influence on the levels of brain prostaglandins, 
which will be part of their mechanism of action (Burian and Geisslinger, 2005; 
Ajmone-Cat et al., 2010).   
 
Most NSAIDs are metabolised in the liver by oxidation and conjugation and excreted, 
mainly via the kidneys.  The polymorphic CYP2C9 enzyme system is involved in the 
metabolism of NSAIDs.  Up to 8% of Caucasians have variants, which mean that 
dose adjustment may be necessary (Ma et al., 2016).  The BNF recommends that if 
one NSAID is ineffective then it is worth assessing a second. 
 
The number and range of side effects associated with these medicines (Day and 
Graham, 2013; Davis and Robson, 2016) are related to the importance and 
distribution of the COX enzyme system within the body.  Cardiovascular side effects 
include an increase in systolic blood pressure and a doubling of hospital admissions 
for heart failure (Davis and Robson, 2016).  In patients with cardio-vascular disease it 
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is reported that they caused more deaths than road traffic accidents  (Davis and 
Robson, 2016). 
 
NSAIDs are often regarded as contraindicated in patients with asthma (Sturtevant, 
1999).  Further work is required to understand the full extent of this problem.  21% of 
patients are reported as suffering with aspirin induced asthma that is cross sensitive 
with up to 100% of NSAID treated patients (Jenkins, Costello and Hodge, 2004).   
Others have suggested that only 10% of patients would suffer with aspirin induced  
asthma and between 80 and 90% of adult asthma patients would be able to tolerate 
aspirin and NSAIDs with appropriate warnings  (Wan, 2012).   
  
Renal side effects of NSAIDs included changes in renal function and rarely, papillary 
necrosis (Whelton and Hamilton, 1991) especially when taken in combination with 
other analgesics (Elseviers and De Broe, 1998).  Systematic reviews have tried to 
assess the risks and prescribers have been reminded that NSAIDs can accelerate 
the progression of chronic kidney disease and to prescribe the lowest effective doses 
(Nderitu et al., 2013).  More recently, because of the widespread use of these 
medicines, there have been calls for further research to determine the absolute risk 
of using NSIADs, especially in older people (Zhang et al., 2017; Davis and Robson, 
2016).  An NHS Medication safety dashboard (NHS, 2018b) reported that from 
amongst 1,000 patients over 65 who were prescribed an NSAID without some form 
of gastric protection approximately one will be admitted to hospital with a ‘gastric 
 
 58 
bleed’.  More recently still the NHS has set out an action plan to improve medicines 
safety and NSAIDs are the 1st to be considered (NHS, 2019a). 
 
For patients with chronic pain who were also taking a prophylactic dose of aspirin 
75mg the addition of an NSAID needs to be considered even more carefully.  The 
action of the NSAID may inhibit the cardio-protective role of the aspirin and increase 
the risk of intestinal bleeding (Rodriguez et al., 2016; Nalamachu et al., 2014).  
Catella-Lawson et al. (2001) reported that ibuprofen but not diclofenac antagonises 
the benefit of low dose aspirin.  A report in 2014 suggested that the most common 
cause of a drug-drug interaction, between an ‘over the counter’ (OTC) (Section 8.2) 
and a prescribed medicine, in the elderly was between aspirin and diclofenac 
(Schmiedl et al., 2014). A prospective analysis of 18,820 hospital admissions on 
Merseyside was published in 2004.  It reported that two medicines, which caused the 
greatest number of adverse reactions warranting an admission to hospital were 
NSAIDs and Aspirin.  (Pirmohamed et al., 2004) and this become more significant as 
the patients age increases (Seager and Hawkey, 2001).  As a result, because the 
majority of patients suffering with chronic pain were in older age groups, the selection 
of these medicines should be considered carefully and Hall (2016) suggests that their 
use should probably be restricted to when pain flares.  Such a use would be in line 




1.6.5. TOPICAL TREATMENTS FOR PAIN 
If pain is limited to one particular site such as a knee, a post-herpetic area or the 
soles of the feet, there may be benefit in treating that area with a topical agent rather 
than by systemic administration.  There are potentially three agents to choose from, 
NSAID gels, lidocaine plasters and capsaicin creams and plasters, depending upon 
the type of pain being treated.  
 
A Cochrane review (Derry et al., 2016) reports that for a minority of patients with 
chronic osteoarthritis NSAID topical gels provide a good levels of pain relief but there 
is no evidence for their use in non-arthritic conditions.  The authors also noted that 
there is an apparent placebo effect from the gel itself.  It is important with these 
preparations to calculate the total dose of active ingredient which is applied to ensure 
that it remains below that which would have been taken orally.  Medicines, which are 
applied to the skin are perforce absorbed systemically, en-route to elimination.  
Patients for whom NSAIDs are truly contraindicated should avoid these medicines. 
 
Lidocaine 5% medicated plaster is licensed for pain due to ‘Post-herpetic neuralgia’ 
(PHN) (NHS, 2017b; Goddard and Reaney, 2018).  Patches should be applied to the 
skin for 12 hours and then removed for 12 hours.  
 
Capsaicin 0.075% cream is licensed to treat pain due to ‘Post-herpetic neuralgia’ and 
under expert supervision painful diabetic neuropathy (NICE, 2011).  Care is always 
necessary with these products to ensure that the active medication is not transferred 
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to ‘personal’ mucus membranes or superficially to (significant) others, from and to 
unprotected areas.  There is also a capsaicin plaster 8% which is licensed for focal 





CHAPTER 2 SYSTEMATIC REVIEW 
2.1. Introduction 
This chapter will set out the methodology of the systematic review, its search terms, 
the robustness of the results returned and the possibility of bias.  The application of 
the selection criteria to the papers returned will then be addressed.  The papers in 
the exiting systematic reviews will then be examined in detail.  This will be followed 
by a detailed examination of the papers selected to be included in this systematic 
review, the determination of the topics for the narrative synthesis and their 
contribution to this research topic.   
2.2. The rationale for this systematic review 
Background reading for the research pharmacist’s place in the CPT revealed that the 
literature about this role had been reviewed twice in the relatively recent past.  Firstly, 
‘Educational interventions by pharmacists to patients with chronic pain’ (Bennett et 
al., 2011) and secondly, ‘Effectiveness of pharmacist-led medication review in 
chronic pain’ (Hadi et al., 2014a).  Most of the references reported in these two 
reviews related to pain with a specific diagnosis.  Therefore, this systematic review 
aims to update those reviews by searching for literature, not previously included, 
about the role of a pharmacist working in a chronic pain team, with patients whose 
pain is generally without a diagnosable cause.  This systematic review will then 
consider whether the medicines advice, which can be offered by a pharmacist in a 
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CPS, results in any improvements in the patient’s pain and through an educational 
intervention, their understanding of pain medicines. 
2.3. The systematic review 
2.3.1. METHODOLOGY 
2.3.1.1. The search terms 
The search terms were chosen to represent the type of role and intervention carried 
out by the researcher and other pharmacists working with patients in a face to face 
role within a CPT.   
 
The context for the intervention in this research is patients being treated for their 
chronic pain by a multi-professional CPT in face to face consultations.  The selection 
of patients and the problems that they reported to the pharmacist, were to some 
extent driven by the referral (to the pharmacist) criteria extant within the CPT 
(Section 4.4).   
 
The explanation of the role of medicines in the treatment of chronic pain is carried out 
in the South Staffordshire CPS by the research pharmacist but in other CPTs this 
may be undertaken by other HCPs e.g. physiotherapists, therefore the search terms 




The focus of the pharmacist’s intervention is around medicines education and 
change in medicine taking behaviour, therefore medicines and analgesia were 
included.   
 
The target cohort of patients in this research were suffering with chronic pain and 
who were attending a clinic based chronic pain service.  This was covered by the 
search terms. 
 
The search terms used were  
 
Ø Pharmacist* OR physiotherapy* OR multi* 
Ø Medicine* OR analgesi* 
Ø Chronic AND pain AND clinic 
 
A model search using these search terms is included at Appendix 8.5.  The same 
search terms were used for each data base. 
 
A general literature search together with an appreciation of the historical 
development of pain services for patients had demonstrated few publications relating 
to this type of clinical pharmacy role prior to 2000.  It was therefore decided that the 




Seven data bases were searched CINHAL, Cochrane, Embase, International 
Pharmacy Abstracts (searched up to the date of termination) Ovid Medline, Ovid 
Psychinfo and Web of Science.  Searches were also undertaken on OpenGrey and 
Bielefeld Academic Search Engine (BASE).  At the same time a weekly Google 
Scholar alert’ with the terms for ‘pharmacist’ and ‘chronic pain’ was initiated. 
 
The inclusion criteria for titles was based upon the practice of the research 
pharmacist as set out above - a medicines review for patients with chronic pain, with 
no detectable damage or illness or whose pain intensity bore no relation to the extent 
of any detectable damage or illness, referred to the pharmacist’s clinic, for a face-to-
face clinic consultation.  
 
The exclusion criteria were non-English texts and papers that did not relate to adults 
(18 years and over).  No research papers returned by the search process was 
rejected for either of these two reasons.   
 
In the United States there is an increasing problem with the abuse of prescription 
opioid analgesics with the pharmacist becoming involved in maintaining the security 
of the supply of opioid analgesics to patients with chronic pain.  Those papers which 




2.3.1.2. Robustness of the results 
Each of the papers which came through into the final selection were then assessed 
for robustness of the evidence which it might contribute to this systematic review.  
Only two of the papers, which covered different aspects of the same research, 
involved a randomised controlled trial (RCT).  In addition, there was no new robust 
data which added to our knowledge about the benefits which a pharmacist could 
bring to a CPS and which could reasonably be considered suitable for meta-analysis.  
Therefore, the decision was taken that this work would be presented as a Systematic 
Review with a Narrative Synthesis.   
 
The UK Economic and Social Research Council (ERSC) has proposed a method to 
improve the quality of narrative approaches to evidence synthesis, which is widely 
used including in Cochrane reviews (Popay et al., 2006).  Within this guidance there 
is use of the Jadad scale (Jadad et al., 1996) which uses three yes:no answer 
questions to grade published papers into five groups.  The patients must be 
randomised, the research must be double blinded and there must be information 
about withdrawals and dropouts.  Additional points are awarded for appropriateness 
of the randomisation and the blinding and points withdrawn if these are not 
appropriate.  The scores range from 0-very poor to 5-rigorous.  A Jadad score was 
determined for each of the papers in this systematic review. 
 
The simplicity of this approach has been criticised because it makes no mention of 
allocation concealment which is necessary to minimise the subconscious allocation 
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of patients to appropriate groups and which Cochrane considers important (Popay et 
al., 2006).  Other systems for grading the robustness of clinical trial data are 
available such as the Delphi expert consensus route or the CONSORT checklist.  
Neither of these systems claim that they are suitable for rating the quality of research 
evidence, but have on occasions been used for this purpose. (Berger and Alperson, 
2009).   
 
The methodology for incorporating research results into reviews needs to be more 
structured (Docherty and Smith, 1999).  But if it is to increase the quality of research 
outcomes being incorporated into reviews or other guidelines and thereby improve 
the evidence base of therapy it must depend upon some type of scoring system.  The 
robustness of any rating score used in a systematic review and/or meta-analysis will 
always depend upon the extent and validity of the information contained within the 
papers, the rigorousness of the execution in the original research as well the 
interpretation of the reporting by the reviewer (Berger and Alperson, 2009).  Berger 
and Alperson (2009) conclude with suggestions for the points which should be 
considered in any evaluation system: each trial outcome must be analysed effectively 
and comprehensively, scores allocated only when scores are justified and differences 
in scores accentuated by using a multiplier rather than an additional sequence.  Then 
because it is very important to stop results which are less reliable from being carried 




2.3.1.3. Risk of bias 
Cochrane promulgates a set of eight questions, each with a four point answer yes, 
maybe yes, maybe no and no, to determine the extent of the bias in a research 
project (Cochrane, 2018).  Each paper in this systematic review was rated from the 
information available for the risk of bias.   
2.4. The results 
A flow diagram of the process for inclusion and exclusion is included below Figure 
2.1.  The titles of the 585 papers returned from the seven data bases were examined 
for duplications and 244 were removed.  Titles of papers were scanned initially for 
‘pharmacist’ and ‘pain’ and then for ‘chronic pain’.  Where there was doubt about the 
type of pain involved further information was sought from the abstract.  Those papers 
which related solely to pain from a physically attributable cause e.g. arthritis or 
cancer pain were discarded as they were not representative of the cohort seen by the 
researcher.  Where there was doubt the full text was examined to determine the 
presence or absence of chronic pain of unknown origin.  As a result, 268 papers 
were removed.   
 
The titles and abstracts of the remaining 73 papers were then examined in more 
detail for how the pharmacists’ interacted with the patient.  If the context of the 
pharmacist patient interaction was not clear the full text was examined.  Only those 
reporting a face-to-face encounter were retained.  This resulted in a further 63 




Efforts were made to obtain further information from ‘conference’ reports.  No further 
information was forthcoming, related to authors’ pending publications.  The searches 
of the grey literature did not reveal any new publications.   
 
The bibliographies of the papers which came through this selection process were 
also scanned for any additional reports which had not been returned to minimise the 
chance of relevant material being missed.  There were two reports from 
bibliographies, which complied with the selection criteria.  These were included, 







































Figure 2.1 Diagram of the review process 
  
Papers identified  
from searching 
(585) 
Additional papers found 
Bibliographies (2) 
Residue after duplicate 
removal 
(341) 
Papers screened in detail 
(73) 
Records included in the review 
(12) 
Titles and abstracts 
examined for pharmacist 
and (chronic) pain, 
attributable pain 
excluded (268) 
Papers excluded because 
the pharmacist patient 
interaction did not meet the 






2.5. Narrative synthesis 
This section will outline the details of the two existing systematic reviews.  It will then 
address those papers from these reviews which were included in this systematic 
review.  Finally, the twelve retrieved papers in this systematic review will be 
discussed. 
2.5.1. PAPERS INCLUDED IN THE EXISTING SYSTEMATIC REVIEWS 
The two previous systematic reviews were retrieved during the search process, 
Bennett et al. (2011) and Hadi et al. (2014a) and the papers which they included 
were reviewed in the same way as all of the other papers returned by the systematic 
review searches. 
 
The first review by Bennett and colleagues (2011) reviewed four papers which met 
their search criteria of an RCT with a control group who received usual care or 
attention, including patients with chronic pain of any aetiology, who underwent an 
educational intervention and had changes in pain score measured.   
 
The second review by Hadi and colleagues (2014a) reviewed five papers which met 
their search criteria.  Their focus was on RCTs and nonrandomized studies with 
controls.  The intervention of interest was a medication review delivered 
independently by the pharmacist or as part of a multi-disciplinary team.  They 
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included patients with chronic pain as defined by the IASP but excluded patients with 
cancer pain.   
  
An assessment of these two reviews using the NIHR Study Quality Assessment Tool 
of Systematic Reviews and Meta-analysis (NIH, 2018) revealed that the answers to 
each of the eight questions in this tool had been addressed appropriately.  Therefore, 
both systematic reviews met the quality criteria. 
 
The search terms for these two reviews were different to those used for this 
systematic review.  Firstly, both had a requirement for an RCT.  Secondly, there were 
differences in their definitions of pain.  Bennett et al. (2011) included pain of any 
aetiology.  The results published by Hadi et al. (2014a) demonstrated an accent upon 
pain which related to a physically discernible cause even though the search criteria 
suggested pain without apparent biological value.   
 
These systematic reviews only included two papers which were common to both.  
Table 2.1 includes the papers listed in the same order as the original publications, 
with duplicates removed and lays out details of the recorded pain aetiology, patient 





Table 2.1 Articles included in the Bennett et al. (2011) and Hadi et al. (2014a) reviews 
Reference Title Pain aetiology  Sample size Pain score 
0-10 scale 




Pharmacist intervention in 
methadone administration to cancer 






Face to face review 
days 1 and 8 then 
phone 
Gammaitoni et al. 
(2000) 
Palliative pharmaceutical care: a 
randomized, prospective study of 
telephone-based prescription and 
medication counselling services for 








mean 1.2 calls per 
patient 
Hay et al. (2006) Effectiveness of community 
physiotherapy and enhanced 
pharmacy review for knee pain in 
people aged over 55 presenting to 
primary care: pragmatic randomised 
trial 





3 to 6 sessions of 
approximately 20mins 
over 10 weeks  
Petkova (2009) Education for patients with painful 
arthritis: a community pharmacy-






Group sessions led by 
pharmacist educator 
and assistants, 4 





Hoffmann et al. 
(2008) 
Pharmaceutical care for migraine 










Face to face average 2 
hours  per patient 
Bruhn et al. (2013) Pharmacist-led management of 
chronic pain in primary care: results 








Pharmacist review and 
prescribe, pharmacist 
review and refer back to 
GP and treatment as 
usual 
Marra et al. (2012) Pharmacist-initiated intervention trial 
in osteoarthritis: a multidisciplinary 
intervention for knee osteoarthritis 






physiotherapist. Face to 
face consultation  
   
N = number, I = intervention group, C = control group, ( ) number completing, 
*Pharmacist and physiotherapy arm.   







All of these papers included references to a Medicines Utilisation Review (MUR).  
This is a generic term which relates to an interaction between a pharmacist and a 
patient where the benefits of medicinal treatment are discussed, treatment optimised, 
possible side effects minimised and the possibility of waste from unused medicines 
or the inappropriate use of medicines reduced.  The literature contains various 
definitions or interpretations of the MUR process (RPS, 2018; NICE, 2016; PCNE, 
2017; Blenkinsopp, Bond and Raynor, 2012).  The details of the specific MUR 
process used was not always clear in the papers retrieved by these systematic 
reviews. 
2.5.2. RESULTS FROM EXISTING SYSTEMATIC REVIEWS 
Bennett et al. (2011) systematic review studied the effects of an “educational 
intervention” defined as “information, behavioural instruction or advice in relation to 
the management of chronic pain” of at least two and a half hours and reported that 
this was worthwhile, resulting in a pain reduction of 0.5 on a 0 to 10 scale.  The 
review also reported that addressing drug related problems helped to reduce adverse 
(drug) events by 50%.   
 
The Hadi et al. (2014a) systematic review concluded that a “pharmacist led 
medication review” led to a slightly larger pain reduction of 0.8 on a 0 to 10 scale.  
There was no mention of side effects.  In addition, it reported a significant 




There was no consistency or detail of what was undertaken during the MURs 
mentioned in any of the papers in either of these two systematic reviews. 
 
Out of the seven papers included in these two reviews only Gammaitoni et al. (2000) 
related to patients attending a chronic pain clinic and one paper Bruhn et al. (2013) 
included patients with chronic pain of unknown origin.  Gammaitoni et al. (2000) 
research used a telephone-based service and therefore was not carried over to this 
systematic review because it did not meet the requirement for face-to-face 
communication.  The research reported by Bruhn et al. (2013) involved an RCT with 
three arms undertaken in six GP practices, three in East Anglia and three in 
Grampian, Scotland.  The three arms were pharmacist prescribing, pharmacist paper 
review with referral back to the GP and treatment as usual.  The two arms involving 
pharmacists both recorded reductions in pain intensity scores, but only in the 
pharmacist prescriber group was the reduction significant.  The scale used to record 
changes in pain was the seven-point Chronic pain grade scale (CPG) rather than the 
more commonly used 0 - 10 scale.  The use of this tool was justified “based on our 
judgement following an earlier feasibility study”.  Because it met the inclusion criteria 
this paper was included in this review.  No other papers from Bennett et al. (2011) or  
Hadi et al. (2014a) were included in this systematic review. 
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2.5.3. PAPERS INCLUDED IN THIS SYSTEMATIC REVIEW 
The criteria for inclusion in this systematic review were ‘a medicines review for 
patients with chronic pain, with no diagnosable cause, referred to the pharmacist’s 
clinic, for a face-to-face clinic consultation’ (Section 2.3.1.1). 
 
All the included papers were assessed for quality and bias (Cochrane, 2018; Jadad 
et al., 1996) and summary details along with pain scores were presented in Table 
2.2.  The papers were ordered firstly by the quality of the evidence (green) and then 




Table 2.2 Listing of the articles retrieved by this search 
 




1 Bruhn et al. 
(2013) 
Pharmacist-led management 
of chronic pain in primary 




UK, medicinal treatment for chronic 
pain with three intervention arms.   
Pharmacists prescribing group 70, 
pharmacist paper review group 63, 
treatment as usual group 63. 
 
RCT six General Practices 
with prescribing 
pharmacists, three in 
Scotland and three in 
England.   
Medium 2 
2 Neilson et 
al. (2015) 
Pharmacist-led management 
of chronic pain in primary 
care: costs and benefits in a 
pilot randomised controlled 
trial 
UK, medicinal treatment for chronic 
pain with three intervention arms. 
Pharmacists prescribing group 70, 
pharmacist paper review group 63, 
treatment as usual group 63 
A further paper on the 
Bruhn, H. research listed 
above, reporting the costs 
of the separate intervention 
arms 
Medium 2 
3 Hadi et al. 
(2016) 
Effectiveness of a 
community-based nurse-
pharmacist managed pain 
clinic 
UK 79 patients enrolled and 35 
returned. Mixed-method study  
A community-based, nurse-
pharmacist pain clinic for 
adults in the north of 
England  
High 0 
4 Gill, Taylor 
and Knaggs 
(2013) 
Less pain - the result of a 
community pharmacy pilot 
pain service evaluation 
UK pilot 176 enhanced medication 
reviews resulting in 182 
interventions.  Only one interaction 
between each patient and a 
pharmacist 
A community pharmacy-
based study aimed at 
providing an increased level 
of service and information 
to patients suffering with 









Community Pharmacy based 
pharmacist, independent 
prescribing clinic for people 
receiving painkillers 
UK pilot 91 patients enrolled and 
22 returners.  Before and after 
study 
A community pharmacy-
based study involving one 
pharmacy and on one GP in 






Improving the quality and 
access of care for people 
living with chronic pain – 
development of a new model 
of care with Community 
Pharmacy   
UK pilot 20 patients enrolled for an 
extended medication review   
A community pharmacy-
based study aimed at 
providing increased levels 










Is pharmacist prescribing a 
painless alternative in chronic 
pain management 
UK prescribing pharmacist 
seconded to a multidisciplinary 
clinic, three months pilot, 29 
patients, 43 appointments  
A hospital pharmacy-based 
study in conjunction with 
Gateshead pain 
management team, 








A pilot study to assess a new 
role for a pharmacist in a 
multidisciplinary chronic pain 
team in primary care 
 
UK prescribing pharmacist 
seconded to an MSK clinic.  32 
patients attending an MSK clinic.  
Mean 2.5 interventions per patient  
Addition of a pharmacist to 
a primary Care MSK 






The Role of the Pharmacist 
Prescriber within a 
Community-based Pain 
Management Service: A 
Case Study 
 
UK case report, pharmacist advice 
sought for one patient 
Patient attending the Fife 
integrated pain 






Clinical pharmacy in a 
multidisciplinary team for 
chronic pain in adults 
93 patients attending an out-patient 
multidisciplinary reference centre 
for chronic pain in adults (Europe) 
 
Pharmacist working in a 
hospital out-patient pain 











Efficacy of an outpatient, 
multidisciplinary VA pain 
management clinic: findings 
from a one-year outcome 
study 
 
Conference report, 546 veterans 
who were opioid users and who 
attended a multidisciplinary pain 
management clinic (US) 
Pharmacist working with a 





evaluation of a pharmacist-
managed chronic pain clinic 
in a primary care setting 
Conference report, 39 patients 
attended a pharmacist led chronic 
pain clinic in primary care (US) 
Pharmacist managed pain 
clinic aimed at improving 
chronic pain-related 
outcomes particularly in 













2.5.4. SUMMARY OF THE PAPERS SELECTED BY THIS SYSTEMATIC REVIEW 
This section provides a summary of the significant details of the papers included 
in this systematic review (Table 2.2).  At the start of the review process it was 
hoped that more data would have been reported since the publication of the 
Bennett et al. (2011) and Hadi et al. (2014a) systematic reviews.  The twelve 
articles which are included in this systematic review include one (Bruhn et al., 
2013) which was included in the Hadi et al. (2014a) systematic review.  In 
addition, there was one paper (Bauters, Devulder and Robays, 2008) which, 
from the date would have been available to the two earlier reviewers but which 
did not meet their inclusion criteria. 
 
Only two of the papers, Bruhn et al. (2013) and Neilson et al. (2015) included in 
this systematic review had a Jadad (Jadad et al., 1996) score of greater than 
zero, because that research involved a random allocation into different 
treatment groups.  These two papers were reports of different aspects of the 
same research.  Bruhn et al. (2013) investigated whether there were any 
differences in outcomes between a pharmacist prescriber, pharmacist paper 
review and referral and treatment as usual (TAU) on patients’ pain and the 
benefits that they created.  Neilson et al. (2015) investigated the differing cost 





The research reported in the Bruhn et al. (2013) papers was not strictly 
comparable to the researcher’s clinical practice for two reasons.  Firstly, the 
exclusion criteria excluded medicines “that can be used for analgesia but whose 
primary indication is not chronic pain (e.g. triptans, antiepileptics or 
antidepressants)”.  These groups included almost all of the medicines used in 
the treatment of neuropathic pain and it was noted in Section 1.5.3 that for 
patients with lower back pain up to 50% reported some elements of neuropathic 
pain.  Therefore, their exclusion would significantly reduce the options available 
for effectively treating chronic pain.  Secondly, the inclusion criteria for the 
Bruhn et al. (2013) review included patients who had “either two or more acute 
prescriptions, and/or one repeat prescription within the last 120 days, for an 
analgesic”.  One repeat prescription for a pain medicines would not necessarily 
support the level of analgesia required for the treatment of chronic pain similar 
to that reported by the patients seen by the researcher.  The mean number of 
pain medicines reported by the patients in the researcher’s cohort was 2.8.  










Table 2.3 Details of the articles retrieved by this search   
 
No Study Condition Participants Intervention Primary study outcome  Notes 
 
Clinician 









follow up  
CPG significant improvement in 
pharmacist prescribing arm from 
66.1 to 58.1  
Pharmacists 2 days training.  
Some GP’s thought some 
recommendations trivial  
Pharmacist  







N/A Involvement of pharmacist in 
treatment of chronic pain in GP 
practice probably not cost-effective 
Pharmacists 2 days training.  
Some GP thought some 
recommendations trivial 
Pharmacist 








education ~ 40 
minutes 
BPI-PSS* 
Worst pain reduced from 8.0 to 7.5  
Average pain reduced from 7.0 to 
6.0 
BPI-PIS** 
Average pain reduced from 7.1 to 
6.1 
No additional training for 
pharmacist, specific training 
for the nurse about problems 
associated with chronic pain 
Pharmacist 
& nurse 











9 (5%) patients referred back to GP 
for possible undiagnosed 
neuropathic pain 
Half day training for 10 
community pharmacists in 
undertaking enhanced pain 
related MUR.  Undiagnosed 

















VAS reduced from 5.6 to 4 Prescribing pharmacist made 
changes to patient pain 












MUR – no 
other details 
Mean VAS = 7 
No 2nd visit, no VAS changes 
recorded 








MUR – no 
other details 
Mean VAS, reduction 2.7 MUR, clinic extended beyond 
initial pilot, because of drug 
cost saving.  Poor 











MUR – no 
other details 
No pain scores recorded Clinic extended beyond initial 
pilot in MSK clinic, because 









1 patient MUR on one 
patient 
BPI-PSS 
Worst pain reduced from 7 to 5 
Best pain reduced from 3 to 2 










93 patients MUR – no 
other details 
No pain scores recorded Clinical pharmacist input in 
hospital clinic setting.   
 




546 patients Pre and post 
clinic 
questionnaires  
Unspecified significant reduction in 
pain 
Multidisciplinary Veterans 










NRS reduced from 6.2 to 5.8 Pharmacist led CPS Pharmacist 
 
*BPI-PSS – Brief pain inventory – Pain severity scale 





Looking at the remaining papers in this systematic review in more detail, they all 
returned a Jadad (Jadad et al., 1996) score of zero.  Therefore, they would be 
regarded as low-quality evidence, but they combined to contribute to the narrative 
synthesis (Section 2.5.5).  
 
Hadi et al. (2016) conducted a qualitative and quasi-experimental study with 35 
patients returning for a second visit.  Gill, Taylor and Knaggs (2013) reported on a 
study in north London where 10 community pharmacists who had been specially 
trained, undertook 176 enhanced medicine reviews (Appendix 8.2) and referred nine 
patients back to their GP for suggested undiagnosed neuropathic pain. 
 
Dougall, Harrison and Lowrie (2015) and Harrison (2015) described outcomes of 
MURs undertaken by community pharmacists with the aim of suggesting 
improvements in analgesic prescribing and or signposting to other services.  Dougall, 
Harrison and Lowrie (2015) noted that the patients who had been seen twice by the 
pharmacist recorded a reduction in their mean VAS score from 5.3 to 4.0.  In the 
paper by Harrison (2015) the pharmacist only saw patients on one occasion and 
therefore was not able to record any changes in pain scores.  The paper by Harrison 
(2015) did observe poor compliance, report that a number of patients who reported 
symptoms of neuropathic pain did not appear to be receiving treatment and comment 




Thomas (2012) and Coleman, Yangphaibul and Begovic (2013) studied the 
outcomes of a hospital pharmacist’s involvement in a chronic pain team.  Thomas 
(2012) reported that “of the patients who had one or more pharmacological 
interventions from the pharmacist a mean reduction in the VAS pain score of 2.7 or 
33% was achieved”.  There was no mention of pain scores in patients who had not 
had a pharmacological intervention.  On the other hand Coleman, Yangphaibul and 
Begovic (2013) made no mention of pain scores, their report concentrated upon the 
therapeutic interventions made by the pharmacist.  Thirty-two MURs were 
undertaken by the pharmacist, and a total of 80 actions were recorded.  Of these 64 
were for medicine optimisation and 13 for the reduction of adverse effects.  In the list 
of actions reported was the suggestion that prescribers should prescribe adjuvant 
medicinal treatment for neuropathic pain, specifically amitriptyline.  
 
There was one (anecdotal) case report, which was therefore probably not 
generisable, as well being very low level evidence  (Dumbreck and Cameron, 2011).  
This described benefits from a pharmacist consultation in terms of improved pain 
control resulting from the use of co-codamol.  The patient also accepted treatment 
with gabapentin which led to a reduction in side effects and to a reduction in the 
overall number of medicines taken.  No pain scores were reported. 
 
Bauters, Devulder and Robays (2008) studied the effects if a pharmacist in a hospital 
out-patient pain clinic who undertook 93 MURs and recorded a total of 107 clinical 
interventions.  No pain scores were recorded only the fact that 21 medicines stopped, 
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22 medicine regimens amended and 21 medicines started.  Of the started medicines 
33% were for anti-depressants or anti-epileptics, which within a pain clinic would 
most likely be prescribed to treat neuropathic elements of chronic pain.  Cost benefit 
of involving pharmacists’ in this form of treatment of chronic pain was mentioned but 
not discussed in any detail. 
 
The Cosio and Lin (2014) and Norman (2015) reports were both abstracts from 
conference reports and were regarded as very low level evidence.  Efforts were 
made to contact the authors but no details were available other than those included 
in the conference abstract.  Cosio and Lin (2014) described the treatment of 546 
patients with chronic pain in a multidisciplinary outpatient clinic, including a 
pharmacist.  No pain scores were presented but it was reported that patients showed 
a significant improvement in their pain along with improvements in mobility and 
activities of daily living (ADL).  Norman (2015) reported on a pharmacist led chronic 
pain clinic in primary care aiming to improve pain and reduce opioid use.  Twenty-five 
patients were seen on at least twice and these patients reported a mean 
improvement in pain score, from 6.2 to 5.8 and a mean decrease in morphine 
equivalent opioid dose from 70.6mg to 66.6mg.  
2.5.5. THE DETERMINATION OF THE TOPICS FOR THE ‘NARRATIVE SYNTHESIS’ 
The themes for which this Systematic Review sought research papers, was the 
success or otherwise of a pharmacist’s intervention in the treatment of chronic pain.  
They emerged from the retrieved publications, which revealed beneficial outcomes in 
 
 87 
the treatment of chronic pain.  Their inclusion in the retrieved papers was outlined in 
Table 2.4 table below and then considered later in more detail. 
 
As discussed in Section 2.3.1.2 a narrative synthesis of the data has been chosen 
due to the diverse nature of the quality of the papers published covering the 
educational involvement of a pharmacist specialising in pain in the treatment of 
chronic pain.  The synthesis was carried out in accordance with guidelines (Ryan, 
2013; Popay et al., 2006) eliciting significant themes from the findings of the 
individually published papers included in the systematic review.   
 
Ø Impact of intervention upon the patients’ pain 
Ø Neuropathic pain 
Ø Patients’ understanding of their pain medicines 
Ø Cost implications of the pharmacists’ intervention.   
 
The twelve papers included in the narrative review are summarised and the 





Table 2.4 Themed summary of the papers with the topics for synthesis. 
 
No Reference Changes in pain scores and 
how these changes were 
measured 
Neuropathic pain Patients understanding of their 
pain medicines 
Cost implications of 
pharmacist intervention 
1 Bruhn, H. 
2013 
Pain intensity improved 
(CPG), significantly in the 
pharmacist prescribing arm 
and non-significantly in the 
pharmacist review arm  
Not mentioned A priori hypothesis that in 
patients with chronic pain 
pharmacist advice would lead 
to better pain control or better 
functioning 
Some practice colleagues’ 
question whether the 
addition of a pharmacist 
was cost effective 
2 Neilson, A. 
2015 
As set out in Bruhn, H 2013 
above.  Research into the 
‘cost effectiveness of a 
pharmacist intervention 
Not mentioned Not mentioned Report suggests that 
pharmacist intervention was 
not cost effective 
3 Hadi, M. 
2016 
BPI pain severity reduced 
from 8 to 7.5, BPI average 
pain reduced from 7 to 6 and 
BPI pain interference 
reduced from 7.1 to 6.1 
Not mentioned Problems with adherence were 
mentioned in passing 
Author suggest that cost 
effectiveness of the 
intervention requires further 
investigation 
4 Gill, J. 
2013 
101 patients completed a 
painDETECT questionnaire. 
Resulted in 28 possible and 
23 likely patients with 
neuropathic pain. 
Out of 76 MURs 9 (5%) 
were referred back to 
their GP for possible 
undiagnosed neuropathic 
pain 
Patient reluctance to take 
analgesia was mentioned - 
even when patients knew pain 
increased as a result 
Suggestion that the 
detection of undertreated 








16 of 21 patients recorded a 
decrease in VAS from 5.6 to 
4.0 
Not mentioned Pharmacists MUR included a 
check of compliance and 
understanding 
Author suggests costs 




Mean baseline VAS pain 
score is 7.0 (no other pain 
scores mentioned) 
11/20 reported 
symptoms of neuropathic 
pain, 10/11 were not 
taking appropriate 
medicines 
35% (8/23) took their 
analgesics at doses lower than 
recommended by their 
prescriber 
Medicine costs increasing 
year on year, would 
pharmacist involvement 




Pain VAS reduction of 2.7 or 
33% in those patients who 
had a pharmacological 
intervention  
Some patients did not 
understand dose 
titrations, an indication 
that neuropathic pain 
may be being 
undertreated 
Patients do not take medicines 
optimally, lack of direction 
clarity, complexity of therapy 
and fear of side effects 
Additional cost justified by 





No measures of pain 
undertaken – aim to ‘add 
value’ to the service 
Report notes that 
amitriptyline was added 
to some patients’ 
prescription, a possible 
indication of neuropathic 
pain 
Pharmacists were able to offer 
advice about optimising 
therapy and enhancing 
adherence 
Other members of the team 
reported that pharmacists 




Case report – pain scale 1-10 
Worst improved from 7 to 5 
Best improved from 3 to 2 
Patient had untreated 
neuropathic pain.  
Pharmacist initiated 
treatment 
Patient reported a greater 
understanding of the use of 




T. G. 2008 
None recorded – report about 
the efficacy of clinical 
pharmacy 
Text includes references 
to medicines used in the 
treatment of neuropathic 
pain 
Not mentioned Authors opined that this 
was not cost effective 
11 Cosio, D. 
2014 
Stated as a significant 
reduction in pain 
Not mentioned Reported reduction in levels of 
fear about taking medicines 
Conference report 






Pain score decreased from 
6.2 to 5.8, scale not 
mentioned 
Morphine equivalent dose 
from 70.6mg to 66.6mg 
Opioid use declined and 
mean non-opioid 
prescriptions increased 
from 1.8 to 2.0 
Compliance increased Conference report  





2.5.6.  THEMES WHICH EMERGED FROM THIS SYSTEMATIC REVIEW. 
The themes identified were then examined in detail for contributions to this narrative 
synthesis and discussed in the section below. 
2.5.6.1. Impact of intervention upon patients’ pain.   
The pharmacist interventions set out in the 12 papers highlighted by this review 
generally fall into two groups: pharmacists as prescribers and pharmacists as 
reviewers with referral back to the prescriber for any suggested changes in therapy.  
The Bruhn et al. (2013) paper reported on research with one arm in each of these 
groups.  Four papers involve pharmacist prescribing for chronic pain patients 
(Dougall, Harrison and Lowrie, 2015; Thomas, 2012; Coleman, Yangphaibul and 
Begovic, 2013; Dumbreck and Cameron, 2011).  In the remaining reports the 
pharmacists reviewed the patients’ therapy and made recommendations for 
suggested changes to the patients’ prescriber or there were insufficient details to 
determine the role of the pharmacist. 
 
All of the papers included by this systematic review reported that the pharmacist’s 
intervention was an MUR of some sort.  The papers then went on to report on the 
effect which this intervention had had on the patient’s pain.   
 




‘a structured, critical examination of a patient's medicines with the objective of 
reaching an agreement with the patient about treatment, optimising the impact of 




Prior to this Blenkinsopp, Bond and Raynor (2012) had made a more general point  
 
‘Medication review is, at heart, a diagnostic intervention which aims to identify 
problems for action by the prescriber, the clinician conducting the review, the patient 
or all three but can also be regarded as an educational intervention to support patient 
knowledge and adherence.’ 
 
These two definitions reveal differences in interpretation of the role of an MUR.  It 
can either be a discussion with the aim of optimising medicinal treatment or a 
discussion aimed at educating the patient, which as a by-product will optimise 
medicinal treatment.  For many of the papers included in this systematic review there 
was no indication of what were the priorities of the researchers during their MUR 




Three of the research projects included this systematic review specified that the 
pharmacist undertook training to undertake an enhanced MUR.  This was aimed at 
improving the consistency of the intervention  
 
Harrison (2015) reported on a research study in west Dunbartonshire, in which 
pharmacists were to undertake an enhanced MUR with patients suffering with 
chronic pain.  All of the local community pharmacies volunteered to participate and 
participation required them to complete a 2 x 3hours training course, consisting of 
presentations, role play and case studies.  This was undertaken to ensure that the 
pharmacist understood how to administer the STarT questionnaire (Section 8.2) as 
well as learning about chronic pain so that they would be able to refer patients on for 
further advice and treatment as appropriate.  The research did not go to plan and 
only 20 of the projected 400 MURs were completed.  At the debriefing meeting one of 
the comments noted was that pharmacists did not feel confident to undertake these 
MURs with their chronic pain patients.  This posed questions about the adequacy 
and appropriateness of the training provided. 
 
In the Gill, Taylor and Knaggs (2013) report, pharmacists undertook a half day 
training.  This included instruction about the BPI questionnaire, neuropathic pain and 
the painDETECT (Section 8.2) questionnaire as well as the LESS PAIN (Section 8.2) 
format for questioning (Gill, Taylor and Knaggs, 2013; Gill, Taylor and Knaggs, 




All of the pharmacists in the Bruhn et al. (2013) undertook a two day course prior to 
the commencement of the research.  This aimed to familiarise them with the 
problems associated with chronic pain and to agree a common approach to the 
treatment being recommended in the two arms of the trial in which they were 
involved.   
 
The MUR undertaken by Dougall, Harrison and Lowrie (2015) included recording a 
VAS pain score.  There was no mention in the report of training to undertake this 
task. 
 
The notes recorded about the MURs undertaken by Hadi et al. (2016), Thomas 
(2012) and Coleman, Yangphaibul and Begovic (2013) suggest that they would be 
encapsulated by the definition promulgated by the RPharmS.  In the remaining 
papers comments were restricted to reporting that an MUR was undertaken. 
 
Bruhn et al. (2013) reported on an RCT which recruited 196 patients suffering with 
chronic pain and who were randomly divided into three comparative treatment 
groups: pharmacist review and prescribing, pharmacist paper review with referral 
back to the GP for prescribing and TAU, ongoing care by their GP.  This research 
used the CPG, which scores 0 to 100.  The CPG aims to enumerate the patient’s 
pain intensity in combination with their pain related disability.  This method of scoring 
is complex and time consuming and insufficient research has been undertaken to 
relate the scores obtained to the more usual 11-point VAS and BPI scales.  In the 
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pharmacist review and prescribing group, the CPG mean intensity score reduced 
from 66.1 to 58.1 (P=0.002) at the six-month follow-up.  This contrasted with the 
pharmacist paper review and referral to the GP for prescribing group who only 
reported a non-significant overall mean reduction in pain from 68.4 to 67.4.  There 
were no reported changes in the pain scores of the TAU group.  The changes at six 
months in all three arms for pain related disability were similar but smaller.  The 
questionnaires were sent to participants at 3 months and 6 months after the research 
had been completed included questions about their satisfaction with the research 
process.  In the ‘review and referral’ group patients questioned why the pharmacist 
was not able to prescribe thereby avoiding another appointment and a longer wait for 
treatment.  All participating pharmacists and GPs were invited to take part in a semi-
structured interview and their responses recorded. 
 
Dougall, Harrison and Lowrie (2015) reported on the success of a prescribing 
pharmacist in this community pharmacy scheme.  Sixty-four patients were referred by 
a local GP for an MUR of the medicines used to treat their chronic pain in the 
consulting room of the community pharmacy.  Patients were seen initially and invited 
to return for a second appointment.  Twenty-two patients returned for at least one 
follow-up appointment and of these 21 recorded two sequential VAS scores.  The 
mean VAS reduced from 5.6 to 4.0, a reduction of 1.6 (29%).  This reduction 
suggested that an MUR under these circumstances could be worthwhile and the 
authors suggest that this work should be expanded.  This paper made specific 




In Gateshead hospital a prescribing pharmacist was invited to join the pain 
management team for a trial period of three months (Thomas, 2012).  The mean pain 
reduction reported for the cohort that were treated (n=29) with a pharmacological 
intervention was a reduction in the pain score of 2.7 or 33%. There were no details of 
how this improvement was achieved nor any mention of any pain changes in those 
patients who did not receive a pharmacological intervention therefore it would not be 
possible to make any general inferences from these results.  The baseline pain score 
was not reported but a calculation from the details reported suggested that the mean 
baseline pain score was 8.2.  The reduction in pain of (2.7) 33% was not dissimilar to 
the (1.6) 29% reported by Dougall, Harrison and Lowrie (2015) from a much lower 
starting pain score level.  The author claimed that the cost savings on the medicines 
used was sufficient to justify the long-term continuation of this service beyond three 
months.   
 
A prescribing pharmacist was invited to join the CPT at the Whittington Hospital in 
London to assess the contribution which a pharmacist could make to a multi-
disciplinary team (Coleman, Yangphaibul and Begovic, 2013).  The report outlines 
the types of therapeutic changes made but made no mention of pain scores.   
 
The case report published by Dumbreck and Cameron (2011) outlined a reduction of 
pain for a patient attending a chronic pain clinic.  The patient reported significant side 
effects with co-codamol in the past and was reluctant to even consider the possibility 
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of benefit from taking medicines, the aim was to minimise the use of pain medicines.  
The prescribing pharmacist was invited by the team to review this patient to see 
whether it was possible to overcome this resistance.  On discharge the number of 
medicines taken by the patient had reduced from seven to four and the patient’s VAS 
scores had improved ‘worst’ from 7 to 5 and ‘best’ from 3 to 2. The prescribing 
pharmacist’s intervention appeared to have facilitated a reduction in both the 
patient’s pain and the number of medicines being taken.     
 
A community-based nurse-pharmacist pain clinic was described by Hadi et al. (2012) 
and Hadi et al. (2016).  In this research the pharmacist undertook an MUR and the 
nurse concentrated on the educating the patient about the use of their pain 
medicines.  A combined report was then sent to the GP with suggestions for 
improving the patient’s therapy.  The effect on pain scores were reported for a cohort 
of 35 who were seen twice and the BPI-PSS ‘worst pain’ reduced by 6% from 8.0 to 
7.5 (p=0.02), the ‘average pain’ reduced by 14% from 7.0 to 6.0 (p=0.02) and the 
average BPI-PIS score reduced by 14% from 7.1 to 6.1 (p=0.02).  These significant 
improvements were, larger than that non-significant reduction in the CPG recorded 
for the paper review and referral group in the Bruhn et al. (2013) study, but not as 
large as that reported by the pharmacist prescribers in Thomas (2012) and Dougall, 
Harrison and Lowrie (2015).  These differences may be related to the face to face 
component of the interventions.  Comparisons with the Bruhn et al. (2013) study, 
prescribing arm, were difficult because of the use of the CPCS rather than the 11 




The three final papers were conference overviews.  Harrison (2015) reported a mean 
baseline pain score of 7.0, Norman (2015) reported an overall pain score reduced 
from 6.2 to 5.8 and Cosio and Lin (2014) reported a significant reduction in pain 
severity.  None of these reports gave any details about the pain scores used and 
there were insufficient details to allow any other comparisons. 
 
An overview of these results with regard to pain suggests that those pharmacists who 
were prescribers achieved a greater reduction in pain than those who undertook a 
review and referred back to the GP.  Much more date would be needed before such 
an impression could be confirmed.   
 
In several of these papers the pharmacists were working as part of a CPT.  
Systematic reviews have reported that multidisciplinary CPTs are the most effective 
means of treating chronic pain (BPS, 2013; Kress et al., 2015; Cheatle, 2016) and 
rehabilitation (Kamper et al., 2015).  The possibility that at least some of the benefit 
reported might have been as a result of the team effort was not addressed and 
should be addressed in any future research. 
 
The reported role of placebos in the medicinal treatment of pain (Muller et al., 2016; 
McCartney, 2015)  was not mentioned in any of these papers even though it is 
reported that in clinical trials involving analgesics the placebo effect is always 
observed  (Vachon-Presseau et al., 2018).  A Cochrane review has suggests that 
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research trials for pain treatments should contain three arms, treatment, placebo and 
treatment as usual (Hrobjartsson and Gotzsche, 2010).  
 
2.5.6.2. Neuropathic pain 
Seven of the twelve reports suggest that patients attending these consultations 
arrived with pain identifiable as neuropathic, but were not currently receiving 
appropriate therapy.  The treatment of neuropathic pain is complex and there are 
many reasons why this proportion of patients with chronic pain may not be receiving 
treatment for suspected neuropathic pain. The complex interrelationship between 
chronic pain and neuropathic pain was outlined in Section 1.5.3 (van Hecke et al., 
2014; Bouhassira et al., 2008; Freynhagen and Bennett, 2009).   
 
Gill, Taylor and Knaggs (2013) reported that of the 176 patients involved in their 
research, 101 completed the painDETECT questionnaire (Freynhagen et al., 2006) 
which was aimed at elucidating lower back pain with neuropathic elements in 
community or hospital.  Of these 101 patients 23 returned a painDETECT score of 
between 19 and 38 suggesting that they had a component of neuropathic pain within 
their overall pain.  Nine patients were referred back to their GP for possible 
undiagnosed neuropathic pain.  The authors went on to suggest that if these results 
were extrapolated nationwide, community pharmacists could identify 50,000 cases of 
neuropathic pain in a year.  This figure depends upon the validity of the questionnaire 
being used.  Cruccu and Truini (2009) suggest that the questionnaires which include 
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some form of appraisal for allodynia (DN4 and S-LANSS) achieve the greatest 
sensitivity and specificity. On the other hand Bisaga et al. (2010) reported that the S-
LANSS was the least sensitive of DN4, S-LANSS and painDETECT at detecting 
neuropathic pain.  In a more recent review Harrisson et al. (2017) reported that the 
frequency of diagnosis of neuropathic pain based upon a questionnaire depended 
upon the questionnaire used.   But this should not distract from the comment by 
Cruccu and Truini (2009) that we badly need an objective means to measure pain 
and pain intensity as well as response to treatment.   This variation would not be too 
problematic if the medicines that are used in the treatment of chronic pain were 
effective.  Unfortunately, the NNTs for a 50% reduction in pain with medicines used 
in the treatment of neuropathic pain vary between 2.2 and 5.0. (McQuay et al., 1996; 
Haroutounian and Finnerup, 2018; Beniczky et al., 2005) and therefore it is likely that 
for some patients no treatment will ever be very effective.  To make up for this lack of 
efficacy it is suggested that at least four different therapeutic options for neuropathic 
pain should be explored (Smith et al., 2012).  Notwithstanding these difficulties if 
pharmacological treatment could be given to the suggested 50,000 patients, this 
could lead to an improvement in their wellbeing.  On the other hand such treatment is 
difficult to initiate successfully, requiring close review and monitoring and the side 
effects at therapeutic doses which can be significant, would need to be balanced 
carefully against any benefit.    
 
Harrison (2015) reported on a pilot project to investigate the feasibility of community 
pharmacists undertaking chronic pain reviews.  During the extended MURs, which 
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included the STarT back questionnaire (Traeger and McAuley, 2013), with the 20 
patients in this cohort 11 patients reported symptoms of neuropathic pain.  Of these 
11, only one was taking medicines which were considered appropriate for the 
treatment of neuropathic pain.  The others were referred back to their GP with 
recommendations to start appropriate therapy.  
 
Four of the other reports allude to undiagnosed neuropathic pain.   Suggestions by 
the pharmacist for the optimisation of pain therapy for the cohort reported by 
Coleman, Yangphaibul and Begovic (2013) specifically included adding amitriptyline.  
In the case report presented by Dumbreck and Cameron (2011) the patient reported 
symptoms to the pharmacist that suggested neuropathic pain and which reduced 
after the addition of gabapentin to the patients’ therapy.  Bauters, Devulder and 
Robays (2008) reported on a pharmacist’s suggestions for improving pain control in 
this cohort of 93 patients attending a hospital out-patient chronic pain clinic.  One 
third of the suggestions made by the pharmacist were for medicines, which would be 
appropriate for the treatment of neuropathic pain.  Finally the Norman (2015) abstract 
summarised the changes found in this cohort of 39 patients attending a pharmacist 
led chronic pain clinic.   Pain scores and morphine equivalent doses went down but 
the mean number of non-opioid adjuvant pain therapies i.e. treatments for 
neuropathic pain (Pergolizzi, 2016) increased from 1.8 up to 2.0.   
 
Clearly, none of these provide any robust research evidence about the frequency of 
neuropathic pain in patients with chronic pain.  In total of the 12 papers included in 
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this systematic review seven refer in some way to improving therapy for neuropathic 
pain.  Any opportunities which pharmacist have to improve the therapy of patients 
with neuropathic pain needs to be explored further, because patients with 
neuropathic elements in their pain report higher pain intensities (Torrance et al., 
2006) and poorer quality of life (Smith et al., 2007) than those without neuropathic 
elements.     
2.5.6.3. Patients understanding of their pain medicines 
Patient adherence to medicinal therapy in all chronic conditions is poor, about 50% in 
‘developed’ countries (Yach, 2003) and this was famously commented on by  
C. Everett Koop, one-time US surgeon general: “Drugs don’t work in patients who 
don’t take them”  (Osterberg and Blaschke, 2005).  
 
Poor adherence/compliance and concordance with medicines in general have been 
widely examined.  There is more understanding for this reluctance where there is 
little relationship between a therapy and the possible benefits as has been reported 
in the treatment of hypertension (Anker et al., 2019).  But in the treatment of pain, 
patients were often aware that less medication means more pain (Broekmans et al., 
2009).  The reasons for this reluctance, which included failure to comply with their 
pain prescriptions were not clear.  Some patients were reluctant to take their pain 
medicines because of a fear of unwanted side effects or concerns about addiction 
(Pound et al., 2005; Horne et al., 2013).  For others the reasons were more complex, 
taking pain medicines in some way ceded aspect of control over their lives to their 
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pain (Pellino and Ward, 1998).  However, pharmacists have a responsibility to ensure 
that patients understand how to take their medicines to maximise any benefit and 
minimise any adverse effects (Graham and Brookey, 2008; Praska et al., 2005; 
Kripalani et al., 2007) because some patients will struggle both with understanding 
dispensing labels and/or the initiation and maintenance of complex dosage regimens 
(Young et al., 2018).  During a clinic consultation there is the opportunity to address 
some of these concerns.   Four papers retrieved by this systematic review (Dougall, 
Harrison and Lowrie, 2015; Gill, Taylor and Knaggs, 2013; Thomas, 2012; Dumbreck 
and Cameron, 2011) specifically reported that initially patients did not take their 
analgesics as prescribed or recommended and that advice from the pharmacist led to 
better outcomes for their pain.  In addition, (Coleman, Yangphaibul and Begovic, 
2013; Bauters, Devulder and Robays, 2008) both reported working with patients to 
optimise their analgesia even though neither include any pain scores which would 
have confirmed such a claim.   
 
NICE reports that controlling chronic pain is challenging and that prescriber’s focus 
should be on reducing pain in a way which improves the patients quality of life (NICE, 
2017).  But, pain medicines come with a multiplicity of side effects as discussed in 
Section 1.5: opioid induced nausea (Moore and McQuay, 2005), constipation (Collett, 
1998), NSAIDs and gastric ulceration (Davis and Robson, 2016), gabapentinoid 
induced brain fog (Zaccara et al., 2011) and TCA induced dry mouth (Cookson, 
1993).  An MUR provides a pharmacist with the opportunity discuss the dilemma of 
efficacy versus side effects with the patient.  This discussion should lead patients to a 
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better understanding of their pain medicines about how to improve efficacy and 
minimise side effects.     
 
The role of the pharmacist has changed and expanded as the use and efficacy of 
medicines in health care has been transformed.  All such changes are aimed at 
better utilisation of the knowledge, which pharmacists have about medicines and 
medical conditions and attempting to ensure that patients got the best benefit from 
their medicines.  The contribution that a pharmacist can make in the treatment of 
chronic pain is recognized by some patients.  In the report of their research Gill, 
Taylor and Knaggs (2013) included ‘individual statements’ from the satisfaction 
surveys that patients were asked to complete: ‘The pharmacist helped me 
understand how my medication would improve my pain’ and ‘The pharmacist helped 
me address possible side-effects’.  
 
2.5.6.4. Cost implications of pharmacist intervention 
The supporting data in the papers included in this systematic review about the costs 
associated with pharmacists’ interventions beyond dispensing prescriptions for pain 
medicines were very limited.  In a pilot study which was aimed at determining 
whether a pharmacist would add value to an MSK chronic pain service (Coleman, 
Yangphaibul and Begovic, 2013), four physiotherapists were interviewed, in a semi-
structured way, after the pharmacist’s interventions were completed.  The reported 
summary presented the opinion that pharmacist added value to the service by 
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providing specialist advice for the patients, which maximized adherence and 
improved the patient experience.  At the end of the pilot, the service was continued 
and expanded from one to two days a week, but the cost benefits were not discussed 
further.   
 
Another report was not as positive.  An the end of the Bruhn et al. (2013) research all 
participating pharmacists and GPs were invited to take part in a semi-structured 
interview and their responses recorded verbatim.  Comments made by GPs about 
the pharmacists’ suggestions in the ‘paper review and refer group’ included “tinkering 
around the edges”, “tried this before” and “when we are short of cash, is this an 
appropriate use of resources?”. 
 
The total cost of the individual arms of this research were investigated separately 
(Neilson et al., 2015).  Medicine costs were taken from the BNF, appointment costs 
from the Scottish Health Service Cost Book and pharmacist and GP time from the 
Personal Social Serviced Research Unit.  These were balanced against the gain in 
quality-adjusted life years (QALY).  The final account suggested that the intervention 
of a pharmacist was probably not cost effective but the numbers were too small to 
give a definitive answer.  
 
The Neilson et al. (2015) paper specifically excluded from their accounting any costs 
borne by the patients, travel, carer costs and loss of employment as well as the 
associated societal losses because these were not relevant to the health service 
 
 106 
costs.  Such omissions are however apposite because Maniadakis and Gray (2000) 
reported that the total cost of back pain for the UK in 1998 was at least £6.650b, 
£1.632b (25%) for direct health care costs and £5.018b (75%) for informal care and 
lost productivity.  If the difference between the costs of the three arms was not 
certain after excluding none NHS costs it would be interesting to see the results 
recalculated in a way which included the additional costs as calculated by 
Maniadakis and Gray (2000).  Many of the costings used by Neilson et al. (2015) 
were from the same sources used by Maniadakis and Gray (2000).  Therefore, it 
should not be difficult to recast the comparative costs in a way which included the 
non-NHS costs or some agreed proportion of them.  There is ongoing debate about 
the appropriateness of the basis upon which QALYs (Section 8.2) are calculated 
(Kirkdale et al., 2010).  On the other hand, Harrison (2015) and Thomas (2012) 
suggest that the additional costs associated with a pharmacists interventions could 
be offset by savings from within the drugs budget.  This is not completely fanciful 
because Neilson et al. (2015) did comment that the most significant part of the 
expenditure in any of the three arms of this study were the costs of the medicines 
being prescribed. 
 
Dougall, Harrison and Lowrie (2015) suggests that the cost effectiveness of a 
pharmacists’ intervention into the treatment of chronic pain needs further 
investigation.  This finding was contrary to the report by Bauters, Devulder and 
Robays (2008) which specifically stated that the intervention of a clinical pharmacist 
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in this way in the treatment of chronic pain was not cost effective.  The remaining 
reports made no mention of costs. 
 
In times of financial constraint, it is important that costs are investigated.  However, 
given the difficulty of treating chronic pain it is important that effective therapy is not 
constrained by the cost of the medicines (RCGP, 2013).  This highlights the 
significance of the Maniadakis and Gray (2000) report and the comment about 
medicine costs in the Neilson et al. (2015) report.  Overall, the papers retrieved by 
this systematic review, reported that a pharmacist in a CPS led to a reduction in pain, 
but the cost benefit was as yet undefined.  
2.6.  Conclusion  
A systematic review of the literature was undertaken to ascertain the extent of the 
published data about the benefit that a pharmacist working as a member of the CPT 
can bring to the treatment of chronic pain.  The small number of new research papers 
which had been published indicated that the pharmacist had made a positive 
contribution to the patients’ pain, however the evidence base for this assumption was 
generally of poor quality, based upon four papers, three brief reports and one RCT 
(NIH, 2018; Jadad et al., 1996). 
 
It is reported that the best outcomes in the treatment of chronic pain result from a 
multi-disciplinary team effort (BPS, 2013; Kress et al., 2015; Cheatle, 2016).  As most 
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of this research took place within a CPT it is difficult to truly separate out the 
pharmacists’ contribution.   
 
These research projects were undertaken in community pharmacies, hospitals, 
clinics and GP surgeries.  A key intervention was the pharmacists MUR either face to 
face or paper based.  In future, greater effort needs to be he made to specify in detail 
this part of the research in order to clarify the impact factor of the intervention.    
 
From these papers it would appear that there are indications that amongst patients 
suffering with chronic pain there is some unsatisfied need for the appropriate 
treatment of neuropathic pain.  The diagnosis of neuropathic pain is problematic and 
its treatment difficult.  Therefore, it was unclear what was the cause of this unmet 
need: was it lack of diagnosis, a failure of therapy resulting from ineffective medicines 
or a lack of treatment or a reluctance on the part of the patient to engage with their 
treatment. 
 
Many of these papers reported either a lack of compliance with prescribed pain 
medicines or lack of understanding about how to take their medicines.  There was no 
indication in these papers about whether the pharmacist’s intervention resulted in an 
improvement in the patients’ pain scores because the patient’s prescriber improved 





The additional cost of the inclusion of a pharmacist in a CPT is not insignificant.  The 
opinions from the staff and patients who interacted with the pharmacist were largely, 
but not completely supportive.  The analysis of costing which was done indicated that 
this addition was not cost effective, but this analysis was not free from bias and it did 
close with the suggestion that the analysis was too small to be certain of the 




CHAPTER 3 AIMS & OBJECTIVES 
3.1. Aims 
This research set out to determine whether a consultation with the pharmacist, within 
the multidisciplinary CPT in South Staffordshire and any resulting medicines advice 
and education changed patient use of their pain medication.  If so, did this improve 
their use of their pain medicines, pain scores or medicine side effects.   
3.2. Objectives 
Patients were seen at normal CPS pharmacist clinic appointments on two occasions 
separated by four months.  The following objectives were assessed and recorded at 
both appointments  
i. Assess and characterise the patients pain using the BPI questionnaire 
(Appendix 8.4.2) 
ii. Assess and characterise the patients neuropathic pain using the S-LANSS 
questionnaire (Appendix 8.4.3) 
iii. Take a full medication history using the Researchers Drug Dataset 
questionnaire (Appendix 8.4.4) to determine medicines actually taken and any 
resulting benefit  
iv. Explore patients attitudes towards compliance with their pain medicine therapy 
with the help of the BPI questionnaire 
 
The differences between the results at the 1st and 2nd appointments were then 
compared for any changes.  
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CHAPTER 4 METHOD 
4.1. Introduction 
This chapter will commence with the ethical approvals obtained before this research 
commenced and the subsequent protocol amendment.  It will then lay out the detail 
of the patient recruitment, the inclusion and exclusion criteria and the research 
processes including the intervention.  It will conclude with details of the data handling 
and statistical review.  
4.2. Ethical approval  
Ethical approval for this research was sought and received from 
i. University of Birmingham approval ERG Reference: RG 14-049 dated 6th 
January 2016. 
ii. NHS ethical approval from Brighton and Sussex NRS Committee – 
16/LO/0353 – IRAS 181743 – NHS SSI 287948 
 
It was anticipated at the commencement of the research period that sufficient 
patients would be recruited through the normal clinic appointment system.  
Unfortunately, whilst this research was extant a new Patient Administration System 
became operational within the Trust and there was concern that this might create a 
problem with recall appointments.  In anticipation of such a shortfall in numbers, a 
Protocol amendment was sought and approved, seeking permission to contact 
patients by phone if necessary, to complete the research project.  This proved 
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unnecessary and all the patients who had been enrolled were offered a 2nd 
appointment except for those who had been discharged from the CPS 
4.3. Patient recruitment 
The referral pathway of patients to the pharmacist’s clinic is summarised in Figure 
4.1. 
 
Patients always arrived at their first full appointment with the pharmacist by one of 
two routes.   
i. Patient referral from another member of the CPT.   
Any other member of the CPT was able to refer a patient to the pharmacist’s clinic.  
Such a referral would normally occur when member of the team was concerned 
about one or more of the following aspects of the patient behaviours 
a. Taking their medicines incorrectly even after advice. 
b. Appeared to have unresponsive central sensitisation or neuropathic pain. 
c. Taking doses of strong opioids whilst still reporting high levels of pain 
d. Expressed a wish to reduce their use of strong opioids 
e. Lacked confidence in the healthcare professional managing their medicines 
f. Specifically asked for a second opinion with the pharmacist 
g. Demonstrated a lack of understanding about their medication 




These referral criteria encourage team members to make appropriate patient 
referrals to the pharmacist when they believe that advice about their pain medicines 
would give them benefit, irrespective of any other facet of their treatment.  The pain 
of the patients in the research cohort was no different, overall, to those seen prior to 
the commencement of the research.  Patients with pain associated with a painful 
physical condition such as arthritis were only referred to the pharmacist where this 
had caused pain which was disproportionate to that which would be expected for that 
particular condition.  The referrals to the pharmacist’s clinic therefore contained a 
disproportionate number of patients suffering with pain ‘wind-up’ or ‘central 
sensitisation’ (Appendix 8.2).  Referrals also included patients who demonstrate a 
lack of understanding of the role of pain medicines in their treatment or who were 
reluctant to become involved with the use of pain medicines.   
 
ii. Patient self-requested an appointment following pharmacist’s presentation at a 
PMP.   
The pharmacist’s presentation and subsequent discussion at the PMP occupied half 
of one three-hour session (90 minutes).  At that time the role of medicines, in the 
treatment of chronic pain were outlined along with suggestions for how pain 
medicines could best be used.  At the end of the presentation/discussion patients 
were offered the opportunity for an informal conversation over coffee or a later 
individual clinic appointment.   
 






Figure 4.1 Flow diagram of referral process into the pharmacist clinic, 
including the research appointments 
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4.4. Research process 
Prior to the commencement of the research all members of the CPT were briefed 
about the protocol and the consent process.  Therefore, once the research had 
commenced when a member of the CPT referred a patient to the pharmacist they 
explained the pharmacist was undertaking a research project, provided patients with 
verbal information about the project and began the consent process, emphasising 
that participation was voluntary and would not influence their care in any way.  
 
During the research period all patients attending for a pharmacist’s appointment were 
offered the opportunity to participate in the research.  The letters inviting patients to 
attend the pharmacist’s clinic were sent at least two weeks prior to the clinic 
appointment and contained, in addition to the normal appointment letter the following 
paperwork, which had been approved by the Brighton and Sussex NRS Committee 
NHS ethics committee. 
i. Patient Information Sheet (PIS) (Appendix 8.3.1).   
ii. Patient Consent Form (PCF) (Appendix 8.3.2).  
iii. Patient’s Pain Medicine Question (PMQ) (Appendix 8.4.1).  A bespoke 
questionnaire asking about the pain medicines patients were currently taking 
or had taken in the past. 
iv. The BPI (Appendix 8.4.2).  A self-completion questionnaire, which included 
questions about pain intensity, pain medicines and the patients’ attitude 
towards the use of pain medicines. This was validated for use in Chronic non-
cancer pain by Keller et al. (2004) who collected data on 250 patients with 
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arthritis and low back pain at two time points and compared this with other 
generic pain scales. 
v. The S-LANSS questionnaires (Appendix 8.4.3).  A self-completion 
questionnaire to determine the presence of neuropathic pain.  This was 
validated for self-assessment and postal research by comparing results from 
interviews with results from the questionnaire for the same groups of patients 
(Bennett et al., 2005).   
 
After enquiries by the researcher it was understood that both the BPI and S-LANSS 
questionnaires were freely available for NHS research.  The S-LANSS questionnaire 
had been issued to the patients attending the pharmacist’s clinic for a number of 
years.  This was used to inform the pharmacist’s approach to the discussion about 
the type of pain from which the patient was suffering.  The BPI short form is a 
standard outcome measure used by the CPS.  This was changed for the pharmacist 
research because the complete BPI includes questions about the patient’s use of 
medicines in relation to their pain. 
 
Additional copies of all the paperwork were available in clinic if required. 
 
All patients in this research cohort undertook the same, minimum, intervention and 




Letters offering appointments were issued at least two weeks in advance of the clinic 
date. Therefore, patients would have two weeks to consider whether they wished to 
enter into a discussion with the pharmacist about participating in the research. 
 
At the 1st appointment, the opening discussion determined whether the patient was 
prepared to consider participating in this research project. If the patient was willing to 
participate the pharmacist would: 
 
i. Ensure that the patient understood the PIS. 
ii. Ensure that the patient was given the opportunity to ask any questions. 
iii. Confirm with the patient that their treatment would be exactly the same 
whether or not they agree to participate in the research. 
iv. Confirm with the patient that they were free to withdraw from the research at 
any time without any change to their treatment 
v. Confirm with the patient that the research process would only involve looking 
at the information, which was the same in every way as a normal clinic 
session, with the exception of the complete rather than short version of the 
BPI. 
vi. Agreed with the patient that if they were willing to participate then together the 
patient and the researcher would sign the PCF.  
vii. Record a 'Patient Identification Number', to ensure patient anonymity in 
subsequent data analysis.  This number was stored securely, separate from 




Once the patient had agreed to participate, the clinic appointment followed the 
normal format viz. characterisation of their pain, a full medical history, understanding 
of the effectiveness of each pain medicine used and pain medicine optimisation 
advice.  At the end of the appointment an agreement was reached about any 
suggested changes to therapy and a follow-up appointment was arranged. 
 
Patients were asked to complete the questionnaires sent with their appointment letter 
prior to attending for their 1st and 2nd clinic appointments.  These included the 
following quantitative pain scales. 
 
i. The eleven-point (0-10) NRS 
ii. The BPI pain severity scale (BPI-PSS) comprised four, eleven-point scales 
viz. worst, best, average and now.  The information which accompanied the 
BPI suggested that each of these scores was valid of itself as was the mean 
overall PSS if all four scores are available (Cleeland, 2009). 
iii. The BPI pain interference scale (BPI-PIS) comprised seven, eleven-point 
scales viz. general activity, mood, walking ability, normal pain, relationships, 
sleep and enjoyment of life.  The information which accompanied the BPI 
suggested that each of these scores was valid of itself as was the mean 
overall PIS.   The mean was also as regarded as valid if four or more scores 
were included (Cleeland, 2009). 




Following the 1st appointment, regardless of whether the patient was participating in 
this research a letter was sent to the GP, with copy to the patient, outlining any 
agreed suggestions for improving their treatment.   
 
All of the data collected during each clinic appointment from both the questionnaires 
and the conversation was recorded on the Researchers Drug Datasheet (Appendix 
8.4.4).  These data were then used to create a spread sheet which became the basis 
for subsequent analysis. 
 
Letters inviting patients for their follow-up appointment, at least four months after the 
initial appointment contained the same documents and questionnaires as their 
original invitation letter.  Four months was chosen to allow the pharmacist letters to 
be prepared, posted and delivered, for patients to arrange an appointment with their 
GP to discuss and agree any new medicine plan and finally time for any changes in. 
therapy to become effective.   
 
At their 2nd appointment all research participants were asked to re-confirm their 
willingness to proceed as before even though continued attendance was regarded as 
indicative of implied consent.  The datasets collected for both the 1st and 2nd 




Following the 2nd appointment, regardless of whether the patient was participating in 
this study, a letter was sent to the GP, with copy to the patient.  If a third appointment 
was necessary this took place outwith the research according to normal clinical 
practice 
 
The datasets from the two clinic appointments, comprising S-LANSS and BPI 
information as well as a detailed resume of pain medicines used and their 
effectiveness were them examined for any (statistically significant) changes including 
i. Pain scores 
ii. Pain medicines used 
iii. Perceived effectiveness of pain medicines used 
iv. Answers to questions 24-30 in the complete BPI (Appendix 8.4.2) 
 
Each patient who agreed to participate in the research was asked if they were willing 
for their GP to be approached by the researcher as part of the study.  If the patient 
consented the Practice Manager of the patient’s General Practice was informed 
about the on-going research.  In addition, the practice manager was approached later 
for information about any extant protocols used by the Practice for the treatment of 
Chronic Pain. 
4.5. The intervention 
The intervention, took place during each clinic appointment and lasted between 
45mins and one hour.  Firstly, an MUR was undertaken.  As full a history, as 
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possible, of the patient’s pain medicines to date and the effectiveness of individual 
pain medicines was recorded.  Other medications, including OTC products, were also 
reviewed because of the possibility of drug duplications or interactions.  Explanations 
were then given to the patients about how their pain medicines could best be used to 
treat their pain.  Two points were always included.  Firstly, the patient needed to be 
aware of whether the pain medicines being take were helpful.  Secondly, that they 
should have an action plan for using their pain medicines when their pain flared or to 
facilitate important necessary life events which had the potential to cause pain.  The 
agreed salient points were included in the letter to the patients GP.   
4.6. Research guidelines  
4.6.1. CHECKLIST FOR COHORT STUDIES 
The STROBE Statement (Strengthening the reporting of observational studies in 
epidemiology) set out a suggested checklist of items that should be included in a 
cohort study (ISPM, 2014).  This guidance was followed during the planning of this 
research.  
4.6.2. CHECKLIST FOR BIAS CONTROL 
A checklist promulgated by the Cochrane Collaboration to minimise bias in cohort, 
observational studies was published in 2018 (Cochrane, 2018).  This includes eight 
points which should be considered when undertaking such studies to minimise bias 




Comparison of this research process with the Cochrane bias tool revealed that there 
was a chance of bias in this research.  All patients included in this research were 
suffering with chronic pain and were expected to have high pain scores at 
presentation.  The sub-group who were referred to the pharmacist’s clinic were at 
approximately the same point in their care and within the same time frame.  They 
were all exposed to the same processes during consultations with the pharmacist 
and similar data were recorded for each patient.  The data for patients who were 
seen once and those who were seen twice was kept separate and used either as 
total data or paired data.   
4.7. Inclusion and exclusion Criteria 
The following Inclusion and Exclusion criteria were applied to this research. 
4.7.1. INCLUSION CRITERIA 
i. Adult patients attending the Chronic Pain Service in the South Division of the 
Staffordshire and Stoke on Trent Partnership NHS Trust 
ii. Patients who were willing and able to give full, voluntary, informed consent. 
4.7.2. EXCLUSION CRITERIA 
i. Patients who were not willing or not able to give full, voluntary informed 
consent 
ii. Patients who were not able to fully comprehend the paperwork through age, 
incapacity or insufficient literacy in English  
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iii. For patients’ not able to read the research paperwork because of insufficient 
literacy in English. If a translator was advised for the patient’s clinic 
appointment and was available then an effort was made to include these 
patients. As a researcher self-funded study there were no funds for the 
translation of any paperwork into other languages. 
iv. Patients taking medicines in a separate clinical trial, which may confound the 
results of this research. 
 
4.8. Data handling and security 
All the data collected for this study was handled in accordance with Trust and 
University procedures.   
 
All data from the ‘Researchers Drug Datasheet’ was transferred to Excel and 
Software Package for Social Science (SPSS) version 19.0 research spreadsheets for 
analysis.  
 
Each patient attending the Chronic Pain Service had a unique set of notes, relating 





All patients who were entered into this study were given a unique sequential number 
starting with M(ale) or F(emale).  The file linking these numbers and the patient’s 
name was stored separately. 
 
During this study, all patient research data was stored on Trust encrypted computers, 
which were controlled by the Trust's governance policies. Any paper records were 
stored in a Trust office along with other patient records in a locked filling cabinet in a 
locked office. 
4.9. Statistical review 
4.9.1. STATISTICAL ANALYSIS 
Prior to the commencement of data analysis statistical advice was sought from 
James Hodson (Hodson, 2017), Institute of Clinical Sciences, Medicine and Medical 
Education, University of Birmingham. 
 
This study cohort was made up of patients suffering with chronic pain who had been 
referred to the pharmacist’s clinic.  As a result, it was highly likely that their pain 
would be skewed towards higher results on a 0-10 NRS pain scale and a 0-24 S-
LANSS scale, resulting in a non-normal distribution.   Therefore, prior to any analysis, 
pain scores were assessed for normality. 
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4.9.2.  POWER CALCULATION 
No data were available to estimate the degree of improvement that would be 
expected from any intervention, nor what distribution these improvements would 
take.  For this reason, the power calculation was performed based on a sign test, 
using the assumptions set out below by the statistician.     
 
‘The recruitment target for this research was for 100 patients to be recruited between 
April 2016 and August 2017.  Assuming that 80 patients returned for a second 
appointment after four months, the minimum detectable difference would be that 66% 
of patients show some degree of improvement in their VAS or S-LANSS pain scores 








CHAPTER 5 RESULTS 
5.1.  Introduction  
This chapter will set out the demographics of the patients involved in this research.  It 
will then record the patients NRS and S-LANSS pain scores and the pain medicines, 
which they reported using at their 1st visit.  It will then examine any changes in pain 
scores and perceptions of the effectiveness of their pain medicines, which the 
patients reported between their two clinic visits.  It will conclude with any changes in 
patients’ attitude towards their pain medicines.   
5.2. Baseline information about the research cohort 
The aim was to recruit 100 patients between April 2016 and August 2017 
 
Much of these data were extracted from the BPI and S-LANSS questionnaires.  
These are relatively complex questionnaires to complete, unsupervised and not 
every patient provided an answer to every question.  There was insufficient clinic 
time to go through each questionnaire with each patient. 
5.2.1. DEMOGRAPHICS OF PATIENTS AT ENROLMENT 
Every patient referred to the pharmacist was offered the opportunity to participate in 
this research and Table 5.1 shows the distribution of the patients recruited between 
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each centre.  Because of the way that patients were recruited to this research 
(Section 4.3) no inferences can be drawn from the overall numbers at each clinic.  
 
The English Indices of Deprivation 2015 divides the country into small areas from 1, 
the most deprived to 32,844 the least deprived.  This index is based upon aliquots of 
1,500 people and ranks then according to seven domains: income, employment, 
education, health, crime, housing and environment. These data can be used to track 
individual areas over time or compare areas geographically (GOV-UK, 2015).
 
 
5.2.1.1. Distribution of cohort across clinics and relative deprivation of each clinic locations 
Table 5.1 Distribution of the research cohort between the five centres (n=100) 
 
Clinic location  Rank position out of 32,844 
(where 1 is most deprived) 







Burton 4,393 20% most deprived 5 (19%) 12 (16%) 17 
Lichfield 11,524 40% most deprived 6 (22%) 11 (15%) 17 
Tamworth 16,701 50% least deprived 3 (11%) 11 (15%) 14 
Rugeley 8,589 30% most deprived 8 (30%) 18 (25%) 26 
Stafford 8,272 50% most deprived 5 (19%) 21 (29%) 26 
Total   27 (100%) 73 (100%) 100 
 
* percentage at this location 
 
The literature suggests that there may be a relationship between social deprivation and chronic pain.  Therefore, the UK Index of 






5.2.1.2. Age distribution of research cohort  
A systematic review by Fayaz et al. (2016) reported that chronic pain increases with 
age.  This normally collected data were included to compare this research cohort with 
the Fayaz et al. (2016) results. The age distribution was set out in Figure 5.1.   
 
 
Figure 5.1 Distribution of the ages by deciles of member of the cohort at 
enrolment (n=100) 
 
There was a wide distribution of ages.  The greater proportion of males were aged 
over 50 years with the largest decile in females being between 40 and 49 years.  The 





















Patient age in years in decile groups
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The numbers of patients in each major decile are set out in Table 5.2.  The table also 
includes the number of patients with NRS>=7 and S-LANSS>=12 pain scores in the 
same decile groups. 
 
In all age groups over 82% of patients presented with severe pain, defined by  Breivik 
et al. (2008) as NRS >=7 and more than 49% of patients reported an S LANSS score 
of >=12 which Bennett (2001) suggested as indicative of elements of neuropathic 






Table 5.2 Age of patients in the cohort with NRS>=7 & S-LANSS>=12 (n=100) 
 











Total with  
S-LANSS>=12** 
Total with both NRS>=7 
& S-LANSS>=12** 
Up to 39 1 (4%) 11 (15%) 12 10 (83%) 6 (50%) 5 (42%) 
40 < 49 7 (26%) 31 (42%) 38 34 (89%) 23 (61%) 22 (58%) 
50 < 59 10 (37%) 13 (18%) 23 19 (83% 13 (57%) 11 (48%) 
60 < 69 5 (19%) 8 (11%) 13 12 (92%) 9 (69%) 8 (62%) 
> 70 4 (15%) 10 (14%) 14 13 (93%) 7 50%) 7 (50%) 
Total 27 (100%) 73 (100%) 100 88 (88%) 58 (58%) 53 (53%) 
 
* Percentages are of the total in this group - male or female 





5.2.1.3. Time since receiving their diagnosis (BPI question 6) 
In order to take account of any impact the period of time patients had waited prior to 
being referred to the CPS and then seen in the pharmacist’s clinic, the waiting time 
was recorded.   
 
Figure 5.2 Time that patients reported waiting (months) (n=85). 
 
The BPI questionnaire asks patients to record the time since diagnosis in months. 
Some patients did not have a (remembered) diagnosis or a definite start point for 
their chronic pain.  Most were reporting the time since the commencement of their 
pain. 
 
More than half of the patients had experienced their pain symptoms for more than 36 





















































Waiting time in months
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median for male patients was 67.5 months and for female patients 60 months.  The 
range of waiting times was one month up to 47 years.   
5.2.1.4. Educational achievement, employment and relationship status of 
the research cohort 
In order to compare the demographics of this cohort with previous research, and to 
set markers for the future the educational status, employment status and patient 
relationships as recorded in the BPI are tabulate below.  Most members of the cohort 
had some level of educational achievement, the largest employment groups were 
retired or unemployed and the majority of the cohort were married.  The number of 
patients with the worst pain (NRS>=7 and S-LANSS>=12) were also included in 
Tables 5.3, 5.4 and 5.5. 
 











Education with  
NRS>=7 & S-LANSS>=12 (%)** 
Left school with no 
formal qualifications! 9 (33%) 14 (19%) 23 16 (70%) 
GCSE or equivalent 10 (37%) 33 (45%) 43 21 (49%) 
A level or equivalent 2 (7%) 10 (14%) 12 6 (50%) 
Degree or equivalent 5 (19%) 12 (16%) 17 8 (47%) 
Not stated 1 (4%) 4 (5%) 5 2 (40%) 
Total 27 73 100 53  
 
* Percentage with this qualification in this group 
** Percentage with this pain score in this educational group 















Employment with NRS>=7 
& S-LANSS>=12 (%)** 
Employed f/t 2 (7%) 7 (10%) 9 5 (56%) 
Employed p/t 0 7 (10%) 7 4 (57%) 
Homemaker 0 9 (12%) 9 5 (56%) 
Retired 11 (41%) 19 (26%) 30 15 (50%) 
Unemployed 9 (33%) 16 (22%) 25 14 (56%) 
Not stated 5 (19%) 15 (20%) 20 10 (50%) 
Total 27 73 100 53 
 
* Percentage with this employment status in this group 
** Percentage with this pain score in this employment group 
! These titles equate as nearly as possible with those in the BPI 
 











Relationship with NRS>=7 
& S-LANSS>=12 (%)**   
Married 13 (48%)  38 (52%) 51 28 (55%) 
Single 6 (22%) 10 (14%) 16 7 (44%) 
Divorced/separated 5 (19%) 15 (21%) 20 12 (60%) 
Co-habiting 0 3 (4%) 3 1 (33%) 
Widowed 2 (7%)  5 (7%) 7 3 (43%) 
Not stated 1 (4%) 2 (3%) 3 2 (67%) 
Total 27 73 100 53 
 
 
* Percentage with this relationship status in this group 
** Percentage with this pain score in this relationship group 
! These titles equate as nearly as possible with those in the BPI  
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5.2.1.5. NRS and S-LANSS scores at enrolment  
Pain scores represented by NRS and S-LANSS scales were recorded at 1st and 2nd 
visits to determine any changes between appointment.   As predicted patients 
referred to the CPS had high initial NRS scores with a skewed distribution towards 




Figure 5.3 Initial NRS pain score for each member of the cohort (n=100) 

























Initial S-LANSS scores however were variable with no pattern of distribution across 
the score range of 0 – 24 (Figure 5.4) 
 
Figure 5.4 Initial S-LANSS score for each member of the cohort (n=100) 
 
These results indicate the S-LANSS scores are not normally distributed 
 
 
Table 5.6 Baseline patients’ mean pain scores for the cohort (n=100) 
Baseline pain scores for 
research cohort 
Male 27  Female 73 Total 100 
Mean NRS (0-10) pain score  8.3  8.1 8.1 
Mean S-LANSS (0-24) if >=0  13.7 14.2 14.1  
 
Mean pain score values are presented in Table 5.6.  Although the data were not 
normally distributed, means pain score values are included for comparison with the 























5.2.1.6. Reluctance of research cohort to take their pain medicines 
Objective 4 of this research was to investigate patients’ attitudes towards their pain 
medicines.  At their 1st appointment almost one patient in five (Table 5.7) declared 
that they were reluctant to take their pain medicines, at the outset of their clinic 
appointment.  
 
Table 5.7 Patients’ reluctance to take pain medicines at 1st appointment (n=18) 
Expressions of reluctance to take 
medicines (percentage of 
‘reluctant’ group) 
Male Female Total (%) 
Reluctant to take pain medicines  6 12 18 
Reluctant to take pain medicines 
with NRS >=7 
5 11 16 (89%)* 
Reluctant to take pain medicines 
with S-LANSS >=12 
5 10 15 (83%)* 
Reluctant to take pain medicines 
with NRS>=7 and S-LANSS >=12 
3 9 12 (67%)* 
 
* Percentage with this pain score of ‘reluctant’ group (n=18) 
 
As shown in Table 5.7 a high percentage of patients with pain scores indicating 






5.2.2. USE OF MAIN GROUPS OF PAIN MEDICINES AT ENROLMENT 
The published literature contains suggestions that the severity of pain and the use of 
pain medicines was related to social class and/or levels of deprivation (Bonathan, 
Hearn and Williams, 2013; Wakefield et al., 2016; Torrance et al., 2006; Chen et al., 
2019; Carr and Moffett, 2005; Morgan, Conway and Currie, 2011).  Therefore, in 
Table 5.8 the use of pain medicines is presented by CPS clinic location and level of 
deprivation.  Table 5.9 expands this to include the use of strong opioids and 
medicines for neuropathic pain in relation to NRS >=7 and S-LANSS >=12. 
 
In Burton, the most deprived area, the proportion of patients who reported taking of 
mild/moderate opioids was greater, whilst the proportion of NSAIDs was lower than in 










* Percentage taking this pain medicine at this location 
 
Location Rank deprivation 



























Burton 4,393 17 14 (82%) 14 (82%) 6 (35%) 13 (76%) 6 (35%) 
Lichfield 16,701 17 12 (71%) 8 (47%) 7 (41%) 11 (65%) 10 (59%) 
Tamworth 11,524 14 8 (57%) 8 (57%) 5 (36%) 10 (71%) 8 (57%) 
Rugeley 8,589 26 17 (65%) 12 (46%) 6 (23%) 18 (69%) 13 (50%) 
Stafford 8,272 26 16 (62%) 11 (42%) 12 (46%) 20 (77%) 13 (50%) 




Table 5.9 Patients with NRS >=7 and S-LANSS >=12 by location and the 
numbers of these taking ‘strong opioids’ or neuropathic medicines 
 
 Number in cohort 
at this location 
Number with NRS 
>=7 (%)* 
Number with 
S-LANSS >=12 (%)* 
Burton 17 15 (88%) 12 (71%) 
Lichfield 17 14 (82%) 11 (65%) 
Tamworth 14 12 (86%) 7 (50%) 
Rugeley 26 23 (88%) 13 (50%) 
Stafford 26 24 (92%) 15 (58%) 
Total 100 88 58 
  Number in cohort 
at this location 
Number with NRS 
>=7 taking strong 
opioids (%)** 
Number with 
S-LANSS >=12 taking 
neuropathic medicines (%)** 
Burton 17 6 (40%) 9 (75%) 
Lichfield 17 5 (36%) 8 (73%) 
Tamworth 14 5 (42%) 6 (86%) 
Rugeley 26 5 (22%) 9 (69%) 
Stafford 26 11 (46%) 12 (80%) 
Total 100 32 (36%) 44 (76%) 
 
* Percentage with this pain score at this location 
** Percentage taking this pain medicine with this pain score at this location 
   
Stafford had the highest proportion of patients with an NRS >=7 and at the same time 
had the highest proportion of patients taking strong opioids.  Burton had the highest 
proportion of patients with an S-LANSS >=12 and one of the lower proportions of 
patients taking medicines appropriate for this condition.  Overall, a third of patients 
with an NRS >=7 were taking strong opioids and three quarters of patients with an S-
LANSS >=12 were taking medicines appropriate for this condition.   
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5.3. Changes in pain scores between visits 
5.3.1. INTRODUCTION 
This section will set out changes in the pain scores recorded in the BPI and S-
LANSS between the 1st and 2nd appointments.  It will focus on those which changed 
significantly but mention those that did not. 
 
The number of patients who returned for a 2nd appointment was 55, between July 
2016 and November 2017.  The number of patients who answered individual 
questions in the questionnaires used varied from question to question.  The following 
changes in pain scores were from paired patients (n) unless otherwise stated. 
 
The pain score information collected from each of the patients in this research was 
from four pain scales as described in Section 4.5 (Section 8.4.2 and 8.4.3).  
5.3.2. STATISTICAL ANALYSIS 
Prior to undertaking any statistical analysis, bar charts were produced of the 
frequency of occurrence of each NRS and S-LANSS pain scores of the cohort 
(Figure 5.3 and 5.4).  Neither the NRS or S-LANSS scores were normally distributed, 
therefore, non-parametric statistical tests were applied. 
 
In the event only 55 patients returned for a 2nd appointment.  Advice was sought from 
the statistician, about whether this reduced total was sufficient for meaningful 
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analysis.  The advice was that the statistical tests suggested for use (Wilcoxon 
Signed Rank test, McNemar test and Fisher exact test) were more powerful than 
those used in the original calculations and that therefore there was no necessity to 
change the original statistical basis for the research (Hodson, 2017).   
5.3.3. CHANGE IN PAIN SCORES BETWEEN THE 1ST AND 2ND APPOINTMENT 
Objectives one and two of this research were to assess and characterise the 
patients’ pain.  In order to determine whether changes had occurred between the 1st 
and 2nd appointments, changes in the main scores from the pain questionnaires were 
examined.  This was followed by a more detailed examination of some of those 
results.  Finally, the other measures of pain reported in the BPI were set out. 
5.3.3.1. Changes in the overall NRS, BPI and S-LANSS scores 
As shown in Table 5.10, patient’s pain scores from BPI and S-LANSS reported from 
their 1st and 2nd appointment were compared.  None of the changes were statistically 











Table 5.10 Changes in mean pain scores for paired results between 1st and 2nd 
visits (n=53) 
Pain scale  1st visit   2nd visit  
 Male Female Total Male Female Total 
Mean NRS score 8.7 7.5 8.1 8.1 7.4 7.7 
Mean BPI-PSS* 6.7 7.1 7.0 6.6 6.9 6.8 
Mean BPI-PIS** 8.0 7.1 7.6 7.8 7.4 7.6 
Mean S-LANSS score  12.3 12.7 12.6 12.5 12.4 12.5 
 
* Brief pain inventory – pain severity score 
**Brief pain inventory – pain interference score 
 
The only significant change was reported in Figure 5.5. 
5.3.3.2. Pain score changes in relation to attendance at PMP  
Fifty-five patients returned for a 2nd appointment.  Of these 18 (3 males and 15 
females) had attended a PMP course between their 1st and 2nd appointments (Table 
5.11).  This patient sub-group were a small proportion of the overall cohort.  No 






Table 5.11 Changes in mean pain scores between paired patients who had attended PMP and those who had not. 
 
    2nd appointment before PMP 
sub-group (n=32)* 





Mean scores 1st 
appointment 
(n=55) 
Mean scores 2nd 
appointment 
(n=55) 
Mean scores 1st 
appointment 
(n=32) 
Mean scores 2nd 
appointment 
(n=32) 
Mean scores 1st 
appointment 
(n=18) 









12.6 12.5 12.8 13.4 11.9 11.1 
 







5.3.3.3. Changes to the individual elements of the BPI-PSS and BPI-PIS 
scores  
The individual elements of the BPI-PSS and the BPI-PIS, were examined in detail to 
determine whether any of the individual element scores changed significantly.  This 
revealed that of the 11 elements encompassed by these two overall scores only the 
‘Worst’ element of the BPI-PSS (question 12) reduced significantly, from a mean of 
8.4 to a mean of 7.9. (Figure 5.5) 
  
Figure 5.5 Changes in the four elements of the Pain Severity Score (BPI-PSS) 
for paired results (n=51)  







































This result suggested that patients perceived their ‘Worst Pain’ had improved 
between the 1st and 2nd clinic visits.  An outlier to the results of 2nd visit patients 
reported low score of 2. 
 
Further analysis of these changes (Table 5.12) revealed that when answering the 
four questions of the BPI-PSS scores (Section 8.4.2) the number of patients who 
reported improvements in their pain were similar but overall fewer patients reported 
an increase in their pain in question 12 than for questions 13-15. 
 
Table 5.12 Further analysis of changes in the BPI-PSS scores between 1st and 
















2 or more 
Pain worst (Q 12) 9 (18%) 24 (48%) 9 (18%) 8 (16%) 
Pain best (Q 13) 15 (30%) 16 (32%) 10 (20%) 9 (18%) 
Pain average (Q 14) 15 (30%) 21 (42%) 5 (10%) 9 (18%) 
Pain now (Q 15) 18 (36%) 14 (28%) 9 (18%) 9 (18%) 
 
These results indicate that fewer patients reported a ‘worse’ pain score when 




5.3.3.4. Changes in percentage pain relief during the previous week 
resulting from the use of their pain medicines  
The BPI question 19 (Section 8.4.2) asked patients to record how much pain relief 
the use of their pain medicines had provided, as a percentage, during the previous 
week.  The mean % improvement in pain relief increased from 41% at their 1st 
appointment to 51% at their 2nd appointment i.e. patients reported that their pain 




Figure 5.6 Mean percentage pain relief resulting from use of pain medicines 
(n=50)  




























   
5.3.3.5. How long before pain returns after taking/using pain medicines  
Patients were asked to record (BPI question 20) (Section 8.4.2) how many hours 
before their pain returns after taking/using their pain medicines, by choosing from a 
range of answers ranging from ‘Pain medication doesn’t help at all’ up to ‘24 hours’.  
 
The data were analysed in two ways.  Firstly, did the percentage of patients who 
thought that their pain medicines gave them no benefit change between the two 




Figure 5.7 Did your pain medicines give you any pain relief? (n=40) 































These results suggested that at their 2nd appointment all but 12% (5) of the patients 
now believed that their pain medication gave them some relief. 
 




Figure 5.8 Changes in reported duration of pain relief? (n=40) 
(Wilcoxon signed rank test P = 0.003)  
 
These results suggested that at their 2nd appointment patients reported that the 
benefit of their pain medication was lasting longer.  The combination of these two 
analyses suggest that more patients were achieving a significant improvement in 










































5.4. Changes in the reported efficacy of pain medicines 
between visits 
5.4.1. INTRODUCTION 
When the pharmacist was undertaking each MUR, patients were asked about each 
of their pain medicines in turn ‘Is this helpful?’ with a response of yes/maybe/no?  
Analysis of the benefits that patients reported for the five groups of pain medicines 
investigated in this research (paracetamol, mild/moderate opioids, strong opioids, 
neuropathic medicines and NSAIDs) are based upon the answers to these questions.  
The results of this analysis are set out sequentially.  Firstly, the changes in overall 
helpfulness of the five analgesic groups and then each medicine/group in more 
detail. 
 
Analysis of the ‘helpfulness’ of analgesics was limited to the overall helpfulness of 
each group.  The number of reports for many of the individual medicines was too 
small to allow for meaningful analysis in any greater detail. 
 
These data ‘does this pain medicine help? – yes/maybe/no were relatively complex.  
Statistical guidance was sought on how the answers to these questions could best be 
analysed.  It was decided that if patients responded with ‘unsure’ of any benefit that 
this would be recoded as ‘no benefit’ (Hodson, 2017).  The analysis was then 
undertaken using binary yes/no data.  Two analyses of these data were undertaken 
initially to check the validity of this approach.  Firstly, using the answers from all of 
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the patients using a medicine at each appointment, the Fisher exact test was used.  
This test accepts the use of unequal sized groups.  Secondly, using only answers 
from the patients who were using the same medicine at both appointments the 
McNemar test was used.  This test required groups of equal sizes. 
 
Table 5.13 presents two sets of data.  Firstly, the overall changes in pain medicine 
taken between the two visits because patients both stopped and started medication 
between visits.  At the 2nd appointment 19 of 55 patients reported taking a new pain 
medicine, but 47 of 55 reported stopping a pain medicine.  The overall trend was for 
more pain medicines to be stopped except for neuropathic therapies where more 
where started.  Secondly, changes that patients reported for the perceived 











Table 5.13 Changes in the overall numbers of patients who used each of pain medicine groups and their reported efficacy 
between 1st and 2nd visits 
 
     Analysis - patients taking pain 
medicine at each visit using Fisher 
exact test (FET) 
    Analysis - patients taking pain 
medicines on both visits using 
McNemar test 
  
Pain medicine   visit 1  visit 2  P value visit 1  visit 2  P value 
Analgesic Start* Stop** n Helpful (%)+ n 
Helpful 





Paracetamol 0 22 41 22 (54%) 33 20 (61% 0.079 31 18 (58%) 31 19 (61%) 1.000 
Mild/moderate 
opioid 5 8 35 18 (51%) 32 26 (81%) 0.010 27 12 (44%) 27 22 (81%) 0.006 
Strong opioid 2 5 18 9 (50%) 15 11 (73%) 0.284 13 8 (62%) 13 10 (77%) 0.625 
Neuropathic 9 4 39 23 (59%) 44 32 (73%) 0.246 35 22 (63%) 35 23 (65%) 1.000 
NSAID 3 8 28 16 (57%) 23 15 (65%) 0.580 20 10 (50%) 20 13 (65%) 0.375 
Total 19 47           
 
* Starting an analgesic between 1st and 2nd appointments 
** Stopping an analgesic between 1st and 2nd appointments 
! Fisher exact test  





There was generally little change observed in the perceived helpfulness of pain 
medicines between visits.  The only significant change was that a larger number of 
patients reported that mild/moderate opioids (codeine, dihydrocodeine and tramadol) 
were more helpful at their 2nd visit than their 1st (Fisher exact P = 0.01, McNemar 
P=0.006).  The numbers of patients taking mild/moderate opioids were sufficient to 
allow further examination of these results.  At their 1st appointment 9 of 17 (53%) 
patients reported tramadol as helpful and this increased to 14 of 15 (93%) at the 2nd 
appointment.  Changes in the percentage of patients reporting benefit with codeine 
increase from 50% to 60%) and with dihydrocodeine the increase was from 25% to 
60% based on smaller samples. 
 
5.4.2. THE EFFECTIVENESS OF INDIVIDUAL PAIN MEDICINES  
The analysis of whether the individual pain medicines, were regarded as effective, 
was then expanded in the same way for each group of pain medicines, does this 
medicine help with your pain yes /maybe/no?  The statistical significance of any 
change was then determined, after conversion to binary data, using a McNemar 







Paracetamol can be a very effective pain medicine, in some situations, if it is used 
correctly.  On their 2nd visit there was a trend for patients to report that they were 
clearer about the use of paracetamol and more positive about its effectiveness, but 
the changes were not statistically significant (Figure 5.9). 
 
 
Figure 5.9 Paracetamol, does it help with your pain control? (n=31) 
 
There was still some uncertainty at the 2nd appointment.  The proportion of patient 
taking paracetamol who reported it as not helpful increased, but the proportion who 





























5.4.2.2. Mild moderate opioids 
At their 1st appointment a slightly smaller proportion of patients regarded 
mild/moderate opioids (codeine, dihydrocodeine and tramadol) as effective, 
compared with paracetamol (Table 5.13).  When they returned for their second 
appointment the percentage of patients who reported that mild moderate opioids 
were helpful increased from 51% to 81%.   
. 
 
Figure 5.10 Mild moderate opioids, do they help with your pain control? (n=27) 
(Fischer exact P=0.01 and McNemar P=0.006) 
 
In addition, smaller proportions of patients regarded them as ‘not helpful’ or were 
































5.4.2.3. Strong opioids  
The strong opioids patients reported taking or applying included morphine, 
oxycodone, buprenorphine and fentanyl.  As with paracetamol and mild/moderate 
opioids just over half of the patients regarded these medicines as helpful at their 1st 
appointment (Table 5.13).  The proportion of patients finding these helpful increased 
when they returned for their 2nd appointment but the change was not statistically 
significant (Figure 5.11). 
 
Figure 5.11 Strong opioids, do they help with your pain control? (n=13) 
 
Thirty-six of the patients in this cohort of 100 were taking a strong opioid at their 1st 
appointment and of these 36 patients, 32 (89%) had an NRS pain score of >=7.   
 
Three patients in this cohort made considerable efforts to reduce their strong opioid 
dose, including three who were successful.  Two patients stopped their 






























pain.  The third patient who had been using a Fentanyl patch (50microg/hour) was 
able to reduce this to 12microcg/hour.  
5.4.2.4. Medicines used in the treatment of neuropathic pain. 
Thirty-five patients were taking medicines for neuropathic pain (gabapentin, 
pregabalin, amitriptyline, nortriptyline and duloxetine).  The proportion of patients who 
regarded medicines for neuropathic pain as helpful at their 1st appointment was 
higher than for strong opioids (Table 5.11).  This proportion improved at the 2nd 




Figure 5.12 Medicines for neuropathic pain, do they help with your pain 
control? (n=35) 
One unexpected finding was that some patients reported, spontaneously, initiating 






























changes were made either in response to changes in their pain, or the side effects of 
the medicines were too problematic for continuous therapy. 
5.4.2.5. NSAIDs  
The Oxford league table of acute pain medicines reported NSAIDs as medicines for 
acute pain with the lowest NNT (FOPM, 2007).  The proportion of patients at their 1st 
appointment who regarded ibuprofen, naproxen and diclofenac as helpful was almost 
as high as for therapy for neuropathic pain (Table 5.13).  This increased at the 2nd 
appointment but the change was not statistically significant. 
 
 
Figure 5.13 NSAIDS, do they help with your pain control? (n=20) 
 
These were the only medicines, where the number of patients who were taking them, 





























5.5. Changes in answers to the questions in the Brief Pain 
Inventory.  
5.5.1. INTRODUCTION 
The following sections set out the patients’ responses to BPI questions 24 -30 
(Section 8.4.2) which explore patients’ attitude to and understanding of their pain 
medicines.  They are presented as paired results.  Not every patient answered all the 
questions on both appointments in each questionnaire.  As a result, the ‘n’ for each of 
these questions is different. 
 
As with the answers to the questions about the efficacy of medicines the BPI includes 
three possible answers yes/maybe/no.  These data were transformed into a binary 
yes/no form for a McNemar significance test.    
5.5.1.1. Patient preferences for taking their pain medicines – (BPI 
Questions 24 and 25) 
These two questions ask patients about medicine taking routine and about how 
frequently they preferred to take their pain medicines.  Table 5.14 shows that patients 
reported few changes in their medicine taking habits between the 1st and 2nd visits.  





Table 5.14 Answers to BPI questions 24 and 25 at 1st and 2nd appointments 
 
BPI question 24 






On a regular basis 35 36 
Only when necessary 11 13 
Do not take pain medicines 1 1 
BPI question 25 
I take my medicines  
  
Not every day 2 2 
1 to 2 times a day 7 9 
3 to 4 times a day 30 38 
5 to 6 times a day 6 2 
More than 6 times a day 0 0 
 




5.5.1.2. Did patients feel they needed stronger pain medicines (BPI 
question 26)? 
It was anticipated that patients who had been referred to a chronic pain clinic would 
think that they needed stronger pain medicines.  At their 1st appointment 57% 
reported this. At the 2nd appointment this reduced significantly to 37% (Figure 5.14). 
 
 
Figure 5.14 Changes in the percentage of patients who think that they need 
stronger pain medication (n=49) 
(McNemar P=0.002) 
 
These changes suggested that at their 2nd visit fewer patients thought that they 




























5.5.1.3. Did patients feel they needed to take more pain medicines than 
prescribed (BPI question 27)? 
It was also anticipated that patients who had been referred to a chronic pain clinic 
would be tempted to take more pain medicine than had been prescribed by their 
prescriber, if their pain was not adequately controlled.  At their 1st appointment 33% 
reported this.  At the 2nd appointment this reduced significantly to 21% (Figure 5.15). 
 
 
Figure 5.15 Changes in the percentage of patients who think that they need to 
take more pain medication than had been prescribed (n=45) 
(McNemar P=0.004) 
These changes suggested that at their 2nd visit fewer patients thought that they 
































5.5.1.4. Were patients concerned they are using too much pain medicine 
(BPI question 28)? 
Patients often express reluctance to take pain medicines.  At their 1st appointment 
46% were concerned that they were taking too much pain medicine.  At their 2nd 
appointment this reduced significantly to 31% (Figure 5.16). 
 
 
Figure 5.16 Changes in the percentage of patients who think that they are 
taking too much pain medicine (n=48) 
(McNemar P=0.004) 
These changes suggested that at their 2nd visit fewer patients thought that they were 




























5.5.1.5. Did patients feel they needed more information about their pain 
medicines (BPI question 30)? 
In clinic, patients often asked questions about the risks and benefits of their pain 
medicines.  At their 1st appointment 76% of patients recorded that they would like 
more information about their pain medicines.  At their 2nd appointment this reduced 
significantly to 45% (Figure 5.17). 
 
 
Figure 5.17 Changes in the percentage of patients felt the need for further 
information about their pain medication (n=45) 
(McNemar P=0.001) 
These changes suggested that at their 2nd visit fewer patients felt the need for further 

























Need further info - yes
Need further info - no
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5.5.1.6. Were patients experiencing problems with side effects (BPI 
question 29)? 
Many patients complained about the side effects of their medicines.  At their 1st 
appointment 64% reported experiencing side effects.  At the 2nd appointment this had 
reduced to 52% (Figure 5.18).  This was not a significant change. 
 
 
Figure 5.18 Changes in the percentage of patients who experienced side 
effects with their pain medicines (n=47) 
 
(McNemar P=0.146) 
These changes suggest that at their 2nd visit fewer patients experienced side effects 































5.6. Pharmacist recommendations to GP’s about patients’ pain 
medicines. 
At the 2nd appointment patients were asked ‘what changes had been made to their 
pain medicines?’  If any changes reported were in line with the pharmacist 
recommendations a record was made.  Of the 55 patients who returned for a 2nd 
appointment 30 (55%) reported that at least one of their pain medicines had been 
changed along the lines of the pharmacist’s recommendations.  For many of the 
patients in this research, the pharmacist made more than one suggestion for 
improving their pain treatment.  Therefore, no attempt was made to correlate the 
number of suggestions with the number of changes. 
 
5.7. Contact between the research pharmacist and the GP’s 
treating the research patients 
One of the subsidiary objectives of this research was to ascertain what systems GPs 
had in place to assist with the management of chronic pain.  This was particularly 
with regard to referral letters from the chronic pain service and protocols to be used 
for the treatment of chronic pain 
 
Letters were sent to the Practice Managers of the 80 GP practices which had 
referred patients to the CPT, unless there was an appropriate email address on the 
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Practice web page in which case the request was sent via email.  Of these 80 
practices only three responded.   
 




CHAPTER 6 DISCUSSION 
6.1. Introduction 
This chapter will discuss the results from this research, addressing each one in turn, 
with an accent upon those that are most significant.  Each section of results will have 
its own conclusion.  The chapter will finish with comments about the limitations of this 
research, and recommendations about how these might be addressed in future work. 
6.2. Baseline information about the research cohort 
6.2.1. DEMOGRAPHICS OF THE PATIENTS AT ENROLMENT 
The ratio of women to men who were recruited into this cohort was approximately 
3:1.  Other studies have demonstrated different ratios; Bruhn et al. (2013) and Marra 
et al. (2012) ~ 1:1 Petkova (2009)  and Hadi et al. (2016) ~ 2:1. Epidemiological 
studies suggest that women suffer more frequently and at greater severity with 
chronic pain than men (Bartley and Fillingim, 2013).  The reasons for this are, as yet, 
not understood but may include phenotype variations or different hormonal 
influencers on internal pain modulators (Bartley and Fillingim, 2013).  These 
variations were reported as women having lower pain thresholds and responding 
differently to analgesia.  There were also suggestions that women report higher 
levels of pain intensity, thermal pain, pressure pain and had greater levels of 
acceptance (van Hecke, Torrance and Smith, 2013; Rovner et al., 2017).  When 
women and men reported similar levels of pain intensity women were more accepting 
and maintained higher levels of activity.  Men, on the other hand were more subject 
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to mood disturbance, reported higher kinesiophobia scores and lower activity level 
(Rovner et al., 2017).  Patients pain acceptance and kinesiophobia are behaviourally 
defined and as a result can be changed (Rovner et al., 2017).  This ability to change 
behaviour was one of the tenets of biopsychosocial chronic pain treatment, where the 
maintenance of mobility and patient well-being go along with acceptance of some 
residual pain.   
6.2.1.1. Geographic distribution of cohort 
The researcher undertook clinic sessions and recruited patients from five locations, 
Table 5.1 and Figure 1.1. 
  
Risk factors for chronic pain include advancing age, female sex, lower 
socioeconomic status, lower educational level, obesity, history of a physically 
strenuous job, childhood trauma, tobacco use, history of injury and depression or 
anxiety (Reid, Eccleston and Pillemer, 2015b).  These factors are also associated 
with a lesser ability to cope with chronic pain (Bonathan, Hearn and Williams, 2013; 
Wakefield et al., 2016).  The English Indices of Deprivation (GOV-UK, 2015) included 
domains for income, employment, education and health.  It could therefore be 
suggested that areas with high deprivation are likely to suffer with a higher incidence 
of chronic pain.  The deprivation scores for the five areas of this research were 
included in Table 5.1 with four of the five areas being in the lower half of the 




The relationship between chronic pain and deprivation, in its widest possible 
definition, is circular.  Chronic pain prevents people from doing the things that they 
would like/needed to do, such as employment, relationships and activities of daily 
living.  In turn, their (perceived) inability to do such things can make them more 
withdrawn and more depressed, which in turn can make their pain worse (Bailly et 
al., 2015; Bonathan, Hearn and Williams, 2013; Mittendorfer-Rutz and Dorner, 2017; 
Wakefield et al., 2016; Muneer, 2015; Joud et al., 2014).  The opposite is also true, if 
pain is improved significantly then fatigue, depression and sleep interference also 
improve (Moore et al., 2013).   
 
Table 5.8. sets out the different ‘Deprivation scores’ for the areas around each clinic 
location.  Tables 5.8 and 5.9 also set out differences between the five research 
clinics with regard to pain medication use and pain scores.  This cohort was too small 
to determine whether these related to the locale, the idiosyncrasies of individual GP 
practices in terms of prescribing or coincidence.  
 
The clinic in the area with the lowest ‘Deprivation’ (0=worst) score was Burton and 
the highest was Lichfield.  In Burton the proportion of patients reporting paracetamol 
and mild-moderate opioid use were the same (82%), whereas in Lichfield 
paracetamol use was 71% and mild-moderate opioids 47%.  This could be explained 
by the additional use of strong opioids which were the second highest.  Only, Stafford 




The clinic with the highest proportion of patients with an NRS>=7 was Stafford which 
also had the highest proportion taking strong opioids.  It ranked lowest for the 
proportion of patients with S-LANSS>=12 and second best of the use of neuropathic 
therapy.  Evidence has emerged that opioid prescribing was more prevalent in areas 
of higher deprivations (Chen et al., 2019) at the same time that the benefits of opioids 
in the treatment of chronic pain was increasingly being questioned (NHS, 2015).  
Opioids are valuable for the treatment of acute pain and the pain encountered in 
cancer treatment and palliative care but this usefulness does not extend to chronic 
pain, where they are associated with serious adverse effects (Stannard, 2018).   
 
The focus on the biopsychosocial model of treatment for chronic pain however 
introduces the opportunity of other treatment options instead of opioids.  Sullivan and 
Ballantyne (2016) question how important it is, in the treatment of chronic pain and its 
associated suffering that pain is reduced.  At the same time others are reporting that 
alternative treatment regimens for chronic arthritic pain may offer better overall 
outcomes than opioids (Krebs et al., 2018).  But overarching all of this is the 
possibility that as a result of the pressure to move the treatment of chronic pain away 
from opioids their availability may, in some way, be restricted (Alford, 2016) because 




6.2.1.2. Age of the cohort 
It is generally reported that the prevalence of chronic pain increases with age (Fayaz 
et al., 2016; Johannes et al., 2010; Docking et al., 2011; Thomas et al., 2007; BMA, 
2017).  In a survey of over 17,000 female and male patients suffering with chronic 
pain, the highest prevalence was in females and males in the 55-59 age group, but 
the highest proportion was in the 20-24 age group (Blyth et al., 2001).  This may not 
be surprising because people in the 20-24 age group may be more sensitive to 
anything which interferes with their daily lives or they may be less accepting of 
unsuccessful therapy. 
 
The mean age of patients at recruitment into this research was 51 years, with the 
mode decile for males being between 50 and 59 whereas for females it was between 
40 and 49 (Table 5.2 and Fig 5.1).  This was lower than the ages reported by Bruhn 
et al. (2013) and Marra et al. (2012) but higher then Petkova (2009) and Hadi et al. 
(2016).  The inclusion criteria for Hay et al. (2006) was set at over 55.  Overall there 
was little robust evidence about how the experience of pain changes with age 
(Taverner, 2005; El Tumi et al., 2017; Schofield, 2018).  Therefore, it is probably 
wrong to suggest that patients should be excluded from research into chronic pain 
solely on the grounds of their age, but given the lack of published data it should 




Table 5.2 also included the proportion of those who reported the most severe pain 
(NRS>=7 & S-LANSS>=12).  In this small cohort the results did not indicate any 
trends. 
6.2.1.3. Waiting time prior to appointment with the pharmacist 
The CPS makes strenuous efforts not breach the UK-NHS 18-week rule, for 
treatment after receiving a referral.  It is generally successful, except for those 
aspects of the service such as spinal injections, where others control the resources.    
 
The lengths of time reported by patients in this research in answer to BPI question 6 
(Section 8.4.2), “how long since you knew your diagnosis’” were recorded.  The 
mean wait was 106 months and almost two thirds reported suffering with their pain 
for more than 36 months.   This was explored graphically in Figure 5.2 and this 
appears to indicate that patient waiting times for specialist chronic pain treatment are 
divided into two groups.  Firstly, the decreasing numbers waiting over the first few 
years, possibly whilst the patient and their physician decide that a referral to an 
expert was deemed necessary.  The remainder of the patients were in a group which 
appears to be waiting an inexplicably long time.  The range of patient waits were 
larger than, but similar to those reported in an audit from the Royal College of 
Anaesthetists (Black, 2017) followed up by more localised figures from University 
Hospital Leicester (UHL) (Ingle and Vasu, 2018) (Table 6.1).  The questions used in 
these audits related solely to the times between commencement of pain and referral.  
This was different to Question 6 of the BPI, used with this cohort, which made 
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mention of a diagnosis.   The length of time that patients had had their pain was 
reported in one of the papers in the systematic review (Harrison, 2015) and these 
were also included in Table 6.1.   
 
Table 6.1 Length of time – pain onset, to pain clinic appointment  















Range 5 months 
– 27 years 
Mean 74 months. 




Range 2 years 
- 20 years 
Mean 106 
months. 
Range 1 month –  
47 years 
 
1 (Ingle and Vasu, 2018) 
2 (Black, 2017) 
3 (Harrison, 2015) 
*This research asked for time from diagnosis 
In addition to the wait for a referral there was the wait for an appointment after the 
referral was made and as mentioned above, for this service, these were generally 
less than 18 weeks.  Waits for a CPS referral appointment are well documented.  A 
Scottish report in Jan 2019 recorded that 399 of 2,798 patients waited for more than 
27 weeks (NHS, 2019b).  A similar investigation in Australia recorded waits of up to 
86 weeks with a national median wait of 15 weeks (Hogg et al., 2012). 
 
Waiting time prior to appointments are relevant because not only is it associated with 
an increased risk of mortality, independent of other socio-demographic effects 
(Torrance et al., 2010) it also doubled the suicide risk (Liddy et al., 2017).  There are 
suggestion that some forms of chronic pain and its sequelae can worsen whilst 
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waiting for treatment within as little as five weeks (Lynch et al., 2008).  Furthermore, 
whilst awaiting referral, fear-avoidance beliefs, where the anticipation of pain 
resulting from movement inhibits further movement, may contribute to worsening 
levels of kinesiophobia and poorer overall physical ability (Gatchel et al., 2016).   
 
6.2.1.4. Educational achievements of the research cohort 
More than three quarter of patients declared some educational qualifications (Table 
5.3).  These results were similar to those reported by Hadi et al. (2016) but different 
to those reported by Bruhn et al. (2013),  who reported a more equal division 
between those with an education certificate that those with none.   
 
The relationship between educational achievement and chronic pain is complex.  
There were reports that the prevalence of chronic pain was associated with lower 
levels of educational achievement (Currow et al., 2010; Saastamoinen et al., 2005).  
Alternately Roth and Geisser (2002) suggested that the level of educational 
achievement was unrelated to pain severity and intensity but was inversely related to 
self-reported disability i.e. as the pain intensity goes up, reporting that pain causes a 
problem goes down.   
 
Table 5.3 also included the proportion of patients with the most severe type of pain 
(NRS>=7 & S-LANSS >=12).  The results from this small cohort appear to indicate 
that the proportion of patients with NRS>=7 and S-LANSS >=12 pain reduced as 
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their education achievements rises.  In addition it has been reported that chronic pain 
intensity decreases as health literacy increases (Koppen et al., 2018) and heath 
literacy is related to patient’s literacy and competences to understand the treatments 
being offered (Wittink and Oosterhaven, 2018). 
6.2.1.5. Employment status of the research cohort 
The distribution of employment status of the recruits was set out in Table 5.4.  For 
males, over 40% are ‘retired’, which was likely to be due to the age distribution of the 
cohort (Table 5.2) and a third were unemployed.  The largest group of females was 
also ‘retired’ but with a much smaller percentage (26%).  More females were 
recorded as employed both part time and full time, in addition to being younger.  
 
Overall, this cohort was approximately equally divided between employed, 
unemployed and retired.  For Bruhn et al. (2013) the largest group was retired, whilst 
for Hadi et al. (2016) the largest group was unemployed.  Unemployment or life on 
benefits almost inevitably means fewer socio-economic benefits.  If this relationship 
was as reported then the commencement of chronic pain with all of its sequalae 
could easily lead to a downward spiral of greater disadvantage and more severe 
pain. 
 
Table 5.4 also includes the proportion of those patients who suffered with the most 
severe type of pain (NRS>=7 & S-LANSS>=12).  These results did not give any 
indication of variation with employment status. 
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6.2.1.6. Relationship status of the research cohort 
Just over half of the original cohort of patients reported that they were married, Table 
5.5.  This was similar to the proportions reported by both Bruhn et al. (2013) and 
Hadi et al. (2016).  It has been widely reported that marriage is associated with 
improved psychological and physical well-being in both men and women (Shapiro, 
Lee and Keyes, 2008). However, there was only weak support for the hypothesis that 
being married helped with pain related emotional suffering (Wade et al., 2013).  
 
Table 5.5 also includes the proportion of those patients who suffered with the most 
severe form of pain (NRS>=7 & S-LANSS>=12).  These results did not give any 
indication of variation with their relationship status. 
6.2.1.7. Reluctance to take (pain) medicines 
At their 1st appointment 18 patients expressed openly at the outset that they were 
resistant to taking pain medicines (Table 5.7).  Of these 16 (89%) had an NRS pain 
score of >=7, 15 (83%) had an S-LANSS score of >=12 and 12 (67%) had both.  The 
reasons why patients with such high pain scores were unwilling to take their 
analgesia were difficult to ascertain.  For some patients it was avoiding side effects, 
for others it was ineffective therapy.  There was also a group of patients who seemed 
to regard taking medicines as something that they were unwilling to do, almost that 
acquiescing to treatment gave their pain power over their lives.  This might have 
resulted from a lack of understanding about the correct use of pain medicines.  
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Alternatively, it might have been belief in inappropriate or wrong facts about their pain 
medicines.   
 
The relationship between medicine side effects and compliance with therapy has 
been explored by others (Leporini, De Sarro and Russo, 2014) but the literature, 
particularly in relation to patients over 65 is very limited (Gellad, Grenard and 
Marcum, 2011).  What is contained in those reports is that a multi-faceted approach 
to non-adherence is better than focussing solely on the prescriber/patient 
relationship.  Such an approach is practiced by this CPT and may well have 
contributed to its relative success.  It is well documented that many of the medicines 
used in the treatment of chronic pain had unpleasant side effects viz. opioid induced 
nausea (Moore and McQuay, 2005), gabapentinoid induced brain fog (Zaccara et al., 
2011) and tricyclic induced dry mouth (Cookson, 1993) and these will always deter 
some patients regardless of the severity of their pain.  Whatever the reason, these 
patients may have deprived themselves of potentially effective treatment (Horne et 
al., 2005).   
 
6.2.1.8. Conclusion  
The role of the pharmacist is to empower patients to engage with their chronic pain 
therapy in ways which enabled them to judge their personal need for the medicine 
relative to their concerns about the potential adverse consequences (Horne et al., 
2013).  The improvements in pain scores reported by the patients in this research 
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would suggest that such empowerment can have benefits in terms of both the extent 
and duration of analgesia. 
 
Chronic pain and the treatment of chronic pain are context specific (Scott, 2019; 
Crofford, 2015) and no aspect of chronic pain can be independently and objectively 
verified.  The best quantitative measures that we have are based upon the plethora 
of extant measuring questionnaires (BPI, S-LANSS or CPG).  Unfortunately, 
research tells us that patients use these as relative scales rather than absolute 
measures (Robinson-Papp et al., 2015).  Therefore, in chronic pain research it is 
important to record the demographics so that research findings can be related to 
those which have gone before. 
6.2.2. BASELINE S-LANSS SCORES IN RELATION TO EARLIER AUDIT 
Tables 5.2 and 5.6 reported that for this research cohort out of 100 patients 58 
reported an S-LANSS score >=12 with a mean score of 14.1.  These results were 
similar to those reported from the audit which had initiated this research project.  In 
that audit of 100 patients 57 patients reported an S-LANSS>=12 with a mean of 13.6.  
The results from these two cohorts suggest a consistent number of patients attending 
the pharmacist’s clinic within the CPS with neuropathic elements in their pain as 
defined by the S-LANSS questionnaire. 
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6.3. Changes in pain scores between visits 
6.3.1. INTRODUCTION 
This section discusses the changes in patients’ pain scores between the 1st and 2nd 
clinic appointments.  
 
Consideration of changes in pain scores often lead to discussions about whether it is 
possible to define an objective minimum change in a pain score.  Some research 
suggested that regardless of the level of the initial pain score a specific change in the 
score would result in an effect which the patient regarded as clinically significant 
(Kelly, 2001).  Other reports suggests that the reduction must equate to two points on 
an 11 point scale (Dworkin et al., 2008).  Todd et al. (1996) and Kendrick and Strout 
(2005) suggested that for patients in a trauma unit changes of less than 1.3 VAS 
were not clinically significant with no attempt to relate this to the patients’ original 
pain score.  This was countered by the suggestion that the higher the original pain 
score the greater the change required before the patient would regard it as clinically 
significant (Bird and Dickson, 2001).  Dworkin et al. (2008) and Farrar et al. (2001) 
adopts a different approach and suggested that the clinical significance of any 
reduction was related to the percentage change and this may need to be 30% before 
it would be regarded as clinically significant.  Other researchers suggesting variation 
between genders and pain type (Mark et al., 2009), but even this has been refuted, 
Kelly (1998) reported a lower clinically significant change of 0.9 VAS with no 
differences between gender, age or cause of pain.  Underlying all of this is the 
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comment in Section 6.2.1.8. that patients regard all of these scales as relative 
(Robinson-Papp et al., 2015) and therefore any improvements recorded and 
discussed may relate to something else altogether. 
 
The changes in NRS pain between the 1st and 2nd appointment for this research 
cohort appeared to be similar to those reported in by Bennett et al. (2011).  This 
reported that patients who received a 2.5 hours intensive education program from a 
pharmacist, recorded an improvement in their pain score of 0.5 on an eleven-point 
scale.  Less intensive intervention was ineffective.  In this research patients recorded 
a mean 0.4 improvement in their NRS score with a 0.5 improvement in their BPI PSS 
‘worst’ pain score (Table 5.10 and Figure 5.5).  By the time of their 2nd appointment 
all patients would have had 1st appointment with the pharmacist which lasted up to an 
hour.  Eighteen of the 55 patients, (Table 5.11) had attended the PMP programme, 
which includes a 1.5-hour presentation and discussion with the research pharmacist.  
This would represent an overall total of 2.5 hours of interaction with the pharmacist 
which was similar to the input suggested by Bennett (2011) as being effective.   
 
The pain scores in Table 5.11 set out the differences in the mean NRS and S-LANSS 
scores for those patients who had and had not attended a PMP between the two 
pharmacist appointments. At their 2nd appointment the largest change was in the 
NRS score of the small group who had attended a PMP.  This reduced from 8.4 to 
7.5.  Of those who had not attended, the S-LANSS increased from 12.8 to 13.4.  An 
indication in the complexity of measuring pain scores.  Overall the improvements in 
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pain scores of the small subgroup who had had the additional intervention appeared 
larger than those who had not, but the numbers were small.   
 
The mean NRS score of the patients in this research on their 1st visit was 8.1 (Table 
5.10).  Only two reports retrieved for the Systematic Review dealt with patients who 
had an NRS score of this magnitude, all others were less.  Firstly, Thomas (2012) 
reported a mean reduction in the NRS score of 2.7 or 33% for those patients who 
had a pharmacological intervention.  There was no record of the actual NRS scores 
reported, but mathematically, if a reduction of 2.7 is 33% then the baseline NRS 
score would be 8.1.  It would be interesting to discover the analgesic strategies used 
to achieve such a large reduction in the patients’ pain scores.  Secondly, Hadi et al. 
(2016) reported that the ‘Median BPI ‘worst pain’ was 8 with a reduction to 7.5 
(P=0.02). 
6.3.2. CHANGES IN PAIN USING DATA FROM THE BPI AND S-LANSS 
QUESTIONNAIRES  
The overall mean pain scores from the four measures of pain included in this 
research changed very little (Table 5.10).   
 
More detailed analysis of the data of the total paired group from the two 
questionnaires revealed three significant changes, reduction in worst pain, increase 
in perceived pain relief and increased duration of analgesia. 
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6.3.2.1. Reduction in the ‘Worst Pain’ element of the PSS 
Analysis of the individual elements of the BPI-PSS and BPI-PIS revealed that the 
worst pain’ element reduced significantly from a mean of 8.4 to a mean of 7.9, 
P=0.023 (Figure 5.5).  Out of the 53 patents in this group 8 (16%) reported that their 
pain reduced by at least 2 points (Table 5.12).  Two points in an 11-point pain scale 
had been reported as clinically significant as discussed previously (Section 6.3.1). 
 
6.3.2.2. What percentage pain relief did patients receive from taking their 
pain medication in the previous week (BPI question 19)? 
The percentage of pain relief recorded by patients after taking their pain medicines in 
the previous week increased significantly from 41% to 51%, P < 0.001 (Figure 5.6). 
This change was consistent with the reduction in the BPI-PSS worst pain score 
between the two visits, because benefit might be more noticeable when the pain is 
worst.    
6.3.2.3. How long before the pain returns after taking pain medication 
(BPI question 20)? 
In the treatment of chronic pain, the time period when a patient’s pain is reduced by 
their pain medication is important.  Pain medication rarely results in a continuous 
pain free state, but patients needed to be able to plan their use of pain medicines so 
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that they can use any benefit to facilitate ‘life events’ which were essential but which 
are known to cause or increase pain.   
 
The BPI question 20 (Section 8.4.2) asks ‘how long does it take before your pain 
returns’.  This apparently specific question about the duration of pain relief is actually 
asking a second equally important question at the same time, i.e. how many pain 
medicines were being taken with no perceived benefit?  An enquiry about the efficacy 
of each pain medicine taken by the patient is a routine part of the pharmacist’s 
normal intervention. 
 
Between the 1st and 2nd appointment the number of patients who reported that their 
analgesia didn’t help at all went down significantly, from 42% to 12% P=0.001 (Figure 
5.7) leaving12% (5) individuals who may benefit from further optimization of their pain 
medication.  This represented an opportunity for the pharmacist in the CPS, at a 
subsequent appointment, to continue counselling patients about improving the use of 
their pain medicines.    
 
It follows that if fewer patients reported no benefit then the periods of time which 
patients recorded that their analgesia was effective had increased.  This change was 
also significant.  More patients reported longer periods of benefit at their 2nd visit, 




There are several possible explanations for these changes in the patients’ pain 
between the 1st and 2nd appointments.  Firstly, had the patients GP taken up one of 
the pharmacist’s suggestions and prescribed a different more effective therapy?  
Alternatively, did the patients improve the way that they used their pain medicines, as 
a result of the pharmacist’s interventions?  If so, the time when they were most likely 
to notice any benefit would be when their pain is at its worst.  The advice from the 
pharmacist was aimed at improving how patients could use their pain medicines to 
best advantage. This included reducing the patients’ reluctance to take their pain 
medicines by improving their ability to manage both the benefits and the side effects.   
 
Adherence to medication, particularly for chronic conditions, averages about 50%, 
less in developing countries (Yach, 2003). Other reports suggest that between a third 
and two thirds of all US hospital admissions result from poor medicines 
adherence/compliance possibly because the ability of doctors to recognise non-
compliance is poor (Osterberg and Blaschke, 2005).  In addition, poor 
adherence/compliance, such as taking prescribed naproxen and OTC ibuprofen, can 
lead to adverse drug reactions, which would further discourage patients from taking 
their pain medicines appropriately (Leporini, De Sarro and Russo, 2014).   
 
However, one point should not be overlooked totally, the power of the placebo 
(Muller et al., 2016; McCartney, 2015).  Table 1.2 includes the proportion of patients 
who achieved analgesia with a placebo during placebo-controlled trials of medicines 
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used in the treatment of neuropathic pain.  The position of placebo in the treatment of 
chronic pain is uncertain and  Price, Finniss and Benedetti (2008) reported that whilst 
undertaking a review they noted that the degree of analgesia sometimes varied, with 
the length of the trial.  A later Cochrane review suggested that in clinical trials for pain 
treatments there should be three arms, treatment, placebo and treatment as usual 
(Hrobjartsson and Gotzsche, 2010).  Such an arrangement might give a better 
indication of the actual place of the placebo in the treatment of that condition. 
 
In this research the following measures of pain have improved significantly – 
i. Mean ‘Worst pain’ score reduced from 8.4 to 7.9 
ii. Mean ‘Relief from treatment’ improved from 41% to 51% 
iii. The proportion of patients taking analgesia from which they perceive no 
benefit, down from 42% to 12% 
iv. The overall duration of analgesia increased 
 
This group of significant results raised one of the fundamental paradoxes of pain 
therapy.  Why did such a small reduction in a pain score create such a large 
improvement in the perception of benefit?  The difficulties of converting changes in 
pain scores to clinically significant improvements have been addressed previously.   
in addition, there is research in primary, secondary and A&E care which suggests 
that reported pain score changes were intertwined with patient satisfaction at the end 
of an episode of care (Dawson et al., 2002; Shindul-Rothschild et al., 2017; Fallon et 
al., 2016; Kelly, 2000).  If pain scales are relative (Robinson-Papp et al., 2015) are 
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the patients attending the pharmacist’s clinic simply recording satisfaction with the 
way that they have been treated. 
 
Cochrane reported that attendance at a multi-disciplinary biopsychosocial pain clinic 
was reported as more effective than usual care in the treatment of chronic low back 
pain (Kamper et al., 2015).  Recommendations for patients to attend such courses 
are increasing, but there is still some controversy because their greatest benefit 
seems to be on patient functioning and wellbeing rather than their pain (WIlkinson 
and Whiteman, 2017; Wilson, 2017).  It may be that at least some of the benefits 
achieved by the patients in this cohort resulted from their involvement with the CPS. 
6.4. Changes in the reported efficacy of pain medicines 
between visits. 
6.4.1. INTRODUCTION 
At their 1st appointment between 50% and 60% of patients reported that their pain 
medicines were helpful for all of the five groups of pain medicines (paracetamol, 
mild/moderate opioids, strong opioids, neuropathic treatments and NSAIDs) with 
medicines for neuropathic pain showing the greatest benefit at 58%.  After the 
pharmacist’s intervention, during the medicines review, when patients returned for 
their 2nd appointment the proportion of patients who regarded their pain medicines as 
helpful had increased for all five groups.  The only increase which was significant 




These results may suggest that the pharmacists’ intervention was having a positive 
influence.  The advice both in clinic and at PMP presentations was that no pain 
medicine was going to make them pain free (NICE, 2017).  Therefore, their use of 
pain medicines should be aimed at facilitating those things in life which are regarded 
as important but are known in advance to cause pain.   
 
The regular use of opioids is known to rapidly lead to the development of tolerance 
and that varying the dose prolongs the effective life of these medicines (Yu et al., 
1997; McAllister, 2016; Chu et al., 2012).  Therefore, it was suggested to patients 
that they should vary the dose of their mild moderate opioids with the severity of their 
pain.  The point was also made that if a patient’s pain had neuropathic elements the 
mild/moderate opioid of choice should be tramadol if it was tolerable and not 
contraindicated by other medicines or medical conditions (Ballantyne, 2017).  
 
Considerable effort was also made to try and overcome patients’ reluctance to taking 
pain medicines, particularly opioids, because of the fear of addiction.  It may be that 
enabling patients to take informed decisions about whether or not to take their pain 
medicines also contributed to improvements in their pain control.  Another aim was to 
encourage patients to obtain the maximum benefit from those medicines which were 
least harmful for treating their pain before moving to more potent pain medicines as 




In all therapeutic groups there was generally, but not always, a reduction in both the 
proportion of patients taking medicines which they didn’t think were helpful and those 
who didn’t know whether it was helpful.  Such changes would also be consistent with 
the pharmacist’s message with this cohort, that because of the possibility of side 
effects patients should be sure that the pain medicines which they take were 
beneficial for their pain. 
6.4.2. USE AND BENEFIT OF PARACETAMOL 
The changes in the use of paracetamol were set out in Figure 5.9.  Of the patients 
who were taking it there was a non-significant increase in the proportion of patients 
who regarded it as helpful, a surprising increase in those who regarded it as not 
helpful and a decrease in the proportion of those who did not know if it was helpful.  
Paracetamol is reported to have different NNTs depending upon the type of pain 
being treated (FOPM, 2007; Saragiotto et al., 2016; Moore et al., 2015c).  These 
differences in NNT may account for the apparent divisions between effective and 
non-effective in patients suffering with different types of pain. 
 
The arguments for the use of paracetamol in the treatment of chronic pain are 
contentious and were set out in Section 1.6.1.  Because the  current balance of 
opinion is that paracetamol is safer than a NSAIDs (Kress and Untersteiner, 2017) 
patients were advised that if paracetamol was effective then in the treatment of their 
pain it was the ‘least worst option’.  This term was used rather than ‘better’ because 
there was still the possibility that it might cause harm. 
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6.4.3. USE AND BENEFIT OF MILD MODERATE OPIOIDS 
At their 1st appointment 51% of patients reported mild/moderate opioids were 
effective.  This was slightly smaller than the 55% for paracetamol.  By the 2nd 
appointment this had reversed and 81% regarded mild/moderate opioids as effective 
compared with 60% for paracetamol 
 
The changes in the use of mild moderate opioids were set out in Figure 5.10.  Of 
those who were taking them, there were significant increases in the proportion of 
patients who regarded them as helpful and the proportion who thought they were not 
helpful or didn’t know decreased (Table 5.13).   
 
A chronic pain patient’s first prescription experience with opioids was often as a 
combination of Paracetamol with a mild/moderate opioid with many prescriptions 
being for co-codamol (30/500) two to be taken four times a day.  This dose of 
codeine is equivalent to about 6mg of morphine.  For a patient starting opioid 
therapy, this often resulted in side effects such as nausea, sickness, constipation and 
dizziness.  Up to 10% of patients do not continue because of these side effects 
(Straube et al., 2014).  The requirement for the bio-transformation of codeine before 
it has any analgesic efficacy also needs to be remembered. 
 
Tramadol is a mild/moderate opioid which has, in addition, the potential to be 
effective in the treatment of neuropathic pain, making it almost unique in the 
treatment of chronic pain.  Pharmacist referral letters to GPs after 1st clinic 
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appointments, with this cohort of patients, suggested on 32 occasions that tramadol 
might be worth an assessment.  Because the improvement in the efficacy of 
mild/moderate opioids was statistically significant these results were examined in 
more detail.  At the second appointment 14 of 15 patients (93%) who were taking 
tramadol reported it as effective.  The proportion of patients who regarded tramadol 
as effective was more than the 60% reported for both codeine and dihydrocodeine, 
but these were based on very small numbers (Table 5.13). 
6.4.4. USE AND BENEFIT OF STRONG OPIOIDS 
At their 1st appointment 52% of users of strong opioids regarded them as effective.  
The comparative figure for mild/moderate opioids was 51%.  There was an increase 
at the 2nd appointment up to 72%. 
 
Patients would not be attending the CPS if opioids and other analgesics, were able to 
control their pain.  Strong opioids are considered the most effective medicines that 
are available for the treatment of (nociceptive) pain but this effectiveness does not 
translate into the treatment of chronic pain (Ballantyne, Kalso and Stannard, 2016).   
 
The changes in the use of strong opioids were set out in Figure 5.11.  Of those who 
were taking them there were non-significant increases in the proportion of patients 
who regarded them as helpful and the proportion of those who thought it was not 
helpful or didn’t know decreased.  The problems associated with opioids and chronic 
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pain, especially with regard to effectiveness and tolerance were explored earlier 
(Section 1.6.2).  
 
The role of strong opioids in the treatment of chronic and/or neuropathic pain is 
controversial (Bostick et al., 2015; Stannard et al., 2016; NHS, 2015).  There is 
insufficient evidence to determine the long-term analgesic effectiveness of opioids 
(Chou et al., 2015).   There are suggestions that opioid side effects often outweigh 
any long-term benefit, especially at doses >100mg of oral morphine equivalence 
daily (Anderson, 2015; Stannard, 2012).  There is also the suggestion that the use of 
strong opioids, even if they help with the pain may actually delay improvements in 
patient function (Ballantyne, 2017).  The Faculty of Pain Medicine (FOPM) and NHS 
England published a report entitled ‘Opioids Aware’ (NHS, 2015).  The Executive 
Summary from this report included the following points.  
 
‘Opioids are effective analgesics but there is little evidence that they are helpful for 
long-term or neuropathic pain’. 
 
‘The risk of harm increases substantially at doses above an oral morphine equivalent 
of 120mg/day, but there is no increase in benefit’.   
 
‘If a patient is using opioids, but is still in pain the opioids are not effective and should 




This message was reinforced by two Cochrane reviews. Els et al. (2017a) reported 
that there was no evidence to support the use of large doses of opioids in chronic 
non-cancer pain because of a shortage of long-term trials at doses used in clinical 
practice.  Els et al. (2017b) went on to expand the ‘harms’ side of opioid therapy and 
reported that compared to control 78% of patients undergoing opioid treatment suffer 
with an adverse effect.   
 
The prescribing of opioids for chronic pain has increased fourfold in the last twenty 
years.  Much of this increase driven by guidelines, which suggest S/R formulations 
were safer and more effective than I/R formulations (Volkow and McLellan, 2016).  
Unfortunately, these long acting formulations do not address the patients real 
analgesic needs, how to cope with the varying level of pain with a constant level of 
analgesia.   Sullivan (2014) suggested that there was insufficient evidence to 
determine whether there was any real difference between the opioid analgesic 
efficacy or the incidence of side effects between I/R or S/R formulations.  A paper the 
following year by Miller et al. (2015) reported that patients often preferred I/R 
formulations because this allowed them to match their use of pain medicines with 
their level of pain and thereby take some control their total opioid dose.  A 
subsequent review by Ballantyne (2017) confirmed that the analgesic benefits of 
opioids were preserved if they were not used continuously and that intermittent use 




Five patients, in this study, who were taking doses of S/R opioids were also taking 
top-up doses of an I/R opioid.  Where patients reported taking mixed duration 
formulations they mostly acknowledged their therapy was effective.  Some were 
taking the same medicine in two different formulations others were taking different 
opioids in different duration formulations.   This raised two questions.  Was one more 
effective than the other.  Alternatively, were they both effective and was it varying the 
opioid dose which reduced the tendency towards tolerance as has been suggested 
by Miller et al. (2015) and Ballantyne (2017).  A much larger cohort of patients taking 
strong opioid pain medicines would be needed to explore such questions. 
 
Out of the 100 patients in this cohort 36 patients were taking a strong opioid at their 
1st appointment.  Of these 32 (89%) still had an NRS pain score of >=7.  This poses 
several questions.  Were those patients tolerant to their opioid, would their pain be 
much greater without their opioid or was their opioid truly ineffective for their pain. 
 
Eighteen of the paired patients (33%) arrived at their first clinic appointment using 
one or more strong opioids medicines.  Nine (50%) reported that they were helping 
with their pain control, 6 (33%) did not think that they were effective and 3 (17%) 
were not sure.  Therefore, 9 (50%) were taking or using a strong opioid preparation 
from which they perceived uncertain or no benefit.  The number taking strong opioids 
reduced to 15 at the second visit, but of these the proportion of patients who thought 
that they were effective rose from 53% (8) to 73% (11).  Therefore, even after the 
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pharmacist’s intervention four patients taking these potent medicines, which can 
cause serious adverse effects, without any certainty of benefit.  
 
If there was no real benefit from strong opioids the following possible factors were 
considered: did the patient’s pain include elements of neuropathic pain or was there 
evidence of opioid induced hyperalgesia.   At their 2nd appointment 72% of patients 
(Table 5.13) reported that medicines for neuropathic pain were reported as effective.  
If opioid hyperalgesia was suspected the patient was encouraged to undertake a trial 
of a very gradual reduction in their overall opioid dose, aiming for a downward opioid 
dose trajectory with minimal withdrawal potential.  Baron and McDonald (2006) 
reported on a group of 23 patients who were taking or using large doses of opioids 
for chronic pain.  Over a period of time these patients were persuaded to eliminate 
their strong opioid medicines.  All patients demonstrated some reduction in pain and 
the overall mean pain score for these patients went down from NRS 8.0 to NRS 3.5.  
 
For patients hoping to use their opioid therapy to facilitate a return to work the 
message is equally unhelpful.  The use of opioids can delay the return to work 
(Busse et al., 2015; Deyo, Von Korff and Duhrkoop, 2015; Savych, Neumark and 
Lea, 2018) and the likelihood of returning to work is reported as inversely 




Three patients in this cohort made considerable efforts to reduce their strong opioid 
dose (Section 5.4.2.3).  These results suggest that the pharmacist’s intervention 
about the possible dangers of strong opioid therapy had been effective. 
 
There has been a change of tone about the use of strong opioids in the treatment of 
chronic pain since it was being debated as a ‘human right’ (Cousins, Brennan and 
Carr, 2004) and as later expressed in the Montreal Declaration (Cousins and Lynch, 
2011).  This change has been driven by the realisation of the extent of the opioid 
misuse problem.  In the UK the need for caution with the use of these medicines was 
acknowledged with the publication of ‘Opioids Aware’ (NHS, 2015).  Advice to 
prescribers had been issued in various locations on opioid dose reductions (NHS, 
2017a; NHS, 2018c) but a Cochrane Review (Eccleston et al., 2017) reported that 
there was no evidence of the relative safety of any of the proposed opioid reduction 
schemes.   
 
Tapentadol was added to the local Stoke Guidance on the treatment of chronic pain 
(Njoku, Rosam and Ashworth, 2017). With a potency between tramadol and 
morphine this was a useful addition to the range of medicines available for the 
treatment of chronic pain.  There were indications of its effectiveness against 
neuropathic pain but as yet it had not been accepted by all GP formularies (Langford 
et al., 2016; Sugiyama et al., 2018)  
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6.4.5. USE AND BENEFIT OF MEDICINES USED FOR THE TREATMENT OF 
NEUROPATHIC PAIN 
One of the problems involved in the treatment of chronic pain, as discussed in 
Section 1.5.3 is differentiating nociceptive and neuropathic pain elements, A higher 
percentage of patients (58%) reported that medicines for neuropathic pain were 
helpful at the 1st appointment than for any of the other medicines in this research.  
This proportion increased at the 2nd appointment up to 72% (Figure 5.12).  Although 
these changes were not statistically significant there is an indication that educational 
advice targeted at careful titration of doses improved patients’ outcomes with these 
medicines.  However, given the size of this improvement the mean S-LANSS score 
only decreased from 12.6 to 12.5 (Table 5.10).  Current questionnaires do not 
facilitate the collection of data which would explore this problem.  More accurate 
historic data is needed to track changes in pain scores with changes in doses.  The 
paradox in the treatment of chronic pain set out in Section 6.3.3 is also relevant here.   
 
Fifty-eight patients in this cohort recorded an S-LANSS score of >=12 (Table 5.9) and 
therefore were regarded as having elements of neuropathic pain (Bennett, 2001).  Of 
these 44 (76%) were taking an analgesic recommended for this condition in the BNF 
or NICE (2013a).  This leaves 14 (25%) possibly not taking appropriate analgesia.  
But more patients were taking medicines suitable for neuropathic pain than had an S-
LANSS >=12, which may be an indication of successful therapy either known or 
unrecognised.  It may also suggest their use for other therapeutic indications  




The audit which was basis for this research (Section 1.3), found that of the 100 
patients who were included, 57 patients recorded an S-LANSS score>=12.  Of these 
only 36 (63%) were taking medicines recommended for the treatment of this 
condition.  The number of patients with an S-LANSS>=12 in the audit was one less 
than in this research cohort, 58 (Table 5.9).  The proportion taking appropriate 
medicines in the pilot study was 63% compared with 76% (Table 5.9) in this research 
cohort.  Overall these figures indicate some undertreatment of neuropathic pain that 
could present opportunities for pharmacists to suggest appropriate therapies.  The 
report by Gill, Taylor and Knaggs (2013), outlined in the systematic review suggested 
that expanding the role of Community pharmacists into the diagnosis, treatment and 
management of chronic pain could possibly identify 50,000 cases of undiagnosed 
neuropathic pain in a year.   
 
Sixty-six percent of the patients in this research with an NRS >=7 also had a S-
LANSS >=12 and it was suggested by Torrance et al. (2007) that patients with 
chronic pain of predominantly neuropathic origin more difficult to treat.  For that 
investigation a randomly generated list of 6,000 patients from three UK cities were 
mailed a questionnaire. Three thousand and two were returned.  Three groups were 
identified, patients with no chronic pain and patients who had chronic pain and who 
were either S-LANSS positive or S-LANSS negative for neuropathic pain elements.  
The patients who reported neuropathic elements in their pain reported less pain relief 
from their pain medicines, despite using more, but surprisingly very few were taking 
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medicines specific for the treatment of neuropathic pain.  This report did not include 
details of whether these patients had assessed neuropathic treatments and failed or 
whether they had never been offered.  Patients who were not taking these medicines 
could be amongst those being referred for the management of neuropathic pain if 
greater use were made of community pharmacists (Gill, Taylor and Knaggs, 2013). 
 
The information about the contribution of placebos to the treatment of chronic pain 
contained in Table 1.2 also needed to be considered seriously.  For example both 
duloxetine and gabapentinoids were recommended for the treatment of fibromyalgia 
pain.  Lunn, Hughes and Wiffen (2014) suggest that any benefit from duloxetine in 
the treatment of fibromyalgia may result from its anti-depressant effects rather than 
any direct effect upon the pain.  McCartney (2015) reminded us that in the treatment 
of fibromyalgia about one person in three would receive benefit from pregabalin but 
in addition one person in five would receive similar benefit from a placebo.  Similarly, 
Wiffen et al. (2017) reports that with gabapentin in the treatment of neuropathic pain 
3 or 4 of 10 would receive up to 50% pain relief.  The comparative figure for placebo 
was 1 or 2 of 10.  Given the potential for harm of these medicines, ongoing 
assessment for efficacy are important and represented an opportunity for 
pharmacists to become engaged whilst counselling about the use of pain medicines.   
 
As reported in Section 5.4.2.4 some patients took their neuropathic medication on a 
when necessary basis because of the sporadic or predictable nature of their pain.  
For example, patients who experienced pain only during a certain activity did not 
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require levels of ‘background analgesia’.  Their justification for this was they know 
what was effective but that side effects precluded their use over a longer period.  The 
implication of this method of medicine use was that to achieve the best outcome for 
themselves, these patients have understood both the benefits and the side effects of 
their therapy and had balanced that with their daily living. 
6.4.6. USE AND BENEFIT OF NSAIDS 
The changes in the use of NSAIDs were set out in Figure 5.13.  Of those patients 
who were taking them there was a non-significant increase in the proportion of 
patients who regarded them as helpful up from 55% to 66%.  The proportion who 
thought they were not helpful decreased.  This group of medicines was the only one, 
in this research, where the proportion of patients who were unsure whether they were 
helpful increased.   
 
NSAIDs were reported as very effective analgesics in the treatment of acute pain 
including lower back pain (Enthoven, Roelofs and Koes, 2017).  As a group they had 
amongst the lowest NNTs for the treatment of acute pain as rated by the Oxford 
League Table of Analgesics (FOPM, 2007) with NNTs of between one and two.  
Because they are such good analgesics and older people may tend to have more 
aches and, patients are prescribed more frequently for older than younger patients.  
This may have resulted in poor quality pain management advice (Ferderman, Litke 
and Morrison, 2006) because the side effect profile of NSAIDs worsens with age 




As set out in Section 1.6.4 NSAIDs can cause a wide range of side effects beyond 
the widely known gastric irritation.  As a result, in older people balancing less pain 
with the increased risks of morbidity needed to be a real consideration (Wehling, 
2014).  Given this, at their 1st appointment 43% were taking one of these medicines 
without any perceived benefit.     
 
NSAIDs have been the medicine of choice in the treatment of inflammatory pain 
conditions but their mechanism of action there would suggest little rationale for their 
use in the treatment of neuropathic pain. A Cochrane review reported that there was 
no evidence to support or refute the use of NSAIDs in the treatment of neuropathic 
pain (Moore et al., 2015a) .  Yet Berger et al. (2012) reported that out of a sample of 
31,688 patients with a painful neuropathic condition 56% had a prescription for an 
NSAID compared to 22% in the matched control group.  The mean age of the group 
was 56.1 years and 32.9% (10,434) were in the >=65 age group.   
 
Possession of a prescription and actually taking the medicine are quite different.  
Compliance figures are difficult to obtain.  Many years ago, de Klerk and van der 
Linden (1996) undertook research into compliance with NSAIDs in the treatment of 
ankylosing spondylitis using electronic monitors for an average of 225 days.  Their 
results suggested that patients took 81% of the prescribed doses but not necessarily 
as prescribed.  Interestingly, they also reported that there was no correlation between 
compliance and improvement in reported pain or morning stiffness in a population 
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where it would be expected that NSAIDs would be effective, which would question 
the efficacy of this therapy.  Similar levels of compliance were reported by (Lanas et 
al., 2012) who added that compliance to a regular NSAID prescription went up as the 
pain became more constant.   
 
In this small research cohort, the percentage of patients who thought that their 
NSAIDs were effective (initially 57%) was approximately the same as the 56% of 
patients in the Berger et al. (2012) report.  Given these results and the difficulty of 
treating patients with chronic pain it would be difficult not to suggest that in any 
patients’ pain NSAIDs should be assessed for efficacy, regardless of the 
pharmacological logic.  However, these were the medicines most likely to lead to an 
emergency hospital admission (Pirmohamed et al., 2004) therefore they must only be 
taken if they were perceived to be effective, with appropriate gastric protection (NHS, 
2018b), at the lowest dose for the shortest possible time. 
6.4.7. CONCLUSION 
The improvement in pain resulting from the use of pain medication was only 
significant for the mild moderate opioid group.  Other groups caused apparent 
improvements but the changes were not significant.   
 
One positive outcome was that overall, more patients reported stopping a pain 
medication than starting one.  This was important because one of the pharmacists’ 
messages was that pain medicines should only be taken when they were perceived 
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to give benefit.  The pharmacist can easily advise on OTC medicines, however not 
being a prescribing pharmacist in the CPS, any advice about stopping a prescribed 
medicine would need to be endorsed and changes made by the patient’s GP.  This 
additional step for patients to add or change therapy indicates the benefit of an 
independent prescriber pharmacist (IP) (Section 8.2) in the CPT. 
 
In the Review Synthesis one of the contextual points was that pharmacists had a 
beneficial role in the treatment of chronic pain and that this was an expression of 
maximising the use of the pharmacists’ basic skill set, i.e. knowledge about 
medicines.  From the researchers’ clinical practice many patients demonstrated a 
lack of knowledge about their medicines.  As a result, the educational input of the 
research pharmacist provided patients with an opportunity to understand how to use 
their pain medicines more appropriately and empowering them to act effectively upon 
this new knowledge.   
 
Hadi et al. (2014b) published an outline of the recommendations made to GPs about 
the patients who were included in the Hadi et al. (2016) research.  These included 
‘stopping n=19’, ‘adding n=30’, ‘titrating n=29’ and ‘substituting n=23’ medicine.  
There was no indication in the text to indicate whether these were prescribed or 
‘OTC’ medicines.  Comparable ‘medicines optimisation’ figures for this research were 
‘stopping n=44’, ‘adding n=19’.  These included both ‘OTC’ and prescribed 
medicines.  Overall the number of changes to prescribed therapy as a result of the 




6.5. Changes in answers to the questions in the Brief Pain 
Inventory (Questions 24-30) 
6.5.1. INTRODUCTION 
The BPI (Section 8.4.2) was designed to explore patient’s pain in several ways.  It 
explored the severity of the pain, the effect of the pain on their lives and their 
understandings of pain medicines.  Some patients’ are reluctant to take any 
medicines (Osterberg and Blaschke, 2005) which could be difficult to understand.  
Sometimes they appeared to conflate information from one group of medicines to 
another, NSAIDs cause gastric irritation and codeine can be addictive, therefore all 
pain medicines cause gastric irritation and are addictive.  Taken in isolation these 
statements about NSAIDs and codeine are factually correct, but in the treatment of 
chronic pain undue concentration on these particular points are not always helpful.  
For these patients the advice needs to be nuanced with advice about varying the 
dose to minimise the development of tolerance.  For example, tolerance and 
dependence may go hand in hand and are physiological responses to opioid 
medicine being taken but addiction is a behavioural response following on from these 
changes.  
 
Concordance and adherence are recognised problems with any medications.  When 
collecting medicines, pharmacists will usually reinforce the labelled directions. For 
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example, ‘gabapentin 600mg tds’ is usually translated onto the label as ‘three times a 
day’.  This may be interpreted as “breakfast time, lunch time and bed time” or 
“breakfast time dinner time and bed time” with no understanding that this relates to 
every eight hours.  Gabapentin, when use for chronic pain should be administered 
every eight hours for optimal effect, and minimal side effects.  Exploring what the 
patient understands is an important aspect of shared decision making and is certainly 
a conversation that both specialist and generalist pharmacists, with their 
understanding of pharmacokinetics, should explore with the patient.  
 
In this research, of the 55 paired patients at the 1st appointment 18 (33%) started off 
from the stand point that they did not want to take pain medicines (Table 5.7).  This 
went down to 16 (29%) for patients with NRS>=7, 15 (27%) for patients with S-
LANSS>=12 and 12 (22%) with both NRS>=7 and S-LANSS>=12.   Because pain 
medicines were so important for the management of chronic pain in this research, it 
was important to try and understand more about this problem.   
 
The BPI questions 24-30 asks questions about patients’ responses to their pain 
medicines.  The 2nd answers were from patients who were at least four months 
further along their treatment pathway.  The only significant thing, which may have 
happened within the CPS for some of these patients, since they completed the BPI 
for the 1st time was the pharmacist intervention and their individual reaction to it.  
Questions 24 & 25 asked about the frequency with which patients took their pain 
medication (Table 5.14) and the answers demonstrated little difference between the 
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1st and 2nd appointments, maybe because they are outwith the pharmacist’s purview. 
The answers to questions 26-30 were sufficiently different to warrant further analysis.   
6.5.2. PATIENT INVOLVEMENT WITH THEIR PAIN MEDICINES 
6.5.2.1. Did patients feel the need for a stronger type of pain medication 
(BPI Question 26)? 
The percentage of patients who believed that they needed stronger pain medicine 
reduced significantly down from 57% to 37% (Figure 5.14).  Patients’ had often 
waited a long time before arriving at the CPS (Figure 5.2) and therefore it was not 
surprising that many patients reported, at that time, that they needed stronger pain 
medication.  The significant reduction in the answers at their 2nd appointment was 
more surprising.   
 
6.5.2.2. Did patients feel the need to take more pain medication than 
their doctor has prescribed (BPI question 27)? 
The percentage of patients who believed that they need to take more pain medicine 
than was prescribed reduced significantly down from 33% to 21% (Figure 5.15). 
During clinic consultations some patients mentioned that they took more than the 
recommended dose of paracetamol.  There was also some double dosing with 
NSAIDs, prescribed naproxen and OTC ibuprofen either deliberately or through lack 
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of knowledge.  There appeared to be a misconception that because these were freely 
available OTC they were less dangerous.   
 
6.5.2.3. Were patients concerned that they used too much pain 
medication (BPI question 28)? 
The percentage of patients who believe that they are taking too much pain medicine 
reduced significantly down from 46% to 31% (Figure 5.16).  In clinic, patients often 
demonstrated a tenuous understanding of the rationale for their pain medicine 
therapy.  Some were also intentionally resistant to taking any in pain medicines for 
complex or personal reasons which have been reported previously (Chen, 1999).  
This resistance which was explored briefly in Section 6.5.1 and may result from a 
lack of understanding of the potential complications of the illness being treated or 
patients may conflate health warnings about different medicines. It may be because 
the medicines that they had tried previously had given them minimal benefit and 
intolerable side effects.  Many patients reported that they took their medicines 
because they had been prescribed or they took the ones that didn’t make them feel 
worse.   
 
Patients’ attitude to their medicines may be affected by difficulty with understanding 
the labelling of their medicine or incomplete briefing about a complex medicine 
regimen.  The significance of both of these could be reduced by more concordant 
prescribing and a greater accent on appropriate counselling when medicines are 
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issued.  Alternatively, the avoidance of analgesia may be perceived as exercising 
personal control over their pain (Pellino and Ward, 1998)  and as such is probably 
outwith the purview of both the prescriber and the pharmacy   
 
The excess of medicines stopped (47) over medicines started (19) as set out is Table 
5.13 was an indication that some patients had heeded the pharmacist’s advice during 
the intervention and were acting upon it.  The freedom of action of the research 
pharmacist with regard to prescribed medicines has been addressed (Section 6.4.7) 
but if a patient, after consideration, is confident that one of their pain medicines is 
giving no benefit then this presents an ethical dilemma.  The patient should be in 
concordance with their GP about their pain therapy and therefore it is incumbent 
upon the patient to agree any changes with their prescriber, otherwise their health 
records are incomplete.   
 
NICE (2017) suggests that in the treatment of chronic pain the aim is to reduce a 
person’s pain and improve their quality of life.  This balance between pain and quality 
of life is important and not accounted for in the WHO pain ladder because many of 
the medicines which would then be involved can be associated with serious harm 
and may not contribute to improving quality of life. 
 
Whatever the reasons for patients believing that they were taking too much pain 
medicine, each pharmacist-patient interaction was an opportunity to improve the 
patient’s understanding of how to use their pain medicines to improve the quality of 
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their lives and reduce their concern over the use of these medicines.  The significant 
change in the answers to this question may be an indication that the intervention 
from the pharmacist was having a positive influence upon the patients’ use of 
medicines for their pain.   
6.5.2.4. Did patients feel the need to receive further information about 
their pain medication (BPI question 30)? 
The percentage of patients who felt that they needed further information about their 
pain medicines, reduced significantly from 76% to 45% (Figure 5.17). Often, in clinic 
patients responded to the pharmacist’s explanations about how they could take their 
medicines differently either to improve benefits or minimise the side effects, in ways 
which suggested they had not considered this previously.  There were two possible 
explanations for this.  They were concepts or ideas that had not been verbalised by 
their prescriber/pharmacist or they had not been remembered by the patient.  Either 
way this means that some patients may not have received the information that they 
want and need, to enable them to take their medicines to best advantage.  
Sometimes the lack of appropriate verbal communication during 
patient/GP/pharmacist interaction meant that patients only received the information 
that they needed when they asked for it.  (Young et al., 2018).  From experience with 
patients in clinic it would be unwise to assume that all patients had sufficient self-
confidence and background information or health literacy to understand the questions 
that they needed to ask, in addition to the having the intellectual capacity to cope with 




There were also the problems of patients believing inappropriate things about their 
pain medicines.   Whose responsibility was it to ensure that patients understand their 
pain medicines, the prescriber or the pharmacist?  In the absence of real information, 
we should not be surprised when the void in patient’s knowledge was filled with half-
truths and erroneous impressions.   
 
The significant change in the answers to this question at the 2nd appointment reflects 
the importance that the pharmacist placed upon helping the patient to understand 
their pain medications.  One of the roles of the pharmacist’s in the CPS was to guide 
patients towards the optimal use of their pain medicines because the other members 
of the team would be concentrating on other aspects of the patients’ treatment.  
Other members of the team hear the pharmacist’s message during the PMP 
presentation and are therefore in a position to reinforce this message at appropriate 
moments. 
6.5.2.5. Did patients have problems with side effects from pain 
medication (BPI question 29)? 
The answers to this question (Figure 5.18) did not change significantly between the 
1st and 2nd appointments reducing from 64% to 42%.   
 
During this research patients demonstrated poor understanding of their pain 
medicines and the management of any resulting side effects.  Within the Systematic 
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Review there were four references which mentioned the problem of side effects.  
Harrison (2015) reported that 35% of patients suffered side effects, Thomas (2012) 
recorded a much higher proportion of 75% needing advice about side effect 
management.  Gill, Taylor and Knaggs (2013) reported that 20% of patients were 
referred back to their GP for management of side effects.  On the other hand 
Coleman, Yangphaibul and Begovic (2013) reported that 16% of the actions as an IP 
related to the management of side effects.  All of these publications reported an MUR 
of some sort but with no real information about what was involved or how this might 
have influenced the recording and reporting of side effects.   
 
The report by Thomas (2012) recorded that 50% of the cohort needed advice about 
medicines safety.  Safety and side effects are different concepts and there was no 
mention in the text of how the difference was defined.  This differentiation should be 
explored in any further research. 
 
These four reports suggest that in the treatment of chronic pain the side effects of the 
medicines can be troublesome both for the patient and the HCP who are involved in 
their care.  Given that chronic pain is a debilitating, widespread condition that may be 
lifelong, those involved in the treatment of these patients need to be aware of the 
potential adverse effects of their actions.  Additionally, it is essential to ensure that all 
communications are tailored to the patients’ ability to understand.  Carter et al. (2014)  
reported that it is critical that either the prescriber or the pharmacist ensure that the 
patient understands the potential side effects before a pain medicine is prescribed or 
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dispensed because side effects can lead to a reduction in the appropriate use of a 
medicine (Dibonaventura et al., 2012).   
 
The decision about whether side effects are serious is, for the patient, a subjective 
decision and if it is an intensely personal effect then regardless, a patient probably 
would not disclose the effect unless specifically asked. During any patient clinician 
interaction this could lead to a divergence of opinion, either overt or covert, about the 
level or significance of potential side effects (Cooper et al., 2015).   The post 
marketing attribution of serious side effects to a medicines can lead to the withdrawal 
of its Product Licence (McNaughton, Huet and Shakir, 2014) as exemplified by 
rofecoxib and valdecoxib.  In 2019, a systematic review reported that the 
discontinuation of antidepressants, including tricyclics and duloxetine both of which 
are used in the treatment of chronic pain, was more problematic than had been 
thought heretofore (Davies and Read, 2019).   From clinical experience with chronic 
pain patients the problems associated with the side effects of the medicines used in 
the treatment of this condition are not always treated with the seriousness that they 
deserve.   
6.5.3. CONCLUSION 
The answers to four of the five questions at the end of the BPI questionnaire 
changed significantly between the 1st and 2nd appointments.  These improvements 
suggest that the input of the pharmacist before the 2nd appointment contributed to 




During this research, conversations between the pharmacist and the patients have 
consistently explored three ideas.  Firstly, the apparent ineffectiveness of many of the 
pain medicines prescribed for patients.  Secondly, the balance that the patient 
needed to strike between the benefits for their pain and the problems with side 
effects from their pain medicines.  Lastly, what caused the patients reluctance to take 
medicines and how can this be reduced. 
 
Having explored these three ideas with patients at their 1st appointment and for some 
also at a PMP presentation this was the group of patients that returned nine 
significant improvements or changes in four groups.   
 
i. Their pain medicines gave them more benefit 
ii. Their analgesia lasted longer.   
iii. The benefit for their use of mild/moderate opioids improved  
iv. Their attitudes to the use of their pain medicines improved  
 
When taken together these indicate that after discussion with the pharmacist patients 
had a better understanding of their pain medicines.  They engaged with the 
pharmacist in the CPT in ways which guided them towards using their pain medicines 
to maximise the benefits and minimise the harms of their medicines i.e. right drug, 
right dose, right time.   
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6.7. Limitations and recommendations 
6.7.1. WAITING TIME FOR PAIN CLINIC APPOINTMENT 
Waiting time since the commencement of pain until they received a pain clinic 
appointment was for some inexplicably long.  These were similar but not the same as 
other reports (Harrison, 2015; Black, 2017; Ingle and Vasu, 2018).  Further 
investigations into the cause of these waiting times and therefore the additional 
distress caused was both urgent and important. 
6.7.2. RECRUITMENT IN RELATION TO ATTENDANCE AT PMP 
Eighteen of the 55 patients who returned for a 2nd appointment had attended a PMP 
during the intervening period.  This meant that they would have experienced up to 
three times the length of pharmacist input time compared with the remaining 38 
patients.  Because of the small size of this group the only analysis which was 
undertaken was of the different changes in NRS and S-LANSS between patients who 
had attended and those who had not (Table 5.11).  The NRS of those who had and 
attended reduced by 0.9 whilst those who had not only reduced by 0.5.  The 
difference between the S-LANSS of the two groups was different.  For those who had 
not attended the S-LANSS increased by 0.6 whilst for those who had the reduction 
was 0.8.   
 
Attendance at a PMP course between the 1st and 2nd research appointments 
introduces a potential source of bias because it would potentially increase the time 
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available of the pharmacist’s intervention.  Some but not all of the additional 
intervention would be a duplication and therefore it would need to be controlled in 
any future research work into this topic. 
6.7.3. COMPLETENESS OF PATIENTS’ INFORMATION ABOUT THEIR MEDICATIONS 
The medicines that patients actually took were recorded and reported, particularly in 
relation to the benefits that individual medicines gave to the patients.  The patient’s 
clinic invitation letter asked them to complete the Patient’s Pain Medicine 
Questionnaire (Appendix 8.4.1), the BPI (Appendix 8.4.2) and the S-LANSS 
(Appendix 8.4.3) questionnaires and prior to their arrival at the clinic.  Patients 
generally arrived with a completed BPI and S-LANSS questionnaire but they were 
not so rigorous with completing the Patient’s Pain Medicine Questionnaire.  Some 
patients arrived with the ‘request’ copy of their current FP10, some with a bag of 
medicines and some with neither.  They were generally, but not always, able to be 
certain about their current medication.  The further back the questioning went, the 
less certain they were of their answers.  In the clinic invitation paperwork, they were 
asked specifically to be prepared to answer questions about their previous 
medicines.  Therefore, this bifurcation in their preparedness was not anticipated.   If 
this research is repeated work would be required to formulate a questionnaire, to be 
sent out with the invitation letter, to elicit information about the efficacy of previous 
medicines.  It may be that any pre-clinic preparations should be a request for a print-
out of the patients’ prescription history.  This could then form the basis of a 
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questionnaire to be completed by the patient.  In the event of non-completion, time 
would need to be found to work through this during the clinic.  
 
6.7.4. COMPLETENESS OF PATIENTS’ INFORMATION ABOUT SIDE EFFECTS 
The balance between side effects and the perceived benefits of pain medications is 
an important factor in determining optimal therapy for the treatment of chronic pain.  
Patients were often not able to discuss the side effects of their pain medicines with 
any certainty even though their invitation letter specifically asked them to prepare for 
that.  Any extension of this research would require work to formulate a questionnaire, 
to be sent out with the invitation letter, to clarify what side effects previous medicines 
had caused.  It may be that this could also be based upon the prescription history 
provided by the GP.    
 
This would need to be worked through during the appointment.  Some patients 
demonstrate a tenuous understanding of their side effects and which medicines may 
be causing these effects but given what has been revealed during this research this 
is no longer surprising.  
6.7.5. COMPLETENESS OF INFORMATION ABOUT MEDICINES FOR NEUROPATHIC 
PAIN 
One of the objectives of this research was posited on an S-LANSS scores (Section 
3.2), above or below 12 the guide score for elements of neuropathic pain.  One point 
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was omitted, which was obvious with hindsight.  Medicines for neuropathic pain were 
demonstrably effective for some patients, therefore had existing therapy already 
given them some benefit and reduced their S-LANSS score from above 12 to below 
12.  For those patients the appointment would then be about optimisation rather than 
finding something which gives benefit.  Any future research would have to control for 
this.   
 
There was also a paucity of data relating individual medicines to specific neuropathic 
conditions as outlined in Section 1.6.3.  Therefore, in any future research greater 
attention needs to be placed on records of diagnosis and the medicines assessed to 
date.   
6.7.6. PSYCHOSOCIAL AND DEPRIVATION DIFFERENCES 
The papers from both Bruhn et al. (2013) and Hadi et al. (2016) were the only two 
papers returned by this systematic review where societal characteristics of the 
patients were reported.  Societally, they appeared quite different to each other and 
different again to this cohort.  Because chronic pain is treated in a psychosocial 
context, societal differences need to be explored (Meints and Edwards, 2018) before 
a full understanding of its initiation, maintenance can promulgated.  Such work would 
require much larger cohorts in areas with different deprivation scores and different 
societal groups using both qualitative and quantitative methods.   
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6.7.7. LOCUS OF CONTROL 
It became apparent during this research that the patients who were most successful 
in developing personal strategies to improve their pain control were the ones who 
were able to understand and engage more fully with managing their medicines.  
Research has revealed that a high internal locus of control (ILC) was important in 
predicting improvements in chronic pain control with external controls being mainly 
negative  (Keedy et al., 2014; Nafradi, Nakamoto and Schulz, 2017).  Patients with 
high ILC believe that their outcomes are as a result of their own abilities.  Continuing 
involvement with the CPS and more particularly attendance at a PMP are premised 
upon the patients’ willingness to engage with the concept that at least some of their 
pain is self-manageable i.e. do not have a low locus of control score.  Therefore, in 
any further research it would be important to incorporate some ‘locus of control’ score 
such as a Duttweiler (1984) Internal Control Index (ICI).   
6.7.8. SHORTFALL IN THE NUMBER OF RETURNERS INTRODUCING THE 
POSSIBILITY OF BIAS 
Of the 100 patients who were enrolled in this study only 55 returned for a second 
appointment.  The small number of returners in this research limited the analysis 
which could be undertaken, particularly regarding the efficacy of individual medicines.   
 
The introduction of the new Trust computer system made it difficult for the 
administration staff to book patients and arrange recall appointments for all of the 
members of the Chronic Pain Team, not just the pharmacist.  It also limited the 
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availability of comparative epidemiological information between the research cohort 
and the total service. 
 
Lists were generated regularly by the pharmacist to assist the administration staff 
with the names of those patients who specifically needed to be recalled for this 
research.   
 
The original power calculation for this research was based upon 80 returners 
(Hodson, 2017).  The difficulty of persuading patients to attend for a second 
appointment has been mentioned elsewhere (Dougall, Harrison and Lowrie, 2015).  
The research appointments were stopped four months after 100th patient had been 
recruited because of the time constraints of the DPharm. timetable.  Unfortunately, by 
that time only 55 patients had been seen for a second time.  The reasons for the 
cessation of recruitment in this research were specific to this project.  During any 
further research, adherence to a Gantt chart would minimise the likelihood of a 
recurrence of such problems.  The loss of so many patients to follow up was one of 
the two most significant potential source of bias in this research.   
 
The new Trust computer is now well embedded making data about patient bookings 
more available to interrogation.  The patient’ pathway of care through the CPS and 
the length of time that their involvement lasts is individual to them, their pain and their 
circumstances and patients could be retained within the CPS if the patient was 
waiting for a research appointment.  The full cohort could have been recruited but for 
the external time constraints.   
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6.7.9. QUALITATIVE DATA 
Pain is a subjective experience that varies on an ongoing basis.  Analgesia can be 
very effective and the use of pain medicine should be closely related, in the patient’s 
mind, to the pain they experience and yet patients often demonstrated not only a lack 
of understanding on how to use their pain medicines or manage their side effects but 
also a reluctance to take their pain medicines at all.   There are no quantitative 
measures available which would improve our understanding of this human paradox.  
But this personal aspect of a patient’s involvement with their pain medicines could be 
explored using qualitative methods.  Such research would facilitate the exploration of 
how patients’ pain and their attitude to their pain medicines interrelates with their 
suffering and their personal circumstances.  It would also improve our overall 
understanding of how the actions of pharmacist interrelate with this situation.  
Qualitative research into pain is mainly undertaken with chronic pain patients 
(Osborn and Rodham, 2010) and suggests that patients completion of quantitative 
pain scales includes experiences and sensations as well as the pain intensity 
(Robinson-Papp et al., 2015).  One report stressed the need to understand the 
context of a patients pain, which might facilitate our understanding of how patients 
use qualitative scales (Morse, 2015).  From clinical experience with patients during 
this research for some patients the context of their pain is very important. 
 
Consideration was given at the outset of this research as to whether to include both 




6.7.10. RECOMMENDATIONS FOR FUTURE WORK 
This research has revealed a dearth of new information about how medicines may 
best be used in the treatment of chronic pain and by extension what should be the 
role of the pharmacist.  It has also revealed during, clinic consultations, how little 
understanding some patients have about managing their pain control and the 
misinformation which abounds about many of the individual pain medicines.  Chronic 
pain is so widespread that almost any practising pharmacist is likely to encounter 
patients who are affected.  If opportunities to improve the lives of these patients are 
not to be missed, consideration needs to be given to what pharmacists are taught 
about chronic pain and its treatment both at undergraduate level and what is 
expected of preregistration students.  Gill, Taylor and Knaggs (2012) points out the 
historically pharmacy students have spent eight hours leaning about pain.  
Comparable figures for doctors are 13 hours, physiotherapists 37 hours and vets 27 
hours.  The current advice for acute and rehabilitative pain is that regular analgesia is 
most effective and should be stepped down whilst healing is taking place is correct.  
In chronic or persistent pain this advice needs to be more nuanced recognising that 
in chronic pain a pain free state is generally not achievable.  Over the lengths of time 
that patient suffer with chronic pain, the long-term harms of pain medicines are more 
likely to become overt and the realistic goal for analgesia has to become how to use 
pain medicines to facilitate those things in life which are necessary but painful.  
Pharmacists’ who are involved in the supply of medicines for patients with pain need 




The pharmacist works as part of the CPT and any benefit which accrues with regard 
to better pain control may need to be seen as part of a team effort.  The Medicines 
Research Council (MRC) have developed and updated guidelines as to how the 
utility of a single intervention within a multi-component package of care can be 
investigated (Campbell et al., 2000; MRC, 2019).   
 
It would be important to control more rigorously for the second appointment being 
before or after attending the PMP.   There was a difference in both the NRS and S-
LANSS scores demonstrated by patients who had or had not attended a PMP.   
 
Further work should be clearer about pain diagnosis, pain medicines used in its 
treatment.  The most difficult results to understand were those that related to the use 
of medicines for neuropathic pain.  Historical changes in S-LANSS scores resulting 
from medicines already being taken needs to be determined and recorded, as does 
the diagnosis in relation to the medicines assessed.  
 
It would also be important to control for pain duration.  The results in Figure 5.2 and 
Table 6.1 suggests that there needs to be greater clarity over the questions asked 
about the commencement and duration of their pain.  
 
The success of some patients in this cohort had with improving their pain may have 
been based upon greater understanding of how to use their pain medicines to best 
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effect.  Therefore, it would be important to try and tease out changes in patients’ 
understanding to a much greater extent.   
 
Of the answers to BPI questions 26 to 30 only Question 29 about side effects 
returned a non-significant result.  Patients’ answer to this question are tied in with 
their relationship with their pain medicines and understanding this are key element 
for further work.  To achieve this, the research must include a qualitative examination 
of the patents pain and their medicines. 
 
One final point, in his report Thomas (2012) differentiates between safety advice and 
side effect management.  The difference between the researchers understanding of 





CHAPTER 7 CONCLUSION 
In conclusion this research set out to determine whether a consultation with the 
pharmacist within the multidisciplinary CPT in South Staffordshire and any resulting 
medicines advice and education changed patient use of their pain medication.  If so 
did this improve the use of their pain medicines, pain scores or medicine side effects. 
 
There were some significant changes in pain scores between the 1st and 2nd clinic 
appointment.  These were limited to four finding: the BPI-PSS ‘worst’ pain score went 
down, the relief which patients recorded after taking their pain medicines improved, 
fewer patients regarded their pain medicines as ineffective and the benefits which 
were recorded lasted longer.  
 
Chronic pain is complex and it is difficult to be certain that any particular intervention 
will be effective, but the pharmacist’s intervention in terms of education, specifically 
regarding timing and optimising of doses is likely to have an important impact.  In this 
research the following four significant changes in patients attitudes to their medicines 
were recorded: fewer felt that they needed stronger pain medicines, fewer felt that 
they needed to take more pain medicines than had been prescribed by their GP, 
fewer thought that they were taking too much pain medicine and fewer felt they 




One accepted premise for the treatment of acute pain is that ‘pain is easier to keep 
away than make go away’.  This leads to pressure for regular analgesia at 
predetermined times with the aim of achieving a, largely, pain free state.   Chronic 
pain often cannot be treated in this way, that fact the patients are attending the CPS, 
with the pain scores they reported, demonstrated that this strategy had been 
unsuccessful for them.   
 
The interventions undertaken by the pharmacist with patients during this research 
were twofold.  Guiding them, to take more control of their pain medicine therapies 
and to use them in ways which maximised their benefits and minimised their harms.  
In addition to accept that their pain will flare and therefore to keep some pain 
medicine in reserve for when this happened. 
 
The results of this research confirm that by encouraging patients to adopt such an 
approach, the pharmacist made a demonstrable contribution to the improvement of 




CHAPTER 8 APPENDICES 





















1    1st pass metabolism – see First Pass 
2    5-HT (serotonin, 5-hydroxytriptamine) – a monoamine neurotransmitter, which 
is involved in both excitatory and inhibitory neurotransmissions.  Medicines which 
alter the availability of this neurotransmitter at its receptor site, can sometimes be 
effective in the treatment of chronic pain. 
3    Acupuncture – This is a type of ‘alternative medicine’ promulgated for the 
treatment of many conditions.  It involves the insertion of fine needles into the body.  
In the treatment of chronic pain, the location of the insertion is related to the site of 
the pain being treated.  Reviews of its efficacy are inconsistent.  Cochrane suggests 
that it may be of benefit in chemotherapy induced and post-surgery nausea and 
vomiting. 
4    Addiction – NHS Choices define addiction as – ‘not having control over doing, 
taking or using something to the point where it could be harmful to you’ 
5    Biomedical model for the treatment of chronic pain.  In this treatment model the 
accent is upon things being done to the patient by other such as injections, surgery 
and analgesia 
6    Biopsychosocial model for the treatment of chronic pain.  In this treatment 
model for the treatment of chronic pain the accent is upon self-management.  The 
patient is equipped with skills, which will hopefully enable them to better manage 
their own condition.  Research has suggested that based on weak/moderate 
evidence this method gives patients with chronic pain the most likely chance of 
functional improvement (Cheatle, 2016; Kamper et al., 2015). 
7    Bio-transformation – The process by which one organic molecule is 
transformed, within the body, into another, such as the conversion of an inactive ‘Pro-
drug’ into its active moiety. 
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8    BPI – Brief pain inventory.  This is a questionnaire, which can be self-
administered, that was originally compiled to assess the severity of cancer pain.  
Subsequently, its use has expanded to be a regular tool used in the assessment of 
many forms of pain as well as in pain research.  It asks questions about the pain 
itself and its effects upon the patient.  It also asks about the way medicines are used 
to treat the pain  (Poquet and Lin, 2016). It includes two well used indices for 
(chronic) pain – Pain Severity Score (PSS) and Pain Interference Score (PIS). 
9    BPS – British Pain Society.   This organisation defines itself as “An alliance of 
professionals advancing the understanding and management of pain for the benefit 
of patients.” 
10    CBT – Cognitive Behavioural Therapy. This is a psychosocial (q.v.) intervention, 
widely used in the treatment of mental disorders.  Guided by research, CBT focuses 
on developing personal coping strategies that target solving current problems and 
changing unhelpful thoughts, beliefs, attitudes, behaviours and emotions. 
11    CCG - Clinical Commissioning Group.  These are the NHS organisations that 
have been established to organise the delivery of care. 
12    Central sensitisation – A medical shorthand for the concept that repetitive nerve 
impulses from the periphery, in some way, change the way that the brain processes 
this information.   Given the way that the brain demonstrated plasticity in response to 
learning or memory this is not surprising.  Implicit within this concept is the 
suggestions that as a result of this change there is more pain with less provocation 
and that this process may be at the root of many painful conditions where there is no 
identifiable pathology.  But as yet there is no certainty over whether the observed 
brain changes are the cause or effect of any variation in perceived pain levels. 
13    Chronic pain – The simplest definition for this is pain that last longer than three 
or six months.  More practically, for the patient, it can be defined as pain lasting 
longer than would be expected or persisting after healing has taken place.  However, 
its definition also needs to be understood in relation to  
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Ø The symptoms of neuropathic pain that are not associated with apparent 
neuronal damage 
Ø Central sensitisation q.v. 
Ø The changes in the brain’s focus of neural activity during the transition from 
acute to chronic pain from the pain centre to those associated with emotion 
and reward. 
Ø The role of glia in the initiation and maintenance of chronic pain 
Ø The modulation of afferent pain impulses by efferent nerve pathways. 
As a result, it is likely that any chronic nociceptive pain will eventually contain 
elements of neuropathic pain. 
 
14    Cochrane – is the term used as a shorthand for the Cochrane Organisation or a 
Cochrane Review.  This is a worldwide independent, non-profit, non-governmental 
organisation formed to organise medical research information in a systematic way, 
which facilitates medical interventions based upon evidence-based practice. 
15    COX-1 – Cyclooxygenase 1 enzyme system – also known as prostaglandin-
endoperoxide synthase (PTGS).  This system is responsible for the conversion of 
arachidonic acid to prostanoids – prostaglandins, prostacyclins and thromboxanes. 
16    COX-2 - Cyclooxygenase 2 enzyme system – also known as prostaglandin-
endoperoxide synthase (PTGS).  This system is responsible for the conversion of 
arachidonic acid to prostanoids – prostaglandins, prostacyclins and thromboxanes. 
COX1 and COX2 are isoenzyme systems with an isoleucine residue in COX1 
substituted with valine in COX2.  This minor change removes the steric hindrance 
to a hydrophobic side pocket thereby facilitating binding to different receptor sites.  
The COX2 system is generally induced as part of the body’s inflammatory 
response.  They are associated with much less gastric irritation, the risk of renal 
complications remains the same and there are indications of increased risk of 





17    CPGS – Chronic Pain Grade Scale. This is a multidimensional measure, which 
assesses chronic pain severity in two ways: pain intensity and pain-related disability. 
It can be used in all chronic pain conditions, including low back pain 
18    CPS - Chronic Pain Service.  The service set up in South Staffordshire to offer 
treatment advice to local GPs.  It was not set up to manage these patients over the 
long term. 
19    CPT – Chronic Pain Team.  The staff who work in the CPS 
20    CRPS - Chronic Regional Pain Syndrome.  This is a long-term painful condition 
that often worsens with time. It is characterized by severe pain, out of proportion to 
the original injury and is often accompanied by sensitivity, swelling, and changes to 
the skin.  
21    CYP – see Cytochrome P450 
22    Cytochrome P450 – CYP450 – or CYP.  These are ‘heme’ containing enzymes 
generally responsible for the insertion of oxygen into an aliphatic moiety in an organic 
substrate.  There are more than 50 enzymes in this group.  90% of drug metabolism 
involves six members of the group, with the most significant being CYP3A4 and 
CYP2D6 (Lynch and Price, 2007). 
23    Delphi study – a research program involving a group of experts who, having 
agreed on the ground rules then discuss a problem using a series of ‘round robin’ 
questionnaires until a consensus emerges. 
24    Dependence – This is specific physical condition where the body has adopted 
to the presence of a medicine.  Sudden cessation of therapy with this medicine will 
result in predictable, measurable symptoms, known as withdrawal.  
25    Deprivation Indices – the use of a series of outcomes measures to concatenate 
the levels of relative deprivation in small areas in England into an overall whole.  The 
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Index of Multiple Deprivation is the most widely used of these indices.  Most of the 
data used for these statistics are from 2012 to 2013.  The information ranks seven 
domains of deprivation; income, employment, education, health, crime, barriers to 
housing and living environment.  It is used as a measure to compare a small area 
with another small area in another part of the country. 
26    DNA – Did not attend.  The term used to describe patients who do not attend 
their clinic appointment without making contact prior to the date and time. 
27    EMDR – Eye movement desensitising and reprocessing.  A psychological 
technique which can be used in appropriate and suitable patients to mitigate some of 
the worst aspects chronic pain  
28    Enhanced medicines review – this is medicines review or MUR q.v. into which 
additional criteria have been added, often requiring specific training. 
29    Facilitated transport.  The name of one of the means by which molecules are 
transferred across a cell membrane from outside to inside a cell or vice versa.  It is 
facilitated to differentiate from active transport. 
30    Fear-avoidance behaviour.  This is the term used to describe a situation often 
observed in patients suffering with chronic pain.  Patients develop pain and then go 
on to avoid doing things, which they believe will make their pain worse.  
Unfortunately, this creates a vicious circle where inactivity leads to loss of muscle 
power, which in turn makes movement more difficult and therefore more painful.    
31    First Pass metabolism.  This is the term used to define the effect that the 
intestinal wall and the liver have upon the blood levels of medicines that are 
absorbed from the intestine and then transported via the Portal Vein through the liver 
before entering the general circulation.  Depending upon the extent of this process 
the amount of medicine entering the general circulation from an oral dose of 
medicine can be significantly reduced. 
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32    Genetic polymorphism – The term used in biology to describe different 
phenotypes in one population.  In this text this is used as a shorthand for the genetic 
variations between individuals, which result in differing frequency of expression of 
individual CYP450 enzymes q.v. acting at differing levels of efficacy.  
33    Glial cells or glia or neuroglia.  These are non-neuronal cells that maintain 
homeostasis, provide support and form myelin in central and peripheral nervous 
systems.  Peripherally they include Schwann cells and centrally astrocytes and 
microglia.  Historically, four functions were associated with glial cells, they support 
neurones, supply nutrition and oxygen, insulate one neurone from another and 
remove bacteria and dead neurones.   
34    HADs scale – Hospital anxiety and depression score.  A scale of 14 questions 
which aims to avoid measuring somatic symptoms.  The aim was to detect and 
measure anxiety and depression in patients with physical health problems 
35    HCP – health care professional.  This often has specific connotations but in this 
document.  it refers to individuals who interrelate with patients in some way ether with 
regard to the treatment of their pain or more particularly about their pain medicines   
36    Independent (pharmacist) prescriber (IP) may prescribe autonomously for any 
condition within their clinical competence. 
37    IASP – International Association for the Study of Pain.  An international learned 
society, which brings together researchers, clinicians and caregivers to stimulate and 
support research into pain and its treatment. 
38    I/R – immediate release medicines.  Formulations where the release has not 
been modified to achieve a more prolonged action.  See also S/R  
39    Kinesiophobia – fear of movement, which may increase during chronic pain, 
particularly whist waiting for treatment. 
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40    KTT – Key Therapeutic Topic, occasional statements from NICE suggesting 
therapeutic treatment options in areas where it is believed that advice would be 
appropriate. 
41    LESS PAIN question format – This approach to questioning was designed to 
facilitate well informed semi-structured discussions between community pharmacists 
and service users with pain related problems. 
42    Levels of expressed need – a five-point scale defining levels of need in relation 
to four help seeking behaviour questions i.e. pain treatment sought recently or often 
and painkillers sought recently or often. 
43    Median and Interquartile range (MIQ) - an alternative statistical approach for 
assessing the significance of changes in a ‘skewed’ data set. 
44    Medicines compliance – is the extent to which a patient correctly follows the 
direction of a doctor issued as expressed on a prescription.  
45    Medicines concordance – involves a doctor and a patient making a decision 
together about a medicine treatment. 
46    Medicines review – a consultation between a pharmacist and a patient during 
which all of the medicines taken or used by a patient are reviewed by a pharmacist 
with the aim of maximising benefit, minimising harm and avoiding waste. 
47    Mild/moderate opioids – A convenient shorthand for the group of analgesics 
comprising Codeine, Dihydrocodeine and Tramadol.  
48    MRC – Medicines Research Council is responsible for the co-ordinating and 
funding medical research in the UK. 
49    MSK – Musculoskeletal clinic.  A clinic generally operated within a 




50    MUR – Medicines utilisation review.  This is a structured process during which a 
pharmacist or other health care worker undertakes a review with a patient of the use, 
efficacy, side effects and compliance of their medicines.  This applies in particular to 
those patients who are taking/using medicines for long-term conditions.  This may be 
‘enhanced’ to include additional questions as part of a specific therapeutic or 
research protocol for which training would be given. 
51    Neuropathic pain – one of two types of pain.  It is generally associated with two 
causes 
i. A lesion or a disease affecting the somatosensory system q.v. and this may be 
central or peripheral in origin. 
ii. Damage to nerve fibres resulting from a physical cause, which then transmit 
incorrect signals to other pain centres.   
It is often described as shooting.  This may be constant or episodic.  In addition, it 
may result in inappropriate responses to non-painful stimuli (allodynia).  Other 
symptoms include burning, coldness, ‘pins and needles’, numbness and itching. 
 
52    NICE – National Institute of Health and Care Excellence.  Originally set up as 
Special Health Authority, the National Institute for Clinical Excellence to reduce 
variations in the availability of health care across the nation.  After merger with the 
Health Development Agency it became the National Institute for Health and Care 
Excellence, developing guidance to prevent ill health and promote healthier lifestyles.  
It offers guidance on all aspects of health care aiming to maximise evidence-based 
practice. 
53    NMDA receptor – N-methyl-D-aspartate receptor.  This is a glutamate receptor 
for an ion channel.  Activation allows positively charged ions to flow into the cell.  It is 
important for controlling synaptic plasticity and memory.  
54    NNH – Number needed to harm – an epidemiological term. This is the converse 
of the NNT q.v.  It is the number of people who need to be treated in a specific way in 
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order that one will experience an adverse event.  In the case of pain how many 
patients need to be given an analgesic for one patient to experience an untoward 
event. This is more difficult to calculate than NNT because side effects are less likely 
to have measurable outcomes i.e. how much constipation is constipation?  As with all 
of science it is more difficult to prove that an event doesn’t happen.  
55    NNT – Number needed to treat – an epidemiological term. This is the number of 
people who needed to be treated in a specific way in order that one will receive the 
anticipated benefit.  In the case of pain how many patients need to be given an 
analgesic for one patient to experience analgesia.  This is usually calculated from a 
measurable outcome such as a 50% reduction in pain. 
56    Nociceptive pain – one of two types of pain.  It is associated with actual tissue 
damage and is described as sharp, aching or throbbing.  
57    NRS – Numeric Rating Scale.  An 11-point pain scale used to assess the level 
of an adult patient’s pain on a scale from 0 to 10 where 0 is no pain and 10 is the 
worst pain imaginable.  With 11 points it does have a mid-point. 
58    NSAID(s) – Non-steroidal anti-inflammatory drugs.  These are medicines that 
inhibit the actions of the COX1 and COX2 enzyme systems.  The resulting diminution 
of prostanoid formation reduces the bodies inflammatory response and often 
therefore pain.    
59    OIH – Opioid induced hyperalgesia.  A clinical situation where opioid receptors 
are sensitised to opioids and paradoxically patients feel more pain.  The practical 
result of this is that patients increase the dose of their opioid in an effort to control 
their pain.  This is similar to, but not the same as opioid tolerance. 
60    OT - Opioid tolerance – a clinical situation where the efficacy of opioid 
analgesics fades with repeated doses.  Because the patient’s response to their opioid 
dose is not as good as it had been in the past an increase in opioid dose is 
requested.   
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61    OTC – Over the counter.  A shorthand for those medicines, which patients can 
buy over the counter from a pharmacist or a pharmacy.  
62    PainDETECT questionnaire.  This is defined as an easy to use, patient-based 
questionnaire used to determine the prevalence of lower back pain with neuropathic 
elements. The answers to the questions score between 0 and 38: 0<12 neuropathic 
pain unlikely, 13<18 neuropathic pain may be present and 19<38 neuropathic pain is 
likely. 
63    PIS - Pain Interference Score, see BPI. 
64    Plastic changes – in biology this is the term used to express the ability of a 
living organism to change in response to its environment.  In this thesis the term is 
used more specifically to describe changes in the CNS as a result of stimulation from 
elsewhere within the body.  These changes may be normal as in growth and 
development or the learning of a new skill.  Alternatively, they may be abnormal as 
demonstrated by changes in the CNS in response to continuous painful stimuli.  
65    PMP – Pain Management Program.  A course where patients who have been 
referred to the Chronic Pain Service are presented with information about and taught 
how they might better self-manage their pain rather than waiting for a solution to be 
given to them by others. 
66    Polymorphism – see Genetic Polymorphism. 
67    Psychosocial intervention – this looks at individuals in the context of their 
psychological state and their social environment to determine what effect these are 
having their physical and mental wellness and their ability to function. 
68    PSS - Pain Severity Score, see BPI 
69    QALY – Quality-adjusted life year.  A measure of the state of health of a person.  
One QALY is one year of life in perfect health.  The measure is used as part of the 
economic assessment of health planning 
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70    RCT – randomised controlled trial.  A research method which randomly 
allocates patients to one of two or more groups.  This could be active treatment and 
placebo treatment or it could include a comparator group as well where patients 
receive a known and tested method of treatment or ‘treatment as usual’ q.v.  This 
may or may not include ‘blinding’ where the patient and researcher have no 
knowledge of which group a patient is in until the trial is completed. 
71    RPharmS – Royal Pharmaceutical Society 
72    Sensitisation – In the context of chronic pain this is a shorthand expression for a 
patients’ pain that is worse than expected from the severity of the lesion or worsened 
by actions, which would not normally be expected to produce such a response.  It 
has no correlation with the time course of the condition or its severity (Woolf, 2011).  
See also wind-up. 
73    SIGN – Scottish Intercollegiate Guidelines Network.  This is a public body set 
up in Scotland in 1993 to improve healthcare by developing and disseminating 
evidence based, clinical practice guidelines. 
74    S-LANSS an acronym for Short Form – Leeds Assessment of neuropathic 
symptoms and signs. 
75    SNRI – Selective noradrenaline reuptake inhibitors.  A group of anti-
depressants that have found favour as replacements for TCAs.  Their side effect 
profile is different to TCAs but recently they have been identified as possibly causing 
occasional, significant and unusual idiopathic effects, which has called into question 
the perception of their overall safety. 
76    Somatic – Relating to the body 
77    Somatosensory system – This is an all-encompassing term used to describe the 




78    SPSS - Statistical Package for Social Science.  A computer program which 
allows individuals to undertake statistical analysis on their data using the full range of 
statistical tests. 
79    S/R – sustained action medicines.  Where the formulation has been modified to 
prolong the action within the body.  This is often done to minimise side effects from a 
dosage spike or to produce a smooth release curve where ongoing action is required.  
They are also of benefit where there are problems with patient compliance. See also 
I/R 
80    SSOTP - Staffordshire and Stoke on Trent Partnership Trust, now incorporated 
in Midlands Partnership Foundation Trust.  
81    SSRI – Selective serotonin reuptake inhibitor.  A group of anti-depressants that 
have found favour as replacements for TCAs.  Their side effect profile is different to 
TCAs but recently they have been identified as possibly causing occasional, 
significant and unusual idiopathic effects, which has called into question the 
perception of their overall safety. 
82    STarT (Subgroups for Targeted Treatment) back Screening Tool is a brief 
screening questionnaire designed for directing initial treatment for low back pain 
(LBP) in primary care 
 
83    Strong opioids – A convenient shorthand for the group of analgesics used in the 
treatment of acute, surgical and terminal pain and whose use in chronic pain is 
undergoing examination outwith the scope of this research.  In the UK this group 
generally comprises Morphine, Oxycodone, Fentanyl and Buprenorphine.  
84    TAU – treatment as usual.  In the context of research, this would be a control 
group for whom nothing changes. 
85    TCA – Tricyclic antidepressant (tricyclics).   Anti-depressant whose chemical 
structure in based upon three rings.  Newer compounds such as SSRIs and SNRIs 
have to some extent, overshadowed the use of tricyclic anti-depressants.  However, 
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more recent analysis suggests that one group of side effects may have substituted 
with another and therefore their possible harms undersold.  
86    TENS - Transcutaneous electric nerve stimulation.  A treatment for chronic pain, 
which uses mild electric currents.  Conductive pads are attached to the skin, in the 
area of the pain and a pulsed current is applied.  This can either be at a high 
frequency with a current below that necessary for muscular contraction or at a lower 
frequency with a current sufficient to produce muscular contraction.  Evidence of 
efficacy is moderate at best. 
87    Tolerance – This is the word used to express the decreasing response to a 
medicine, which results from repeated use.  In relation to opioids this would manifest 
itself as decreasing analgesia.  All of the actions of opioids, both therapeutic and side 
effects demonstrate the development of tolerance over time.  These tolerances 
develop at different rates and may in some therapeutic situations be advantageous 
for example, tolerance to the opioid induced respiratory depression for patients taking 
large doses of opioids for palliative care. 
88    Van Korff Grading for the severity of pain.  This pain grading scale, involving 
both ‘pain intensity’ and ‘pain disability’ using seven questions with answers on in a 
range 0 – 10 to rapidly calculate the severity of a pain (Von Korff et al., 1992).  Some 
of these measures also feature in the BPI q.v. 
89    VAS – Visual Analogue Scale.  A pain scale used to assess the level of an adult 
patient’s pain. The patient is asked to indicate the position on a 10cm line, which 
represents their level of pain where 0cm is no pain and 10cm is the worst pain 
imaginable.  The position, which the patient chooses is then transcribed by the 
observer as a number from 0 to 100.  The suggestion being that this gives a more 
precise outcome that the NRS  
90    Venn diagram – a diagrammatic representation of how two or more groups of 
data interact with each other. 
91    WHO – World Health Organisation.  
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92    WHO Pain ladder – this is a schema originally published in 1986, (WHO, 1996) 
for the treatment of cancer pain.  It suggested that with the appropriate use of a small 
number of medicines the majority of patients would experience significantly less pain.  
The actual estimated percentages of the number of patients who would benefit by 
following this therapeutic regimen have reduced over the intervening years. 
93    Wind up - is the increase in pain intensity over time resulting from a repeated 
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Limits 01-01-1990 to 01-01-2019  
    
#1 pharmacist   
#2 physiotherapist   
#3 clinic   
#4 multi-   
#5 chronic   
#6 pain   
#7 analges*   
#8 medicin*   
#9 #1 or #2  Pharmacist or physio  
#10 #5 and #6  chronic and pain  
#11 #7 or #8  analges* and medicin*   
#12 #9 and #3  pharm/physio and clinic   
#13 #12 and #10   
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